var title_f22_15_22768="Spondylolisthesis";
var content_f22_15_22768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76454&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Spondylolisthesis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Dotted line follows posterior vertebral margins of L5 and the sacrum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore, KL, Dalley, AF II. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22768=[""].join("\n");
var outline_f22_15_22768=null;
var title_f22_15_22769="Closed reduction of a supracondylar fracture";
var content_f22_15_22769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Manipulative supracondylar closed reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 404px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGUAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6looooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAM7xHrVl4d0G+1jVZTFZWcTTSsBk4HYDuT0A9TUHhDxHp3i3w7Z63osrS2F0CY2ZdrcMVII7EEEVyvxq8L61408O2GgaNLBb2lzexvqE8w3hYEO7GzI35YKcZH3aj+DvhPXfBh8R6Zq9xbXmnS3322xuIUEQJlGZV8rJ2KGHAyepoA9GooooAKKKKACiiigAooooAKKKKACiiigBaSuM8VeIzJ4t0rwZpTOdRvka6vZYzg2dmvViezOfkX0Jz6Z7PgdOlABRRRQAUUUUAFFFFABRRRQAVxXi/4k6N4W106RfW2rXV8LL+0XSxsnuBHBuZS7begBU5J4GR612teI/FrwBrmv/EhdbsNKGp6a+h/2Y0aau2nsJDM7kkqCXXaQNp4OfagD1/QdXsdf0az1XSphPY3cYlhk2ldyn2PI+hq/XMfDHRdT8O+AdE0jXbmG51GztxFJJCuEwCdqjgcKu1c4GcZ7109ABRRRQAUUUUAFFFFABRRRQAUUUUAFLSVxvxQ13UNN0i10rw2yf8ACS61N9ksNwyIuMyTsP7saZbvzt4OaANrR/EFprGravY2Mc7rpkiwTXO0eS0xGWjVs8snG70JA61sVm+G9FtfDug2Wk2AP2e1jCbm+87dWdvVmJJJ9Sa0qACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKx9e1WbSbvS5JBbrpc85t7qaRiGiZhiIjtgvhTn+8Petk8UAJRRRQAVneJNas/DmgahrOqSCOzsYWmkORkgDhRnqScADuSBWkK8v1yEfE/xP8A2Oh3eDtDug2pPjjULtOVtx6xocFz3OB2zQA/4HaJeDSL3xj4hXPiLxO4vJgf+Xe3x+5hXPQBMH15AP3a9MpaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiob6SeGyuJbS3FzcJGzRwFwnmMBwu48DPTNAE1FVNI1GDVtMt760LeTMuQGGGUg4ZWHYgggjsQat0AFFFFAB7k4HevNPhpNN4w8Ua344uQP7Ny2l6Gp/590Y+bMP+ujjr1ATHSnfG/Vb+TRrPwf4cdB4h8TO1nEWP+otwMzzH0AXj1+bjJFdn4S0Cz8LeGdN0PTQRa2MKwqT1Yjqx9yck+5NAGtRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGV4s0ODxL4a1LRrltkd5CYxIBkxt1Vx7qwDD3FZPwx8QT+IfCUMmosp1ixkfT9SVeNtzEdr8e/DfRhXWV5Ddaja/Dn4y38upzw2XhrxVa/aftErBI4b2EYcEk4G9MH1LYoA9dpcH0rykeM/FnjrH/CtdOgsdEYlTr+sIwWUA4Jt4fvN7M2AeQQKhv8A4LN4hhYeMfHXirVpnbcywTpbW/4QhWAoA0fip41ELWvhDwpqEDeL9ZmFpEIm3tYxnmSdwPu7VBIzg55GcGu38M6HZeGvD9jo2lx7LSzjEaZ6sepZvViSST3JNeU/BfwT4esPHnivXfD9gkGn2Lro1ixcyFmjUfaJMsSSS+FyD0Dete00AFFFFABRRWF418Qjw1oT3iQG6vppFtbG1U4NxcOcInsM8k9gCe1AF2LWdOm1240aG6STU7eFbiaBQSYkY4UsegJ7AnJHOMVoVzfgPwx/wjWlym7mW71u/kN1qd7jmeY9ceiKPlVeAAOnJrpKACiiigAooooAKKKKACiiigAooooAKKKKAClpKKAOEsNQXw18TZ9AuCU0/wAQo+o6cx6Lcr/x8RD6jbJ2GS/rXeV5p8fdPuW8GQ+ItKiEmq+GbuPVoFx95UP7xCeu0oST/u1ua78RvDOheGtN1vVr8QQ6lAk9pbgF55wyhgEQck8gZ6AkZIoA66qOtavp2hafLfazfW9laRKWaSdwowPTPU+w5rzv+3viR4tGfDWhWvhXS3Hy32ufPdMM9Vt1+4fZ+K86+J3w6sZda8LeHNQ1C+8Q+L/EF8Hu9TupcNBZxfNL5cQO2NfQc9G5p2A9J+ElldeIdS1D4i65G8d1q6eRpVvIMG009Wygx/ekPzn6jHXFenUy3gitbeK3to0ighQRxxoMKqgYAA9AKfSAKKKKACilHNUdJ1S01aGeawk82CKd7cyAfKzIcNtPcBsjPqDQBdooooAKKKKACiiigAooooAKKKKACiiigAooooAK89+PHhH/AITD4cX9vDCs2oWJF/ZqwzukjySmO+5dy49SK9CpRwaAMTwRrtn4n8I6RrOmKqWl3bq6xr0iOMMn/ASCv4VwfijxF4g8c39/4a+G8y2VpbubfU/EcgJSFv4orcD78gB5YYC+oJBHJNbeI/C/jW/+GPhxls9K8RXD6nZ6nvO6wtmBNxFGv94FSF543Z75HumgaPYeH9GtNK0i3S2sbVBHFGvYdyfUk5JJ5JJJpgUvA/hix8G+FdP0HStxtrRMb3+9IxJLO3uSSf0rcoopAFFFFAEd1cQ2lrNc3UixW8KNJJI5wEVRkkn0AFeXfDe71T4jaxb+ONWg+w6BbeZHoWnHlnJyrXUh/vEZVR2BOP7zXv2i21BPgx4lOlSmKXykWUqOTCZFEgH1UnPtmu48PWVvpnh/S7Cy/wCPW1tYoYv9xUAH6CgDQpKKKACiiigAooooAKKKKACiiigAooooAKKWkoAKKKKAI7mCK6tpbe5jWSCZDHIjdGUjBB/CvBv2dfBWkaD4k8WWepwNdeKNCvfs8M9z83lWbrmFogfu7huJI5wcd8V77XkXxSm/4QLx/ovxCRG/smeM6TrnlrkiJjmKXAHVWGCeuNqjrTQHd+PPGWkeCNCfVNcmYKTsggjG6W4kPRI17k/kO+K4b4XeHvE2q+OtS+IPji0i0+5urNbPTNM3bns7ctuIfI4bp75Z8helRfCqzPxA1qf4k+IIvMhaV4PD1pLytpboxUy4yQJHZTk9RjjgjHsNIBKKKKAClpKgv7n7HYXV0Y2l8iJpdidW2gnA9zigDzLx14q1/W/GMvgHwLEIrhYUfVtbYnbpsb/woO8pXlee/sSvonh3RrLw9oVjpGlxmOys4hFGCckgdye5JySe5Jri/gNG9x8PoddvIRHqWv3M+p3Zx1Z5G2j6BAgAr0SgAooooAKKKKACiiigAoorhfit8RbDwFpCllW61m5U/Y7INgsf77/3UHc9+g5q6dOVSShBXb2Qm1FXZ3IZS5QMu8AMVzyAc4OPwP5UtfDFt4u8RWvjMeLo9ReTXy2ZHkz5UsfeFkB/1WOAB0wCDkZr67+G3jrTPHugi/07MF3CQl5ZSNmS2kx0Pqp5KsOCPQggelmWTYrLVF11pLqu/Z+f9IwoYqnXuodDrK4rVPFV7pHxV0jQL6KM6PrVm5s5wMMl1FlnQnPIKFce/wCNdrXmnx+0u4m8GQa/pibtU8NXcerQYGSVQ/vF+m3JP+7XlHQemUlVdJ1C31bSrLUrJt9reQpPE3qrKCP0NWqACiiigDzz406He3ehWfiPQFLeIvDU39oWagkecgx50J9QyA8dTgDvXZeHNZtPEOg2Gsaa4e0vYVmjOc4BHQ+4OQfcGtIda82+B9tHpWneKdDglY2+l6/dQ28Lf8sIW2uij2+YkfWgD0iiiigAooooAo6/pketaDqWlTnEV7bSWzH0DqVz+tcf8CtYn1f4Y6St+wOo6dv026HdZIWKAH32hSfrXfjrXknwk3aX8UvinoBkJiW/h1SJTxg3CF3x/wCOj8KAPWqKKKACiiigAooooAKKKKACiiigAooooA4Lxdr83g/xzol3eTyHw7rjDTpw5+S0uusMgPYOMoeg+UHtXfHg1zPxK8NL4v8AAmtaGQvm3VuwgZjgLMvzRtnthwtZPwQ8WSeMvhtpeoXbltSgBs77P3hPHwSfdhtb/gVAHd0UUUAFZPi7QbbxR4X1TQ74DyL63eEkrnYSPlYD1U4I9xWtSigDy79m2c/8KpsdMmUpfaNc3GnXcZGCkqSscfky16hXkfw7gOhfHb4jaQUZIdSjttYt8nhgQVlYf8DYj8K9coAKKKKACjAIIYAg8EGiigDzT4RXR0TU/EHgC6Lb9Dm8/T2c5MtjMS6c9yhJQn6CvS68u8csND+NngPWlZkj1SG50S5PYjHmQj/vvNepUAJRRRQAUUUUAFFFKOtAHAfFr4kWXgLS1RFS7126U/ZLLd26eZJjkRg/iTwO5HyJqd9e6vqt1qmr3T3mo3Tb5p36n0AHRVA4CjgCvpHXPgDYazrd7ql74s1+W6un3yPMIHb2GfLGFHQAAADgCvFPit4Nh8CeMU0e01C6voJLCK733KoGVmklUj5VAxiMfrX23CVbA060afK3WlfVpWVk3prfZb28jysxjVcXK65V95yNafhjX9T8K69BrOgziG9iG1lbmOePPMcg7qfzBwRgisyuz+EHgSH4geItWsbzVLuwis7aOZPs6RsWLMQc7lPpX2edV8NQwkni4uUHo0v+HR5mFhOdRezdmfUnw58caZ480EahppMNxEQl3ZucyW0mOh9VPUN0I98gdPcQxXNvLb3MaywSoY5EYZDKRggj0IryjwH8FLbwb4og1uy8T6xJLGhjeHbEiTof4XwvK9/UHkEV62Oa/G66pKo/YtuPS+/ztc+mhzcq5tzyr4fT3PgXxTH8OtRWa406ZJbrQr3Gf3AO5oJD/eTJwe4I6cCvVK8hvdUu/FPx90SPw3HHcaX4aguE1O9OTGsky7fJUjguNq8duc9K9erIoKKKKAFrynxVqp+HHxHOu3NrM/hfxGkcOoXMSFvsV1GNqSsAOEZCAfdc9sH1WkdVkjaORVeNwVZWGQwPUEUAJDLHPDHNBIksMih0kQhlZSMggjqCKdXnfgmF/BvjK98HksdEvI21HRSc4hG799bAn+6WDKOysa9EoAKKKKACvGfCsob9qrxskQKhdGtxL6M+ISD/AN8nFezV5PoPlH9prxSbVAQuhW4unHaXeNoPuUx+VAHrFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKODXjOnPF8Kfinf2d4ky+GPGV2s1lOoylrfscPEwH3Q+QQfYDoCR7LXj/wC0bqLzWHhrwzpFv9s8RalqkM9pbr1RYm3NIT/CBwM+hY9jQB7D3pKVuppKACiiigDzL4p3N34W8WeGfGltZiXTLYSadrUiAl47WQqVkwBnajgsfr75HpUE0VxBFPbSpNBKoeOSNgyupGQQRwQR3pZoo54ZIZ40lhkUo8bqGVlIwQQeoPpXjfhKab4YfE2PwPPLI3hLW1e50N5Wz9kmBzJbBj1XnIH+0vUsaAPZqKWkoAKKKKAPL/jkwjvPhy7RAoPFVmDKeiZDjH4/0r1E9TXnP7Qhji+Eus3jgCWye3uYXPVJFnj2ke/b8a9EVt6K2Cu4A4PUUALRRRQAUUUUAFFFFABXyt+0/wD8lStv+wLb/wDo+5r6pr5W/af/AOSpW3/YFt//AEfc19Bwt/yNKX/b3/pLOPH/AO7y+X5o8nr2X9lD/kdvE3/XhD/6G1eNV7N+yf8A8jp4m4/5cYP/AENq+44u/wCRc/VHlZb/ABvkfTdcF8UdR1S5fTfCPhi5+zaxrJbzrpT81nZr/rZR6MchV9ycYIrvh1rzT4evHr3xN8deIgrPHaSx6HayE5CrEN0oHsXYGvyc+hO38M6Dp3hjRLbSdGt1gsrdcKByWPdmPdj1JrToooAKKKKACiiigDzv4179L0XSfFsEbPP4bv47uQJ95rZv3cyj6q2f+A16DbzxXNvFcW8iyQTIJI3U5DKRkEe2Kh1Owt9V0y80++TzLS7heCVP7yMpUj8jXCfArUnn8FPol3KZNQ8N3cujXDEY3eU2EYe2zaPwNAHolFFLQAySWOCJ5ZnWOKNSzu5wqgDkknoK8h/Zl0hIvBuo+JZnee/8Q381y9zKSXkjV2VM5995/wCBfSqPjFPFXxS8Z614U0XUV0jwTppS11O9iTMt3IVDPCh9s7SBgDnO7IWvYtG0y00XSLLTNNiENlZwrBCg7KowOe5460AXKKKKACiiigAooooAKKKKACiiigAooooAzfEmtWXhvw/qGs6o+yysYWmkI6kAdB6knAA7kivPPgjpF7qqXfxD8UR517XhutY25FlY/wDLKJOOMj5ie+VJ5zmP9oKN9ctvCfgyJ5FHiHVo0udhwTbRfPL+XyH8K9XhijghjhgRY4o1CIijAVQMAAelADqKKKACiiigArhPjR4Rk8XeCZ007Ka7pzi/0yZOHSePkAH/AGuV+pB7V3dKODQBzfw68UQ+M/BWla9Aoja6i/fRf885VO11/BgcZ7YNdHXkfhVj4I+Nur+F8FdG8TRtrOnjB2x3I/18Y7cgb8dgFHevXKACiiuH+LXjHUPCOj6evh/TotT1/VLxLKxtJH2qzEEljyPlAHPIxkZIFAHNfFPT7jxd8U/BfhOWUDQ4Vk1rUIAM+cImAjVv9kscf8CPcCvXjya4D4aeEdZ0y/1LxJ41v4b/AMU6mixOLcYgs4FyVhiz2yck9z6nLHvqACiiigAooooAKKKKACvlb9p//kqVt/2Bbf8A9H3NfVNfNH7SXh/XNQ+I1rd6Xoeq6hanSYIvNs7OSZQ6zTkqSoODhlOPevb4crU6GZUqlWSjFX1ei+FnLjYuVCSirvT8zxWvaP2Th/xWHij/AK8oP/Q3ry//AIRTxR/0KfiT/wAFc/8A8TXsn7L+ga1pfiDxLd6to+o6dBLbQRxte2zwb2DOSFDAZxx0r7DijMMLiMA4UqkZO60TTPNwFGpCteUWj3TxLqseh+HdU1WYgJZW0k5z32qSB+OMVzHwU0KTQfhtpMd1k394pv7t2+80sx3nPuAQPwq38W9Kn1v4aeI7CzJFxJaM6AfxFCH2/jtx+NaXgnX7DxP4U0zV9JmE1pcQjDAYIYfKykeoYEfhX5oe4bdFFFABRRRQAUUUUALXlHiqRvAHxSsvEy5Xw74kMenatj7sFyOIJzzwCPkJ6AcnJIr1aue+ImgDxR4E13RSoZ7y0dIge0oGYz+DBT+FAHRY5xXLeOfES6f8ONe13Rr+1LwWUz21yGWSPzQCq+oPz4GPXiuc+H+ty+L/AICQ3Ms0j37aXNZ3DJJ+9EyI0ZJPZzgN+INcFcmz134cfC74eaYzRvrKW9zexIeVtIR5kpb03OvHqQadgPVvhB4bl8LfD3S7G9dpNSmU3l9Kxyzzyne5J7kZ2577a7KlPt0pKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFKOtAHkWoSy+JP2lNJtbcsLPwlpstxcMVODNcrsCZ/wBwqw/3Wr1yvLfBFwmk/Gvx7pOpSBL7VRa6jYl+txAsexgp77GBGPr6GvUqACiiigAooooAKKKKAPLv2g9Lvz4Us/FGgRu+u+Gbpb+3CKWLx5CyoQP4SvJ9lNdt4I8SWnjDwlpev6eCsF9CJNhOTG3RkJ7lWBGfatwcGvHvgfdw6B4p8beAJR5Emn6jJf2ETHraTYYBfZcrn/f+tAHsAZd+zcN+M7c849cV5Vomn3/iT4663rGrTxPpnhdFstLgiJwss0StLI3+1tO0/Uf3ed9biws/inr97ckRPbaFbvLMx4SISzs34cZ/CqfwMEl34Km1+4haG48Q39xqrRt1RXfbGM+mxUx9aAPQqKKKACiiigAooooAKKKKAClyaSigBcn1opKKAAqHUqwyrAgj2rzD9ndDp3gSbw7cRrDqGh39xa3EOfmGZGdWI9GDcHocV6fXj3xy0htButL+IWjTXFneadd26aqLdygvLTzACJAPvYyBz2J9BgA9hooBDAMpBUjIIOQRRQAUUVBqF7badYXN9fSrDaW0bTTSN0RFGST+AoAsda86+IPxb0Dwg01pClzrWtRgk6fpyeYyH/pow4Qeucn2rn9Ct/G/xPtn1PVtWl8MeELty9pY2Mey9uLf+EySnlAwweOoPTGDXpfhvR9D8L28ei6DaW9ioQzCGMfM4BwXZjyxyRySTQBznwv+Juh+O9OgWC9tIdc2FrjTd5EkZ54AYAsAMZIyK73oa8t+NfgUavZ2nijw/ZR/8JVoU6X0BiXa92iEFoWI5OQOOvIwPvGu88Ka/ZeKfDmn63pblrO9iEiZ6qehU+4IIPuKAPGPEeow/Bfx7q9xOjL4O8VxS3ChVJW1v1UlgAOgkz7ckdAlbf7MvgfTvDvgDT9cCNNrOr24lluZOWSInKxp6LjBPqeewxrftHeHV8R/B/XYwF8+xQahCWOApi5b/wAc3j8a63wA1s/gPw21jn7IdNtvKz/c8pcfpTA3qKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHk/xNmttJ+M3wv1e8HlW7yXunvcbeA8kQWJGPuxOPx969ZIxWB458J6X428NXWia3EXtpsMjrw8Mg+7Ih7MP8QeCRXDfs96hrA0vxJ4d8U6pLqWs6Dqj2zSysWYwlF8tsnkgkORnmgD1eiiigAoorgfiL4s12x1jTfDfgbT7XUPEd4huJWuyRBZ24O3zZMEHluAB6Hg8AgHYa1rGm6HZG81rULSwtQcebcyrGpOM4BJ5PHSsLwh8RPCfjG+uLLw3rcF9d2675Igjo23ONwDAbhnHIz1HrXnfinwK+nWVj4k8Z3Q8W+JPt1pBGl0u2ytxJMissUAwOhPLZycHArrPiL8MbHxCsWqeHmTQvFliN1jqVsvl8gcJIB95D06EjPcZBAPQ68q+OmlNpsWlfEDSLfOseHLhJJzHw09kTtljbA5ADE89Bu9a2fhL45m8WabdWGuW4sPFekv9n1OyPGG7SL6o3X/AOtgnuLq3hvLWa1uokmt50aOSNxlXVhggj0INAHgevWL/F/4rX1noPiKSDwfa6Xax6pJYPn7YWd5FiyP9ljnOcYII7V73Z20FlZwWlpEsNtBGsUUajARFGAB7ACvKf2eNIsvC9p4t8MW8QW70vV3EkhHzTROoaF2P+7xj2969boAKKKKACiiigAooooAKKKKACiiigAooooAK5b4rQLc/DDxZEyhwdLuWx7iNiD+GK6mqms2Capo9/p8hwl3byW7H2ZSp/nQBxvgzWLXwr8FtB1bxJqry2ltpkEs15IhLYcLtGFyTjcq+pxzXeRuskaSRncjgMp9QelfPHhXV77xDY+CPhuYAt/pEwfxFDKhKxQWrjy0PZhIRHjGe3avok8mgArzrxPJF4+8QP4RspfM0WwdZddmjPDsCCloD6kjc+OgGM5OK1/iP4gvdI0y207QFWTxJrEhtdPRhkRnGXmYf3I1+Y9ew71W+H1vZaBfX/hLTfLlGmW8Fzd3JJ86e5mLl3k92Cg9T1x0AoA7YBVUKoCqBgAcACuZnaNPibZDD+dLo84zn5QFmi7evzGumrl9R+T4maExGBJpl4gPqRJAcUAdSODXkPgW2HhD4tePtPa+t7Pw1LDDq8VtNIFWJ5M+bIucBV3K2e33fSvXq8D1HwFF8Q/jr4nvNRuyujaVFbWUsCL887NGHKBv4V55xzzgY60AaXiLX734wveeFvBBeHwqHEWreIGBCSrkFoLcfxEjgt0x7EE+waVYW2laXZ6dYp5dpZwpbwpnO1EUKoz9AKTSdNstH0230/SrWGzsbddkUEKhVQewHvk/WrVABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAteGeELO4n/AGrfHV1Ddy29vbWVsJrdB8twWhjC7vpgn1/DOfcq8S8SazZ/Db46ajr+vymDRdf0cbJsZBubfA8v6lMY92AoA9es9Z0691XUdMtLyKXUNP8AL+1W4Pzxb13JkehHOav1518EtMnbw9ceK9ZhRde8TS/b7hh1SE/6iIH+6qYx/vV6KSACSQABkk9qAKOu6tZaDo15quqTCCytIjLK57Adh6k9AO5IFcX8INM1CWHVvF/iCB7fWPEUyzi3f71raqMQxH0O05P155Fcj481u/8AF/hnVPEelFf+Ea0iZBp0Eke5dUullVfNfPWFWJCr/EQScYAr29N/lp5u3zNo3beme+KAOE+Ntz9h8BNfbWYWl/ZTkKMnAuI671utcL8cYWn+E/iMIpYpCk2AeySK5/Ra7iORZYkkX7rqGH0IoA8V+Pdtc+FNZ8PfEDwtGBryXcemXMAGFvoZAcI/uCAAevI/uius+KHxKtPBOjxmCGDUfEM7pDDpEdyvnF3HHyjLEA46DnIrE/aXtLzUvBmi6dpls13eXet20ccCyeXvO1zjd/COOvarPgT4Ww6d4obxX4httMGshNlta2MZ8m1Hdy75aSU93PqcdsMDX+EvhvU9H0q/1bxQyN4n12f7ZfiM/LDgYjhX2RePqTyRg13VLSUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigDywRWvhn9oWa6unEUfirS1jgdhw9zAQDGD6+XtPPU8V3PjHxJZeFNBm1TUN7hWWKGCMZeeVjhI1Hck/49qi8beEtM8ZaL/Z2rrKoSQTQXED7JreVfuyRt2YV5F8QdI8X6Xq/gG213xJaazoP/CRWca+ZaCK5ZwTtLkZDYAbnjJOTQB6j4Q8PXUeoS+IvEvly+I7uMRlUO6OyhzkQRn68s38R9sVm/CyBri+8Y69Nky6lrEsSMe8MGIo/wD0Fq7PWrt7DSNQvI08x7e3kmVP7xVSQP0rE+GcUEfgDQha3Ud4jWyyNPGwYPI3zOcj/aLUAdLXI+K5ltPHHgqeTASWa6s9x7F4dwH1JiArr8H0rjvipGY/DlpqYUk6TqNrf47lVkCv/wCOs1AHYjrXn/wgxcweK9WWTzV1DX7p42x/yzQiJR/44a7bWLwadpV9fMMrbQSTEeu1Sf6VyHwQsmsfhR4bR8+ZNbfaWLdSZWMnP/fdAHcUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlX7TuhJrnwf1VvKD3Fg8d3E2MlcOA5H/AGavVahvbWC+sri0vIlmtbiNopY26OjDBB9iDQA3TUgTTbNLPZ9mWFBFs+7s2jGPbFeb/ABK199e8S2vw00OZ0vtRiMurXUXWzsv4hns7jCjPQMPUU+FPHHgS2h0rRtFi8XaLG3l2chvVtbi2iH3Y5NwKuFHAYc4HIrkPgnb3svx0+IeoeIrFdM1uSCA/YhOJtsb4OQ46/dj6cc9ulAHoHju3s9N0Xwr4a0+3EVpdapaWkcES5CwxN5rfgBF1PrXenqa4vVdt78XNBt5ZCi6dptxexr2kkkZYvx2ru/76FdpigDnviHF5/wAP/E0RG7dplzge/lNirPg25a88H6FdNjdNYQSHHTJjU/1rSvLdbqyuLeQZWaNoyPYjFcX8DL/+0fhP4dkON0ULWxGc48t2j/kooAb44WW7+Inw+slBMS3F3eyY7eXDhc/jJiu8PWvMtN1az1v9oG/gtJTN/YeifZ5MH5UmkmDMPrtCj/8AVXplABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeV/tFyG08KaBqZXMem6/ZXUhx0UMw/mwr1SuG+OOlyax8JfE9rAAZltTcJn1iIk49/koA7e5nS2hmnmO2KJC7n0AGTX5/3vifxpF4kupfDB1LRl1SdpotN0vfGCGJK7Y19R3Ar7k8OXqeJfAOnXsrFk1HTUeTHX54xu/Hk14n4fjk8W+EvhxJcWcuk+ILiWWwt9Ws5ds6WkCOCw2n+IDbg5xyf4qaA8v0Lx7d6PYRTeKG+I8V6JWW6urXU3jRf7g8uVCpbGeCe35ZfjTxJ4t1u8N9YX/iT/AIRWVwLNtcnADMoGSduEJDZIx7V9Kax8Fhqcduk/jXxPcrG+5xfXAuQ3+6GGFPvzVy9+GfhWS8sYfFmvanrJQ5t7LVtSBjLdMrGAvp0FPQR4Za+IviRF8GtY1HWtaivtM1hnsrcSy77pODvdCP4CFZSCc85AGcn6m8Cokfgfw6kZyi6bbhfp5S15pe/D/wAN6P8AF7S49N02KCHU9IvIfs6MfLRwFBcJ0GVcrxXX/BG7e9+E3hmSXO9LXyDn/pmxj/8AZaTGdvRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBRXkOgboP2o/FEcgAF1oME0fqQrop/XNeu15B4kt2079p3wjqGSIdV0i4svq0e6T+RWgDzL9oXxN4v1Lx3BceDo72LSfDshthqdsh8tblgPNVnxwB8qkHjg+tY2mfGjx1cXcVp4j1a4tLCEH7Td6XYwyTE9gN2F545H617T4Mn1Gz1vWfh5psE2ly2Hm30mtMFmM6zSllZFIxvO4glsgbDx6b6eA9StmSS08RQPdKOLm90e2llVv7wZQnP1zT0A+YvEXx58eh57TSNUnNhIzRwXFxYxxXDL0BO0YBx3HfvXs37Nfiu107wzp/hDXLWfSdWVGuLdrs7UvldyxaMnGSCcbRn19cdza6R4+jvYor7WPDepWQb5rmbTXS4Vf9lVfZn61n+NLDw9aW91pfxA1Y3ei38MlzFNqbxq8EyEbhCyqpBwylVAJ+U4zkijQCh4Fsrex/aE+IoXiW5tLK4UY6gphj/31ivWq+efh/qt1pPj/wANan4ll+zR3nhIi7u7w+X8sc7eW8jNxuMYTOfWofHnx8uLy/hsfAcQjszMiSalcxfNMC4BESH7qkfxMM88AcGt6GFq4htUot2V35JdSJ1Iw+Jn0ZRSkYNJXOWFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABTLhI5LeZJgDEyFXB9COax/FHi3QPCsKSeIdWtbAOMokj/O/+6gyx/AV5v48+MOkHwPrc2jad4iuo5LOWKO+j06SOBHYFVYuwGACQelAGl+zLqL6h8HtIDhv9Glnt1ZgfmVZGI/QgfhXD+FtI8R+GfH/AIrufA3heLWtOt7xrWCW9vxCbYtiSWKJWOAuWHOPTnrXs3w1sY9M+Hnhq0hRUWPToMhe7FAWP4kk/jWbfTS6F8UdKS2wNP8AEMMyXMfYXMKBlkHoSgKnHXaO4pgcHqOr/GPUfE2l2NzbaV4T0u+ma3FxF5d44Oxn55POFbGABnrXaWHwk8JR27f2tp/9tahL81xqGoOZZ5W7tuz8v0XFXNUtJdU+KWkLPO0dnpNi99FCDjz5pC0W4+oRc/i4q949upU0RNOtNwu9XmXT42U4KBwd7/8AAUDt9QKQHDfCXwvCfGWseIbfWbjV9EtFOm6K07FxCmczBGP3lDAIG7gHrWt8AZ5Jfh80Uihfs+pXkKgdgJ2P9a73SNOtNI02007ToVgs7WNYoo16KoGB/wDrrhfgRbrb+BZvLdXSTVL11ZTkEee4z+lMD0OiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXlnxU3f8AC1PhV5WPO+23f12eUu79K9Trybx6/nftBfDO3/55wX83/kL/AOtTQF/4p6vdeBNWt/GsEVtdaebcaff2jzCKV13lo3hJ+8wLPle4Ptkc2/7QenT6a+o6Zokktrb7TdR3V9Fb3AUnH7qIkmU+wxXZfFUDTJND8UTxQXNjpFxtu4JlDARTFUMqf7aHBHsWqL4z6Voc3g68N1otje6teYsdO3RKJTcyfLHtfGRg/N16KaQFC2/4WD42klv4L0+C9H2g2Vu9sk93Mf78wbhB/sjn19Ty/wAUvENpoj+C7n4gWthqviCwjuJjpVp84llOFjmywwifLnLDgngHFe0eGrK503w5pVjf3Bubu2tYoZpySfMdUAZsnnkgnmvM28GaV8UNW8U6j4hM728N3/ZumPE2yS0EIxJJG3Q7pC3BBHyjIrWk6amva35ett7Eyvb3dz548c+L9b8dakl54inTyoifs9jCMQwD+bt/tN+GK59wxA8uRo3BDK69VIOQefcV2PxL+HmtfD2dX1FkvtHlbbDqMK4x/syp1Q+4yvuOlcjCklzNbw2vltLcSxwx7mwu52CgkgHjmv1vLauWPBS+rW9mk+ZdbW1v1/rQ+crxr+1XPv0/4B2lt8V/H1vP5q+KLiU5yUmtrdkb2IEYwPoRX0p8HPGsvjrwedQvLeODULa4azuliz5bOqqwZc8gFXU4PQkjnrXylq3g3xFpuux6P5On3t84JZbK7EggH96XgFF9z17A19Gfs5aOdB8O+ItNaYzvDrGXkIxuZrO1Zsegyxx7Yr4jP6mUzpw/s9e9fW10red+tz1cGsQpP22x6zRRRXyx6AUUUUAFFFFABRRRQAUUUUAFFFFABQTgEjHAzz0orhPidcLc3/hjw5eTyWul63dvDdyoxXzFRCy2+7t5hwOOSAQOtAHHeEviN4OsfB6a3czQ6r4ruLhkntbdVmvprosRsjXrsHAUj5QoHfiqXxR1b4mar8N9fvbnS9G8OaN9mzLbzTNcXrRHG4ZUbFyD0IyPrWz4U0Hw23x/12bSbDTraTQtLt7dYraFUCyylmZ8DjcFwufQ163eW0F9aT2l5Ek1tOjRSxuMq6kYII9CKAK2gPBJoOmPaYNs1rEYsdNmwY/TFcv41txdePvAMY37orm6uDtP8KwEc+2WUfjUXw2c6Bc3vgW8uHln0tRPYPJ1msXPyc9yjZjP0WrXmQah8XhEsjNJpGkFigHyhp5B199sX60AWNaSWT4k+GPs7hRFZ3slwMctGfJVR/30Qfwovs33xM0yAf6vS9Plu3/35mEaf+OpL+dVtCjbUvib4k1STeI9Ngh0m3GflJIE0px65aMf8BpfCkhufiJ44k5KwtZWqsR/dhLkD8ZDQA74qeKbnwn4UNzplv8AaNXvbiPT7CM/dM8pwpb2GCffGO9cV8N/Dvj74bW9tp1/Pp2v+GvOw4t8x3NrvO5pRuADIGY5GSccj0rN+Ir+Kfild2UXw8itI9G0PUUuRqd3Jtju7mMkDygAdyKSQW6E9OnO/D4m8QHUE8M/Fjw5ZW+m6xm1g1LTZ3NrI7DiF8nchbkA5GTxjqafQD07TdQstUtFu9LvLa9tWJCzW8qyISOvzKSKs14x458Kab8Lre08aeCrWXT4dNmjTVLG3kYxXdozBXJQkguu4MG9iTmvZYpEmiSWFg8UihkYHggjINIB1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRSjrQBg+NfFOneD9Al1XVjK0YdYooYV3Szyt92NF7sf6GvDtJ8U674m/aS8JHxB4bn8PCCxuvs0Nw255FaJyWJwB2xjtg133h6N/iF4+Pie5XPhnQZJLfRlPK3Vx92S591GNqn2J4Iqt43J/4aK+Gwzx9k1A4HX/VGmB1nxeSN/hf4oEuNv8AZ8pGRnkLkfriuB/aDu7jTvh/4L1kuxbT9YsbmUjgnCtk/n/Ouz+NkjH4e3tjCf8ASNTng0+L/ellVT+ma5D9p2BtR8HWegW0chdvM1AlOdsdsmTn/vsflQgPaHkVI2lYgIq7ifavJ/DPi+38J/BHTtfvYXubm8kkeG3j4e5nmmdkQfXPX0B69K7LUfEGlWHgODUtd1COysrmzQGV+pLpwFUcs3PQc14jovjPRL3xH8LvClvbalHZaZOc3WoW3kJNMsRWMoCTklzkfUUAafi7wL8W/Ft/Y63c6x4f025skc22nQhnWMuMMGLKys2MDJyK84+H/gvSby81Gw8S2d7D4g02cC7tGnEcW7OVdFiCjaSOgyOnXIJ+t9fsb6/t449N1abS5Vfc0kUMchcf3SHBH5V4he+CrSw+PMMfiO91W7g8RaezRXq3DWublCN0WYivGxAQPpirjUlBPldr9hOKe5ZA0fw1poA+x6bZKenyxqT/AFY/ma7j4PW90mna9eXNnc2sOoan9othcxmN3iFtbx79h5UFo3xkA4GccitrRPAvhnQ7sXlhpEP25fu3dyzXM6/SWQs4/OulrMYlFFFABRRRQAUUUUAFFFFABRRVW41GxtpTFcXttDIOSkkqqfyJoAtUVTGq6cemoWf/AH/X/GrME0U8e+CWOVM43IwYZ9OKAH1yvxRPh9fAuqyeLVgbTI4jJiR9h8wAldh6h89Mc11VeIfGaTSZdR8Xw+JpbcSR+HSdGiuyBGXbf5jR54Mu4Rjj5se2aART+GmgWfgGXwDrFsjEeJ7Y2upXM0hZnmlUTQdT1yCn/wBevfO9ecab4T07xn8HPCel3V1KkUFrYzx3Fq43JJEq9Dzzwy+1ejnk0Aec/Fu2vdLudC8aaPbNcT6HMwvooxl5bGQYlAHcrgMB2wTV3wLNFqPjbxjq1oGlsrn7Eltdqv7uZFgydjfxYZyD6Hiu5/lXmGhzR/Drx4PDc8jJ4c1+Rp9IZ2G21uc5kth6K2QyD1JAyTQBq/CzUl1O98cSAEND4intzz/cjiQf+g1xOv6tcWfgX4qXdtM0V1ca42nxODyu5YIePQgMa6H4I6Td6Df+PdP1A77g6/LdCT+/HKiOhx24NcLqRW/0O90CPY91r3j2ZFUZyI45VeST6KEGfrTQHvOhaTa6BodlpWlwrHa2cKwxIPlzgdT7k8k+pJrxv4z+KtUv/By6BqPg/VNP1LUdQtra3nLxzWyP5ysrCVT1+XgYB5r3RuteSfEa11S8+Mfw+sJNW/4kVxcy332Hy1BWa2j3A7sZKncOCeDn2wID0rxPpceueHdV0qXiO+tZbYn03oVz+tcn8CdYfW/hH4auZQRLFbfZHBOTmFjFk/UID+Nd8PvV5b8ALi2h0DxB4fhJWfQ9bu7Z42PIUysyN9Dkj/gJpAeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFeZ/EfW77X9dT4eeFpTHf3cQl1e/XkafaHqB/00ccAehz3yO+13V7HQNHvNV1a4S2sbSMySyueAB29yTgAdyQK8/wD2ebix1XwNNr9vufUtWvp59QlkH7wybztU+wTbgdAD70AeiaTp1ppGl2mnadCsFnaxrDDGvRVAwK8y+JUc1j8aPhlrMgUad5l1p7P3WWWMhAfY9voa9Xrgvjnpst/8NNSuLTi+0tk1O2cdUeFg5P8A3yG/OgCT4mBbnWfAunlwGl1xLjB7iGKR/wCeKxvHFtca38Q9U0u0XzJI/CN2qKG6SzvsUexISrWu3kWs/Ev4Y3VuQ9vJa318vcbWgjCn/wAfqfwyQfi18QbyUhVtbewgVj2Xymc/zpgeWeBkbxL/AGV458RfbLjR/C8y6bZ6fawtNgxxKpnKjkneVJPJ49AK7P4jePfA/ibwJq9nPeqt/wCS/wBjiureSKZbgKTGyblBB3Y5HvV39mIqfg/prrEyb7i5YsRjzD5rfMPUdB+FdD8ZNWs9C+HWs6jeQxSzLA0FsHQMfOkGxMZ92z9AaALPwo1a8134b+HdS1Ni97PaL5znq7D5S344z+NZHx0sbi88FwSaZLHBrVvqNq+nXD/8spzKqg/TDEGup8FaSdC8IaLpTAB7SzihfH98KNx/PNcj+0M8tv8ACrUb2B9ktlcWtyp91nT/ABo6gbPwy8R33iLw/ONcgjt9c026ksL+OI5TzUx8y/7LAg/jXW153oCvpHxn1233N9h8Q6fDqcAK4VZYsRSKPcgoxr0SkAUUUUAFFFFABRRRQAUUUUAFfGPx2t4ZfjJ4qaWGN2823GWUH/l0gr7Or42+OX/JY/Ff/Xa3/wDSSCvpuE4RnmKUlfRnDmLao6Hn/wBjtf8An2h/79ivoz9kRQmheKUT5YxqCYQcAfuh0FfPdfQ/7JA/4kfio/8AUQT/ANFLX03GNKEMFFxil7y6eTODLJN1Xd9D3qvNP2h7SxvfhrdWt1Z2t1fXc0Vnp/nKMpPI4UFT1BAyePT0r0skKCzHCgZJrxrwv4Zm+KF9b+NvF9xdJYxXXm6FpcT7Et4434lk/vO5XJ9vbAH5me6el+CvDlp4R8KaZoWnj9xZQiPd3durMfqxJ/GtqlPJpKACuf8AHnhOw8a+GrjR9SLxhiJYLiP/AFlvKvKyIexH8iR3roKKAPJrTxFcfDe7uv8AhPLC5miuBGJPE9lC0kVwEXapnjXJicDA4BDVz/wUsbXxd8RNf8daeZv+Ect7iaHSYpm58+XDXEu3+HOeAeze1e8kBlKsAVIwQehFV7GxtNPhMNhaW9rEWLlIIwilj1OB396YFmvK7CM+If2idSvfvWXhfSo7NPm4FzcEuWH/AGz+U/hXqgwOTwBzXl/7P22/8M634i6vrus3d4HPXyw+xB9BsP50gPUK8w8CuifHH4nQQxKiGPTZHKjG5zC3P5GvTx1ryv4UyG++JvxU1EhQDqNtZDH/AExiK/1oA9TooooAKKKKACiiigAooooAKKKKACiio7meG0tpLi6mjgt4lLPLKwVUA6kk8AUASUV5B4v+PfhnSGkt9Aim8Q3anG63by7YHPeYjn6oHFX/AIEeLfEvjix1nWvEK2cOn/aBbWMFrGVAKA+Y2WyW5ZRnOMq3ArolhK0KSrSi1F7N9fTuQqkXLlT1KfiewPxF+LR8N6g+PDPhmKC+u7X/AJ/bmQExq3+wq849cjvx6nZ2FpYtcNZW0UBuJPNl8tdu99oXcffCgfhXlHwT086r4x8d+Nrq6me6u9Tl0uODOESGEqFyO7YwPbB9a9grnLCqPiDS4tb0HUtKnkkihvreS2eSI4ZQ6lSR781eooA+d/CNxdeBvH3hbw/48ubayt9Gsrq10/VJWKxX6SMmxdx4RlVcEE9h6jNvxhq13p+ifEpoG3ah4g1WLR9MVcHzi0MafLj0Rm59a9u17RdM8Q6ZJp2uWNvf2Un3op0DDPqPQ+45FedeFvgZ4V8NeLLTXLGbUpvsZd7ezuphJDC56MoxngdMk9j2pgeheFtGg8O+G9L0e0AENjbpACBjdtABb6k5P41wvxjZNS1zwF4a8sSHUNYW6lQjIMNupd8/mK9N6muGvXt7r426VbvFG89joc9yjnrH5kyJkfUKw/OkB3R6157+0Bbm7+EHiK3VtrSpCit6EzR4/WvQTVXU9PtNUsZLPUreO5tZCpeKQZVirBhn6EA/hQB5Fa65KPDXw212/JfULHUxot6c9DIrQOW/4EqNXs5615z8c7KC2+E/iG4s4IoJYXjvwyKFzKsqMXOOpOOtegWs4urSC4UYWaNZAPYjNAEtFeL/AB78Q+LPBGraJr/h3UQul3ObO6s7iISwGYZdCRwy7l3glSv3F9ai8I/tBaNebIPFdjNo9wcA3MWZ7Zj6kgb0/FSB/ershl+IqUfrFODcFo2tbevVGTrQjLkbsz22iqmlalY6vYx3ulXtte2kn3ZraUSIfxBxVuuM1CiiigAooooAK+Nfjl/yWPxX/wBdrf8A9JIK+yq+Nvjl/wAlj8V/9drf/wBJIK+o4Q/5GK9GcGZfwPmcPX0T+yR/yL/ij/sIr/6KWvnavor9knH/AAjvif1/tJf/AEUlfT8af7lH/EvyZwZX/FfoeqfEbXh4Z8C63q//AC0t7ZhEMZzK3yoMf7zLUXwv0XUPDvw/0PSdZuFuNQtoMTOowASSwX/gIIXPfFW/HehHxL4N1fR1IWW6t2WJj0WUfMhP0YKay/hH4tfxp4C0/VrmMxX43W92mMATIdrEexxn2zjtX5ge8djRRRQAUUUUAFFFFAHL/FHWU8P/AA58Sam8nltBYyiNvSRl2p/48y034U6Knh74a+GtMjVkMNjGzg9fMcb3/wDHmasj4/7D8HvEayRiQPHFGFP95pkAP4Eg/hXfQR+TBFETnYgXP0FAEg6ivO/hOtsmtfEJYFKzf8JDK0oPXmKMg/TOa9EHWvHvAU8+kftCfELRbqN0i1S3ttVtWYYDqqhHK+vzOR/wA0AewUUUUAFFFFABRRRQAUUUUAFFFFAHmHxz8f6x4E07S20WwtZmv5JITd3JZkgZVDBdgxuLDcR8wxsPWvl/xL4g1rxTcCbxLqt1qTKdyRysBDGfVYlwgPvjPvX118ZfDDeLPh3qthbx+ZfwoLuzAGW86P5go92AKfRzXxhDIs0SSIcq4DD6GvvODsPg68ZupBOpF7vXR9ltv1PIzOdSDVnoxLjzBbyeQB5u07c8DPavpP4H/E/wXYeE9H8MTzyaJe2kQjK6hhUnkJJdll+6csScEg84r5wprosiFZFVlPUEZBr6XO8jjmsY3m4uO3Y4cLinh29L3Pp39nBHtp/iBaNerMsWvzOsI52Bv4w3cMAMf7tezV8o/sq6gmlfEXU9IDFINTsBLGmeDJE3Qf8AAWY19XV+U4/CTwWIlQnvE+hpVFVgprqFFFFchoFFFFACjrXn/hSWHUPjB46uDgz6fb2Nih24wjI0jD8WP6V6AOtefeCUm/4Wx8SZZGBhLaciAdiLck/+hCgD0CiiigDjPjTGJfhN4rUgkfYJGwPYZ/pUyeMNA8PeDtGvdf1W006OWxhkRJpAJHBQcKg+Zj7AGr3xCtjeeAfEtuOGl024UfXy2xXwjpkcZtIJwuZXjUs7Hcx46ZPNe3kuTPNakoKfKo6vr9xy4rErDxTte57j8ZfjBpfjDw1e+HdA0m4mhnZCNRvD5IjZHDK8ceC56fxbOteNDpz1oor9OynJ6OVwcKTbvvc8HEYmWIacuha0XUtQ0K++26Ff3Wm3Z+9JbSbN/s6/dcezAivrL4DeKNb8YeBDqfiMRNMLuSCCeOLy/tESBRvIBxnfvHAA+XpXyA8VxcvFaWKGS8upEt7dB1aRyFX9TX3d4R0K38M+F9K0SzA8mxt0hBAxuIHzN9Sck/WvjuM1hoVIQpwSm9W126f0z08s52m29DWooor4c9UKjufO+zS/ZfL+0bD5fmZ27scbsc4z1xUlFAHzL4g+NXxH8O65daTrWi+HbW9gOdhimIdD910bzMMpx1HoQcEEDynxLrl94m8R6lrmqpbR3l86O6WwYRrtiSMYDEnogPXvX178UPAGnePtEFvckW2pW+Wsr5Vy0LHqD/eQ4GV79eCAR8fa7o+peHdauNI121NrqEHJXqkiZIEkbfxIccH8DggivveE6uAnNLl5ayXd2kvLz7r5ry8jMY1kt7x/IpV13w8+I+veAbTUbXR7XS7iG8uPtDG7WQsp2hcfKw44rka9A+EHw0ufH1/9rvRLb+GLd9s0yna10w6xRn07M46dBzyPpeIHgo4W+O1SeivZt+Rw4P2rqWpbns/wT8deMvHVxc3mr6VpVr4fiBRLqBZFaeUHBVAzHKju3TPAyc40vgkG0+08UeH5W/eaTrVwiKevkyESRn8dxr0Gxs7bT7KCzsII7e0gQRxQxKFVFAwAAOgrzPxG7eCfjDYeIHYpoPiaJNMv2J+WG7T/AFEjegZcp7ck1+QVJRnNyirJ9Ox9JFNKz1PU6KU8GkqBhRRRQAUUUUAcJ8YCJ9H0HSjjGqa3Z2zDGcqJPNbj6Rmu8bqa8g8W+ItI1D9oHwl4dvNQigbSoJrwRscCa6lXbHFnoGCEuPXcB1NevnrQAleWfFq5t/Dfjz4e+Krp0ito72XSbmQnb8txGdhY9NqshbmvU6xPGnhfS/GXhu70PXIPNs7gdRw8Tj7roezA8/ocgkUAbhGDSV5X8LvE9/o2rN8PPHE+deskzp16w2rqdqPusD3kUAhh14J5IY16rQAlFFFABRRRQAUUUUAFFFFACjg18TfFXw6PCfxE1rTI08uzkk+22gxgeTLlsD2V/MQeyivtivGP2jvh3qPjOLQbvw/Dv1COf7DcEYGLaXq5PohX/wAfNexkeZf2di1WfwtNP+vWxzYuh7eny9T5omtdRtNLs9T1LTbq00y9+a1vJEPkzDJA+boCcZwe3PSmAgjI5B6GvvSy0mxs9Et9Hjt4206C3W1WCRQymNV2hSD14FeZ+KfgN4R1cyTaQtxoF22TmxYGEsfWFsqB7Jt+tfR4HjSUXy4uF13W/wB235HDVytPWmz5q8Ia7/wi3jfw/rzZ8qzugs+P+eUg2P8Aoa+7UdZEV42DIwDKw5BB718j+NPgR4v0uzuTYfZNes9pGbTMVxjH3vKbIJ9lcn0Fe2fs6eIrjxB8MbOPUElTUdKlfTbhZVKsGjxgEHkYUqOe4NeTxJicLjqscVhpXurNbP8ArY6cDCpSi6c0em0UUV80dwUUUUAKvUV5h8B7xta07xV4hcEjVNduHhY94UCpGPw2kV1vxF1n/hH/AAF4g1USiKS1sZXic9pNpCf+PFa4P9lnV7K/+Een2Fudt7pryRXcTDDKzyM6tj0Ibg+x9KYHrtFFFIClrlubvQ9RthyZraSMfipFfn9o3/IMtweqjb+RxX6Hr1r5Z+GfwS/4SGHVJta1iWyis9TuLJrWzhXf8jdfMYkDOeBs6YOea+i4czWjlladStezjbTvdHFjcPKvFRj3PIZJEjUF2C5OBnufQe9dHqXgbxRpvhAeKNQ037HpAmjjZLjKzlXO1ZNn8K7io+bB56Y5r6v8H/DTwp4SkSfSdKja+UY+2XJM0/4M2dv0XArd8V6JbeJfDWqaLegGC+t3gYkZ2kjhh7g4I9wK9HGcZV6s19XjyxTXm35eX9amFLLIRT53dnyz+zr4e/t/4nx3sybrLQoTcsSMgzvlYx9QNzfhX13XmfwB8C3ngXwXJBrSxjW724ee6KMGAA+VFyOCAoz/AMCNel189m+OeOxc6/R7eh24el7GmoBRRRXmm4UUUUAFcd8T/AGm+P8AQxa3h+zajb5eyvkXLwOf/QkOBuXv7EAjsaKqE5QkpwdmhNJqzPkvwP8ABjxFrPiyfT/FNnNpukWD4urhDxeeiwN3VhyW6gccN0+rNOsbXTLC3sdPt47azt0EcUMa7VRR0AFWaSuvHZhiMfNVMRK7SsZ0qMKKtBBWV4r8P2Hirw5f6JqyM9neR7H2nDKeqsp7EEAj3FatQahe2+m2FzfX0qw2ltE000rdERQSSfoBXEann3wC1DVb3wVeW2uak+p3Wm6ncaet04G50jIAye/fk816RXkv7NFrqC+BdQ1O+TyrbWdUn1GzhI+ZInIAJ+pUke2D3r1qgAooooAK4b4q/EK18C6ZbxxQSah4g1EmHTNOiQs08vABIH8IJXPc5wPbuh1rz/wzpOk+IfiFrHjQXD3tzYs2i2iSR7VtPK/1pX1LMzfN6HHc0AeS6P8ACawn+I2iW3joy6h4g1TTbrVNTdZioWcyKF2FMY2biOuMrxxxX0vEgjiSMMzBFC7nOScdye5rzi7CH9o7Ty+Qw8MSbCTwx+0jIHuBzXpNMAooopAcv8QfBll400dLaeR7PUrVxPp+owj99ZzDBDqfTIGRnkehAIzfh74wur+7n8MeLUis/GOnpmaJTiO8i6C4h9VbuOqnIIFd1XJ/EDwTZ+L7a3mWeTTtdsCZNO1SDiW1k/8AZkPQqeCPTrQB1lFcf4C8R6jfGfQ/Fdsln4psEBnWMfuruLOFuIT3Rj1HVTwQOK7CgAooooAKKKKACiiigAooooAKKKKAFryvwVdSxfHz4i6cDi2ktrG6CAcb/KClvqc8+uK9UHJryv4YTQ678UfiL4ishvsPOttLhn7SPChEuD6ZK/XigD1OiiigAoork/ip4wTwJ4F1LXvJS4uIQsdvA7YEsrMFUeuOcnHYGgDiP2grmXXp/DXw800lrvXrtJrzaeYrSJtzMR6EjI/3DUvxE05/Bfjnw34t0O6jsLO9u4NJ1aJ1HkvCeEYgdCuCN3bjtkG/8G/CmqRPeeNPGwDeLtZUbkxgWVvwVhUfw9AT36A85z1fxI8OL4t8C61onSW6t2ELdNsq/Mh/76ApgdKetJXD/BXxPJ4s+HOl3t2zHUrZTZXyvncs8Xytu9yMN/wKu4pALXmWoyjwJ8U4b6RjH4e8WMtvOT9231BRiNj6CRRt/wB5cmvTKxvGXhuw8XeGr7RNWVja3SY3KcNGwOVdT2IIBH0oA2jxSVwHwm8S3t9b3/hnxM//ABVOgOLe6Y/8vUR/1dwueoZcZ9+uMiu/oAKKKKACiiigAooooAKKKKACiiigAryv42/aPEd94c+H9i5RdcnM+pOhw0dlCQz/AE3HAB9RjvXqo5NeceBrf+2fid4y8Usd8EBj0OxOeixfNPj2Mh6/7JoA9CtbeG0toba1jSK3hRY440GFRQMAAegAqSiigAooooAZcTxWtvLcXDrHBCjSSO3RVAySfwrzj9ny2uR8PTql4Nkut39zqojxjYsr/KPxAB/GnfFm+n1i+0r4f6VM8V5ru6S/lj+9b2C/6xvYv9wdjkivQrK1gsbK3s7OJYbW3jWGKNeiIowAPYACgDz343QT6bo1h400uEyap4anFyVUHMtq2Fnj+hU7s9tua7vQ9Wsdd0e01XSbhLmwu4xLDKh4YH+RHQjqCCDTfEFqt7oGp2si70ntZYmX1DIRj9a8J/Zxvrrwxovh6znd5vDHiNJJLKd/+XS9VmV4GPo4QlfVgQBkmgD6FopaSgAooooAO4OBkcZooooAKKKKACiiigAooooAKKKKACiiigDjfjD4ok8IfDrWNVtD/p/li3tB3M0hCKR64zux/s1a+GPhWPwX4G0rQ1IaeCLfcyD/AJaTN8ztnv8AMSB7AVzPxRibxD4+8BeF40V4EvG1u9yudsduMID7M74r088mgBKKKKACvK/i1GNb+IHw38MyhHtJr6bU7iNhkMLePcoI9CWavVa8kjh/t/8AaYluUWU23hnRVhd/4RcTkkD8Y2P/AHzTQHrZ60Dg0lFIDx/QTH4I+P2r6O0nl6X4ttxqNqhztW7QkSKO2WG5j/wEV7DXl/7Qfh+41DwZFr+k/LrnhmYapaOBzhCDIv0KjP8AwECu78K67aeJ/Dem63pzbrW+gWZRnJXPVT7g5B9waANSiiigDkPFnhueTxBpvirQIwddsR9nljL7FvLRm+eJieMj7yk9CPfjsD1pKKACiiigAooooAKKKKACiiigAooooAGBKsFbaxBAbGce9ZXhbQ7Xw3oFppNiXaG3U5kk5aRmJZnb3LEk/WtWigAooooAKiu7mCztJ7q7lWK2gjaWWRzgIijJJ9gBUteb/GlrvWLHSvBOky+Ve+IpzHcSDrDZR4ad/wARtUDvuIoAq/Bayk1u71v4iakjC78QSlLFHGDBYRnbGvsWxuPr8pr1KobG0gsLK3s7KJYrW3jWGKNeiIowAPYACvJvir8a9B8O2eo6T4e1W1uPFYYW0SFSYYJCcFpHPyDbySMnkYI60AeuzP5UMkjI7hFLFUXczYHQDufavFPgLpuleMvgCmh36SG1FzcQSKp2SQOJjIpB7Ou5WBrLHwu8Y6rqWlah498VT+KdGUBnstOlMADPwHXbtV0XOc8HHQdq6DRvCp+C9zeajpuoy3Xgq7nD39rdcyWLMQonRx99ckBhjOADzimB6N4R/tiHTpLLxAm+5sn8iO9DAi9jAG2UjqrEcMD/ABAkcEVt0AhlDKQykZBB4IopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFQabZDV21UWyf2ibcWpuP4vKDFtn0ySat0UUAFFFFAFHXdUt9D0TUNVvm22tlA9xIe+1VJIHvxXC/AXTLuHwW+v6wM6x4kuH1W5JH3Vf8A1aj2CYIHbdiq3x4EutWnhzwValw3iPUUjuSnVbWLEkpH0wv616FqV9p3hzQ5ry+listLsIcs7cLGijAA/QADrwBQBbEgNy0QkjLKgZo8/OMng/Tg/lUlcF8JRe6tb6r4u1S3ktp9emWS2gc8xWaDbCCOxILMfXcDWt4r8R6hp4Nv4Y0U+INSXPmwR3ccK2/GR5jN0J7DHODQBreJZ7a18N6tcagGNnFaTSTgDJ2BCWwPpmvHf2e2ufCBtvCV/dfadL1azXWdDuiNu9XUGWDr95chsDsWPes/wPa6t8SD4tg1bxL4n0LXkd4Z9ImZTb28cqkLtiI+ZcZGeO3POa7LwLpU+mQ+HPCnjq0s5tT0oGbRtQtXOyZYgFPoVcKwBU8MOe1MD1GilpKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKOTXhvgaS8+I3xh17xRFqN/aeHtFKadZRwqUS+UElz5ndN65IHUFQcYrsvjh4iudB8CTW+klv7c1mZNK05UOG86U7cj0wu4g+uK2PB+i3Pha20nw/ZQQnQbLTRH9o3AO1yGGcr/tAs2fXNMDqM85rg9N+EvgvT/DVzoA0OG5sLqR5ZmuPmlLE5H7zhhjoMHIA+pND4neINW0Xxr4OtYvEFpoegX7XC3s80UZO6NQyruk4Xd0/x4roPh1pms6fo9xL4h8QNrdzfXDXUb7FVIYmA2omOoxz6c8epQD/AAJHp+lWt34Z0yxbTotGk8qO3a4aYtC/zJIGYk7WywwehUjtWd8b7tLT4UeI2kXcJbcW4X1Mjqg/9CqHUb630n4tXuo31zBbafb+GxJdSO2NuLglSw9Mb8fj7Vy3hTRPEPxJ1yDxT4xunh8IQ3P23RND8sI0gB/dTT4GTxhgpJyT2HBAPZLeFbe3igj+5EgRc+gGKfSnk0lABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKOtJVTV7+LStIvtRuDiG0gkuH/3UUsf0FAHmvhKQeK/jj4o1tlLWfhyBNFsyRwZmJedh/tA/L9CKreIdAufGnxok0nxTcGTwxpdlDqNlpkZxHdOTtLzf3trBgB0xj1Ob/wCzZCP+FR6bqDndd6pcXF9cyHq8rSsCT+Cr+VO1O7lt/wBo3RIMMsN14emTcejlZt2PqMZ/GmBZ+OfiDUPD/g23TSElEmoXaWDvAuZI42Ridno3y4B/LnFcF4a8J6N4E8Oz+Pfhi+seILpYTHcWE9wB56kjdvUJkOn3sc9Kt6h8Q9S8TeFrzR3t7Gy8b2/iKLTIbeMlljZZQ6zfNzt2qwJH6ZxXu44PGOvagDiNf8If23dad4n0qddH8VxQIBcx5eOWM4LQyrxvTrg8EcEelV/Eeqq3xm8HaPGFeZLK9u5gFyY0KqinPYEhhVPxF4y13TLK60qCCB/F+p388Gh2b4P+jqeJ5MHhAoZsnrwPWr3w38DXWgXl7r3ijUxrPi7UUWO5vAm2OKMciGJcDCAjPQZwDgUgO8ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClpKUdaAPC/F2u2mq/tDaPBqKOPD/hO3Mtxdsn+j295MvyGWToowE2k/xfjXp/iuxg8Y+DtRs9J1CNppE3211azA+VOhDxsGX0YKfpVTQPAWmaf4b1vStQP9oHXJ57jUp5F2mdpSc8dgowBjpjPWuZ8NGP4ceFrTQk0BG8TzpJbWsWmwEi/ERIjmlkA2oCGBYucjJ+lAFvwBY/8ACeeAtJ1zx/pWm6lqsolkjhnt1McAztCqGzjcEDE88n0AFHhf4teGbnTdZm1TUdE0m10u7e0iSO/SXzYkAw6KADg5IAAOccVn+F9S8eeG/B2maEPAr3Wq29v5S3I1GH7Nu7M53bgO5GMntWt4F+EXhTwxY20k2jWF9rIxLcXs0QkLTE5JQNwgB6AAYAHfmmBzHh/4cWnxA8V3fj7xpb3RhuZV/svSZTtjFrGB5bzL1JYjfszgZ5znA9s/lQTmkpAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcX8XY7m98GPo9mk5l1m6g01miUny45HHmMcdF8sPk+9dpS5xQB5J8FpbfwlqeufDq9uJI7qwvJLrS45zzNZSYZSh6MQd27HQ59DjY+Okd9aeCJfEGhER6/ojrcWcuwMQGISRTnqpRjkewq18XPANt498MSWylbbWrYGXTr5TteGUdBuHIVsYP59QK8p074k2th8Mr/wh4gTXtX8aFZLGTSJIHa5JYbflkCkMoGWDcn8MUwNL/hUsB1iy1zxH4g19fGt4n2ptUsoQLS1lVM4IC4AA45IyB2qPT/jgdY8FJpWgytrPj27kksbZba3aMNyQLpwRhF2/Nj1HYZxvtqniXx/p9p4e0nwxq2geG5Ejh1HUdWbyLgwADfFEnLFmAK7zxyeBXpPhrwxofhe0Ft4e0mz0+IKFPkRBWcD+83Vj7kk0Ac/8NvhrpPgZJLmKS51HXbmMLdaneyGSWToSqk/dXPOOvTJOBXcUUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAClyaSigBaSiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACk2J5vm7F83bt34G7Hpn0paKAFzSUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Traction is applied with the elbow in extension and the forearm in supination. The assistant stabilizes the proximal fragment. After traction has been applied and the length regained, the fracture is hyperextended to obtain apposition of the fragments. B) With traction being maintained, the varus or valgus angulation along with the rotation of the distal fragment is corrected.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kasser JR, Beaty JH. Supracondylar fractures of the distal humerus. In: Rockwood and Wilkins' Fractures in Children, 5th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22769=[""].join("\n");
var outline_f22_15_22769=null;
var title_f22_15_22770="Animal bites";
var content_f22_15_22770=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Animal bites (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/15/22770/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22770/contributors\" id=\"au6903\">",
"       Larry M Baddour, MD, FIDSA",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22770/contributors\" id=\"au4656\">",
"       Erin E Endom, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/15/22770/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22770/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/15/22770/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22770/contributors\" id=\"de1811\">",
"       Elinor L Baron, MD, DTMH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?22/15/22770?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANIMAL BITES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Animal bites are a common problem in the United States, with two to five million occurring each year. Children are bitten more often than adults. The vast majority of animal bites are caused by dogs (85 to 90 percent), with the remainder caused by cats (5 to 10 percent) and rodents (2 to 3 percent).",
"    </p>",
"    <p>",
"     The most feared complication of an animal bite is rabies, although skin infection is the most common complication. Some bite wounds can be serious, causing injury and permanent disability. Bite wounds to the hand carry an especially high risk for serious complications because the skin's surface is so close to the underlying bones and joints.",
"    </p>",
"    <p>",
"     This topic review discusses recommendations for care after an animal bite. Prevention of rabies is discussed in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"      \"Patient information: Rabies (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      TYPES OF ANIMAL BITES",
"     </span>",
"    </p>",
"    <p>",
"     The location and type of the injury depends upon the animal inflicting the bite.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Dog bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Victims of dog bites frequently know the dog that attacked them. Most dog bites occur in children, with the highest number seen in boys between the ages of five and nine years old. The head and neck are the most common site of bites in children up to age 10 years, probably because a child's head is close to the level of a large dog's mouth. The arms and legs, particularly the right hand, are the most frequent site of injury for older children and adults. A dog bite can lead to a range of injuries, including scratches, deep open cuts, puncture wounds, crush injuries, and tearing away of a body part. Dog bites rarely cause death.",
"    </p>",
"    <p>",
"     Certain breeds of dog are more commonly associated with bites. German Shepherds, pit bull terriers, and mixed breeds account for the majority of dog bite injuries.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Cat bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cats can cause wounds with their teeth or claws. Two-thirds of cat bites involve the upper extremities (arms and hands). Scratches typically occur on the upper extremities or face.",
"    </p>",
"    <p>",
"     Deep puncture wounds are of particular concern because cats have long, slender, sharp teeth. When the hand is bitten, bacteria can get into the tissue that surrounds the bones or into a joint and result in osteomyelitis (infection of the bone) or septic arthritis (infection of the joint).",
"    </p>",
"    <p>",
"     If infection occurs, it generally progresses rapidly, causing skin redness, swelling, and intense pain as quickly as 12 to 24 hours after the bite.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Rodent bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Rats cause the majority of rodent bites. Most bites occur at night on the face or hands in children five years old or younger. Rat bites are more common in areas where living conditions are poor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Human bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;Children are the most common victims of human bites, usually as a result of aggressive play with another child. Human bites can cause a semicircular or oval area of skin redness or bruising, and the skin may be punctured. Human bites are typically located on the face, upper extremities, or trunk (chest or abdomen).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other types of bites",
"     </span>",
"     &nbsp;&mdash;&nbsp;The bites of most other animals, such as squirrels, rabbits, and guinea pigs, are generally treated the same way as cat bites.",
"    </p>",
"    <p>",
"     Anyone who is bitten by a raccoon, skunk, fox, coyote, or bat needs immediate medical attention, even if the bite is small and does not appear to be infected. These animals can be carriers of rabies, and post-bite rabies medications should be started as soon as possible. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"      \"Patient information: Rabies (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ANIMAL BITE TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     After being bitten by an animal or human, it is important to quickly and carefully clean the wound thoroughly with soap and a large amount of water; this can help to prevent infection. If there is bleeding, a clean towel or gauze should be pressed to the wound to slow or stop the bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Do I need treatment?",
"     </span>",
"     &nbsp;&mdash;&nbsp;Adults or children who have been bitten by an animal or human should see a healthcare provider if:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       An animal bite has broken through the skin and bleeding does not stop after applying pressure for 15 minutes",
"      </li>",
"      <li>",
"       A bone may be broken, or if there is other serious injury",
"      </li>",
"      <li>",
"       A bite victim has diabetes, liver disease, cancer, HIV-infection, or takes a medication that could weaken the immune system.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     It is best to be evaluated and treated within 8 hours of being bitten. Beginning treatment within 8 hours significantly reduces the chance of developing an infection.",
"    </p>",
"    <p>",
"     People who do not meet the above criteria should watch their wound carefully for signs of infection (eg, worsening pain, redness, or warmth, fever, or pus-like discharge); if the bite is near a joint, the person should monitor for pain, swelling, and joint movement. Anyone whose wound appears to be worsening rather than improving should seek medical care. It is not necessary to be evaluated after a cat scratch from a house pet unless there are signs or symptoms of infection (worsening pain, warmth or redness, pus-like discharge, or fever). If the scratch originates from an unknown cat from the outdoors which attacked without provocation, medical advice should be sought regarding rabies risk. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"      \"Patient information: Rabies (Beyond the Basics)\"",
"     </a>",
"     .) &nbsp;",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Antibiotics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common complication of an animal bite is infection. Antibiotics are generally recommended to prevent infection in people with high-risk wounds, facial wounds, wounds involving a bone or joint, and for people with other health problems, such as a weakened immune system or diabetes, which could increase the risk of serious infection.",
"    </p>",
"    <p>",
"     Many experts also recommend antibiotics for any person bitten by a cat because there is a high rate of infection from cat bites.",
"    </p>",
"    <p>",
"     Antibiotics are usually given in a pill form. Some people will require a prolonged course of intravenous or oral antibiotics, especially if the wound becomes infected.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Tetanus immunization",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tetanus is a serious, potentially life-threatening infection that can be transmitted by an animal or human bite. Adults who are bitten should receive a tetanus vaccine (called a tetanus toxoid vaccine) if the last tetanus vaccine was greater than 5 years ago. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      \"Patient information: Adult vaccines (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In addition, tetanus immune globulin may be recommended if the person is not sure of the date of their last tetanus vaccination. The immune globulin provides additional protection against tetanus infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Rabies immunization",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are bitten by an animal that could be infected with rabies MUST seek medical attention to determine if a series of injections is needed to prevent rabies, which is usually a fatal illness. This is discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"      \"Patient information: Rabies (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Sutures (stitches)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some wounds can be sutured (stitched closed) within several hours of the injury, after the wound is thoroughly cleaned. Wounds to the face are usually closed immediately to avoid developing a scar.",
"    </p>",
"    <p>",
"     However, due to the risk of infection, some bite wounds may not be sutured immediately. These wounds may be left open and sutured 72 hours after the injury. When wounds are left open, they are flushed with saline (a salt and water solution), left open to drain, are covered with a dressing, and examined daily to look for signs of infection.",
"    </p>",
"    <p>",
"     Immediate suturing is not recommended for wounds at high risk of becoming infected, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Crush injuries",
"      </li>",
"      <li>",
"       Puncture wounds",
"      </li>",
"      <li>",
"       Bites involving the hands",
"      </li>",
"      <li>",
"       Dog bite wounds that occurred many hours earlier",
"      </li>",
"      <li>",
"       Cat or human bites, except those to the face",
"      </li>",
"      <li>",
"       Bite wounds in people who have a weakened immune system",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Management of an infected bite wound",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who do not seek immediate medical attention after being bitten may develop an infection in their wound. If this happens, surgical treatment and antibiotics may be required. People with an infected wound can be treated at home unless the person is not able to take care of their wound or if there is concern that the infection is worsening; in these cases, hospitalization is recommended.",
"    </p>",
"    <p>",
"     People who are at risk for developing a wound infection should seek prompt medical attention even if there are no signs of redness (see",
"     <a class=\"local\" href=\"#H9\">",
"      'Do I need treatment?'",
"     </a>",
"     above). For example, a person who has a deep puncture wound in their hand from a cat bite should seek medical attention immediately to prevent infection. Medical care usually consists of cleaning and dressing the wound and oral antibiotics that can be taken at home.",
"    </p>",
"    <p>",
"     An x-ray may be done to ensure that there is no bone fracture and that tooth fragments are not buried in the wound. Infected bite wounds are not generally sutured immediately. Severe wound infections may require antibiotics given by intravenous injection",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     hospitalization.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     Adults or children who have been bitten by an animal or human should see a healthcare provider in the following situations:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An animal has bitten and broken the skin. It is not necessary to be evaluated after a cat scratch unless there are signs or symptoms of infection (worsening pain, warmth, or redness, pus-like discharge, or fever).A dog has bitten the hand, foot or head, or has bitten another area and caused a large wound.",
"      </li>",
"      <li>",
"       A bite victim has diabetes, liver disease, cancer, HIV infection, or takes any medications that could weaken the immune system.",
"      </li>",
"      <li>",
"       There are signs or symptoms of infection, including worsening pain, warmth, or redness, pus-like discharge, or fever.",
"      </li>",
"      <li>",
"       Bleeding does not stop after applying pressure for 15 minutes, a bone may be broken, or if there is other serious injury.",
"      </li>",
"      <li>",
"       If the last tetanus shot was more than five years ago, or if the bite victim cannot remember when they received a last tetanus shot. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"        \"Patient information: Adult vaccines (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       If there is a concern about possible rabies",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804631775\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21382741\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/32/28161?source=see_link\">",
"      Patient information: Animal bites (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/39/33395?source=see_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=see_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=see_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=see_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/40/35457?source=see_link\">",
"      Patient information: Cat scratch disease (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21382749\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/55/30578?source=see_link\">",
"      Patient information: Rabies (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20377?source=see_link\">",
"      Initial management of animal and human bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/0/13321?source=see_link\">",
"      Pasteurella infections",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2393?source=see_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1413?source=see_link\">",
"      Rat bite fever",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28038?source=see_link\">",
"      Soft tissue infections due to dog and cat bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/39/20088?source=see_link\">",
"      When to use rabies prophylaxis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31401?source=see_link\">",
"      Zoonoses from cats",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/24/29065?source=see_link\">",
"      Zoonoses from dogs",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26986?source=see_link\">",
"      Zoonoses from pets other than dogs and cats",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000034.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/000034.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?22/15/22770/abstract/1-10\">",
"      1-10",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?22/15/22770?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/1\">",
"      Chen E, Hornig S, Shepherd SM, Hollander JE. Primary closure of mammalian bites. Acad Emerg Med 2000; 7:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/2\">",
"      Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/3\">",
"      Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med 1994; 23:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/4\">",
"      Dire DJ. Emergency management of dog and cat bite wounds. Emerg Med Clin North Am 1992; 10:719.",
"     </a>",
"    </li>",
"    <li>",
"     Edwards MS. Infections due to human and animal bites. In: Textbook of Pediatric Infectious Diseases, Fourth Edition, Feigin RD, Cherry JD (Eds), Saunders, Philadelphia 1998. p.2848.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/6\">",
"      Gandhi RR, Liebman MA, Stafford BL, Stafford PW. Dog bite injuries in children: a preliminary survey. Am Surg 1999; 65:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/7\">",
"      Goldstein EJ. Bite wounds and infection. Clin Infect Dis 1992; 14:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/8\">",
"      Moran GJ, Talan DA, Mower W, et al. Appropriateness of rabies postexposure prophylaxis treatment for animal exposures. Emergency ID Net Study Group. JAMA 2000; 284:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/9\">",
"      Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22770/abstract/10\">",
"      Weiss HB, Friedman DI, Coben JH. Incidence of dog bite injuries treated in emergency departments. JAMA 1998; 279:51.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f22_15_22770=[""].join("\n");
var outline_f22_15_22770=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANIMAL BITES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           TYPES OF ANIMAL BITES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ANIMAL BITE TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22771="ALCL small cell peripheral blood";
var content_f22_15_22771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85991&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Peripheral blood ALK positive anaplastic large cell lymphoma, small cell variant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear with numerous small lymphoma cells. Wright-Giemsa stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ioachim HL, Medeiros LJ. Ioachim&rsquo;s Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22771=[""].join("\n");
var outline_f22_15_22771=null;
var title_f22_15_22772="Nitric oxide: Drug information";
var content_f22_15_22772=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nitric oxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?43/30/44514?source=see_link\">",
"    see \"Nitric oxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      INOmax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      INOmax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F201958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vasodilator, Pulmonary",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7730323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Acute vasodilator testing in pulmonary artery hypertension (unlabeled use; McLaughlin, 2009):",
"     </b>",
"     Inhalation: 10-80 parts per million (ppm) for 5 minutes; commonly used doses: 20-40 ppm.",
"     <b>",
"      Note:",
"     </b>",
"     Measure hemodynamics while on nitric oxide. Doses above 20 ppm should be used with caution; doses &gt;40 ppm provide minimal additional clinical benefit.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Right ventricular dysfunction after cardiac surgery (unlabeled use):",
"     </b>",
"     Usual dose: 20 ppm; dosage range: 5-20 ppm (Argenziano, 1998; Costanzo, 2010; Mosquera, 2002; Paniagua, 1999)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F201952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypoxic respiratory failure associated with pulmonary hypertension:",
"     </b>",
"     Neonates (up to 14 days old): Inhalation: 20 parts per million (ppm). Treatment should be maintained up to 14 days or until the underlying oxygen desaturation has resolved and the neonate is ready to be weaned from therapy. In the CINRGI trial, patients whose oxygenation improved had their dose reduced to 5 ppm at the end of 4 hours of treatment. Doses above 20 ppm should not be used because of the risk of methemoglobinemia and elevated nitrogen dioxide (NO",
"     <sub>",
"      2",
"     </sub>",
"     ), a toxic metabolite.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F201929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gas, for inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INOmax&reg;: 100 ppm (1963 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 1918 L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INOmax&reg;: 100 ppm (353 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 344 L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INOmax&reg;: 800 ppm (1963 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 1918 L]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     INOmax&reg;: 800 ppm (353 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 344 L]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F201914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F201931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In the ventilated neonate, precise monitoring of inspired nitric oxide and NO",
"     <sub>",
"      2",
"     </sub>",
"     should be instituted using a calibrated analysis device with alarms. Sample gas for analysis should be drawn before the Y-piece, proximal to the patient. In addition, oxygen levels should be measured. A backup delivery system should be available in the event of power failure. Do not discontinue abruptly.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F201930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of term and near-term (&gt;34 weeks) neonates with hypoxic respiratory failure associated with pulmonary hypertension; used concurrently with ventilatory support and other agents",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F201954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of adult respiratory distress syndrome (ARDS); acute vasodilator testing in pulmonary artery hypertension (PAH); right ventricular dysfunction after cardiac surgery",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F201956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Withdrawal syndrome (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Cellulitis (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Hematuria (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Atelectasis (9% - same as placebo), stridor (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Sepsis (7%), infection (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Headache (environmental exposure, eg, hospital staff); hypoxemia; pulmonary edema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F201934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nitric oxide or any component of the formulation; neonates dependent on right-to-left shunting of blood",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F201918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Use in patients with left ventricular dysfunction may increase pulmonary capillary wedge pressure and cause pulmonary edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary artery hypertension (PAH) : Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred resulting in acute pulmonary edema.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt discontinuation: May lead to worsening hypotension, oxygenation, and increasing pulmonary artery pressure (PAP).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Doses above 20 ppm should not be used (or should be used with caution [unlabeled dosing]) because of the increased risk of methemoglobinemia and elevated levels of nitrogen dioxide (NO",
"     <sub>",
"      2",
"     </sub>",
"     ), a toxic metabolite. Methemoglobin levels and NO",
"     <sub>",
"      2",
"     </sub>",
"     should be monitored.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lack of response: Worsening oxygenation and increasing PAP may occur in patients who do not respond.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F201923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F201925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F201937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F201949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F201938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Nitric oxide is not indicated for use in adults.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F201927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory status including arterial blood gases with close attention to PaO",
"     <sub>",
"      2",
"     </sub>",
"     , methemoglobin, NO",
"     <sub>",
"      2",
"     </sub>",
"     , vital signs, blood sugar, signs and symptoms of infection.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F201939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      INOmax (AU, CH, CZ, DE, DK, EE, ES, FR, GR, IE, IT, NL, NO, PL, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F201917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In neonates with persistent pulmonary hypertension, nitric oxide improves oxygenation. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which leads to vasodilation. When inhaled, pulmonary vasodilation occurs and an increase in the partial pressure of arterial oxygen results. Dilation of pulmonary vessels in well ventilated lung areas redistributes blood flow away from lung areas where ventilation/perfusion ratios are poor.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F201933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Systemic after inhalation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Nitric oxide combines with hemoglobin that is 60% to 100% oxygenated. Nitric oxide combines with oxyhemoglobin to produce methemoglobin and nitrate. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite respectively, which interact with oxyhemoglobin to then produce methemoglobin and nitrate. At 80 ppm the methemoglobin percent is ~5% after 8 hours of administration. Methemoglobin levels &gt;7% were attained only in patients receiving 80 ppm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as nitrate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Nitrate: At a rate approaching the glomerular filtration rate",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, Committee on Fetus and Newborn, &ldquo;Use of Inhaled Nitric Oxide,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 106(2 Pt 1):344-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/10920164/pubmed\" id=\"10920164\" target=\"_blank\">",
"        10920164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Argenziano M, Choudhri AF, Moazami N, et al, \"Randomized, Double-Blind Trial of Inhaled Nitric Oxide in LVAD Recipients With Pulmonary Hypertension,\"",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 1998, 65(2):340-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/9485226/pubmed\" id=\"9485226\" target=\"_blank\">",
"        9485226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Costanzo MR, Dipchand A, Starling R, et al, \"The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients,\"",
"      <i>",
"       J Heart Lung Transplant",
"      </i>",
"      , 2010, 29(8):914-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/20643330/pubmed\" id=\"20643330\" target=\"_blank\">",
"        20643330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson D, Barefield ES, Kattwinkel J, et al, &ldquo;Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study: I-NO/PPHN Study Group.&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(3 Pt 1):325-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/9480993/pubmed\" id=\"9480993\" target=\"_blank\">",
"        9480993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Inhaled Nitric Oxide in Full-Term and Nearly Full-term Infants With Hypoxic Respiratory Failure.&rdquo; The Neonatal Inhaled Nitric Oxide Study Group,",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 336(9):597-604.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2009, 119(16):2250-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/19332472/pubmed\" id=\"19332472\" target=\"_blank\">",
"        19332472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mosquera I, Crespo-Leiro MG, Tabuyo T, et al, \"Pulmonary Hypertension and Right Ventricular Failure After Heart Transplantation: Usefulness of Nitric Oxide,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 2002, 34(1):166-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/11959233/pubmed\" id=\"11959233\" target=\"_blank\">",
"        11959233",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paniagua MJ, Crespo-Leiro MG, Rodr&iacute;guez JA, et al, \"Usefulness of Nitric Oxide Inhalation for Management of Right Ventricular Failure After Heart Transplantation in Patients With Pretransplant Pulmonary Hypertension,\"",
"      <i>",
"       Transplant Proc",
"      </i>",
"      , 1999, 31(6):2505-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/10500690/pubmed\" id=\"10500690\" target=\"_blank\">",
"        10500690",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo;",
"      <i>",
"       N Engl J Med,",
"      </i>",
"      1992, 327(2):76-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22772/abstract-text/1603139/pubmed\" id=\"1603139\" target=\"_blank\">",
"        1603139",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9447 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22772=[""].join("\n");
var outline_f22_15_22772=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201946\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201947\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201958\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7730323\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201952\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201929\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201914\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201931\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201930\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201954\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201956\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201934\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201918\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299766\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201923\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201925\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201937\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201949\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201938\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201927\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201939\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201917\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201933\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9447\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9447|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?43/30/44514?source=related_link\">",
"      Nitric oxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22773="Fibroblastic osteosarcoma";
var content_f22_15_22773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F87013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F87013&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Fibroblastic osteosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 194px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic appearance of fibroblastic osteosarcoma, which is primarily comprised of malignant spindle cells without obvious osteoid production (A) and rare areas containing malignant osteoid (B, arrows) with pleomorphic malignant osteoblasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M John Hicks, DDS, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22773=[""].join("\n");
var outline_f22_15_22773=null;
var title_f22_15_22774="Estazolam: Drug information";
var content_f22_15_22774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Estazolam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/16/18692?source=see_link\">",
"    see \"Estazolam: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Benzodiazepine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: 1 mg at bedtime, some patients may require 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Insomnia:",
"     </b>",
"     Oral: Initial: 0.5-1 mg at bedtime; initiate at lower dose in debilitated or small elderly patients",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15162459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F167381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F167401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term management of insomnia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F167406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       ProSom may be confused with PhosLo&reg;, Proscar&reg;, PROzac&reg;, Psorcon&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - high; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Somnolence (42%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Hypokinesia (8%), dizziness (7%), abnormal coordination (4%), hangover effect (3%), abnormal thoughts (2%), confusion (2%), anxiety (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (&ge;1%), xerostomia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Lower extremity pain (3%), stiffness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abnormal vision, acne, allergic reactions, agitation, agranulocytosis, amnesia, apathy, appetite decreased/increased, arthralgia, arthritis, arrhythmia, asthma, ataxia, chills, circumoral paresthesia, cough, diaphoresis, diplopia, , dry skin, dyspnea, ear pain, edema, emotional lability, enterocolitis, epistaxis, euphoria, eye irritation, eye pain, eye swelling, fever, flatulence, flushing, gastritis, hallucinations, hearing decreased, hematuria, hostility, hyperventilation, increased SGOT, jaw pain, laryngitis, leukopenia, libido decreased, lymph node enlargement, melena, menstrual cramps, mouth ulcerations, muscle spasm, myalgia, neck pain, neuritis, nocturia, nystagmus, oliguria, palpitation, paresthesia, penile discharge, photophobia, photosensitivity, polyuria, purpura, rash, reflexes decreased, rhinitis, scotomata, seizure, sinusitis, sleep disorder, Stevens-Johnson syndrome, stupor, swollen breast,  syncope, taste perversion, thirst, thyroid nodule, tinnitus, tremor, twitch,  upper extremity pain, urinary hesitancy, urinary incontinence, urinary urgency, urticaria, vaginal discharge, vaginal itching, vomiting, weight gain/loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent use with itraconazole or ketoconazole; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions, including anaphylaxis as well as angioedema, have been reported, and in some cases, following initial dosing. Patients who develop severe reactions should not be rechallenged.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related activities: An increased risk for hazardous sleep-related activities such as sleep-driving; cooking and eating food, and making phone calls while asleep have also been noted; the use of alcohol, other CNS depressants, and exceeding the recommended maximum dose may increase the risk of these activities. Discontinue treatment in patients who report any sleep-related episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disorders: Use caution in patients with depression, particularly if suicidal risk may be present. Pre-existing depression may emerge or worsen during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease. Benzodiazepines may cause significant respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP3A4 inhibitors, moderate or strong CYP3A4 inducers and major CYP3A4 substrates (see Drug Interactions); consider alternative agents that avoid or lessen the potential for CYP-mediated interactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: In older adults, benzodiazepines increase the risk of impaired cognition, delirium, falls, fractures, and motor vehicle accidents. Due to increased sensitivity in this age group, avoid use for treatment of insomnia, agitation, or delirium (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warning/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. Worsening  insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F167394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Benzodiazepines (metabolized by oxidation). Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine.  Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Benzodiazepines (metabolized by oxidation). Specifically, the active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Lansoprazole; Pantoprazole; RABEprazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Estazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; PARoxetine; Sertraline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: Benzodiazepines may enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the therapeutic effect of Antianxiety Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F167372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Serum levels and/or toxicity may be increased by grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11229265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although information specific to estazolam has not been located, all benzodiazepines are assumed to cross the placenta. Teratogenic effects have been observed with some benzodiazepines; however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and &ldquo;floppy infant syndrome&rdquo; (which also includes withdrawal symptoms) has been reported with some benzodiazepines. The use of estazolam is contraindicated in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11229266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Estazolam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (100): $88.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (100): $98.92",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F167352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory and cardiovascular status; CBC and urinalysis periodically during prolonged use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Domnamid (DK, NO);",
"     </li>",
"     <li>",
"      Esilgan (ID, IT, JP, PH, PK);",
"     </li>",
"     <li>",
"      Eslam (TW);",
"     </li>",
"     <li>",
"      Estalin (ID);",
"     </li>",
"     <li>",
"      Estazolam (PL);",
"     </li>",
"     <li>",
"      Eszo 2 (TW);",
"     </li>",
"     <li>",
"      Eurodin (JP, TW);",
"     </li>",
"     <li>",
"      Kainever (PT);",
"     </li>",
"     <li>",
"      Kinzolam (TW);",
"     </li>",
"     <li>",
"      Noctal (BR);",
"     </li>",
"     <li>",
"      Nuctalon (FR);",
"     </li>",
"     <li>",
"      Sedarest (PE);",
"     </li>",
"     <li>",
"      Somnatrol (AR);",
"     </li>",
"     <li>",
"      Tasedan (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 93%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 10-24 hours (no significant changes in elderly)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 0.5-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;5% as unchanged drug, &gt;70% as metabolites); feces (4% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22774/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22774/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergman U, Rosa FW, Baum C, et al, \"Effects of Exposure to Benzodiazepine During Fetal Life,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 1992, 340(8821):694-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22774/abstract-text/1355799/pubmed\" id=\"1355799\" target=\"_blank\">",
"        1355799",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Busto U, Bendayan R, and Sellers EM, &ldquo;Clinical Pharmacokinetics of Nonopiate Abuse Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1989, 16(1):1-26.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iqbal MM, Sobhan T, Ryals T, et al, \"Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant,\"",
"      <i>",
"       Psychiatr Serv",
"      </i>",
"      , 2002, 53(1):39-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22774/abstract-text/11773648/pubmed\" id=\"11773648\" target=\"_blank\">",
"        11773648",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wikner BN, Stiller CO, Bergman U, et al, \"Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations,\"",
"      <i>",
"       Pharmacoepidemiol Drug Saf",
"      </i>",
"      , 2007, 16(11):1203-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/15/22774/abstract-text/17894421/pubmed\" id=\"17894421\" target=\"_blank\">",
"        17894421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9421 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-D60132E406-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22774=[""].join("\n");
var outline_f22_15_22774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167399\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167379\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167380\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15162459\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167381\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167355\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167339\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167401\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167358\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167406\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167397\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167361\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167343\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167394\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167348\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167372\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167349\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229265\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167385\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11229266\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167364\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167352\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167365\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167342\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167360\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9421\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9421|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/16/18692?source=related_link\">",
"      Estazolam: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22775="Prognosis after cardiac transplantation";
var content_f22_15_22775=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prognosis after cardiac transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Allen S Anderson, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Sharon A Hunt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22775/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/15/22775/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 13, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac transplantation has evolved into the treatment of choice for many patients with end-stage heart failure (HF) with severely impaired functional capacity despite optimal medical therapy. Although barriers to long-term survival remain, the outcome among transplant recipients has improved over the past 30 years as a result of careful recipient and donor selection, advances in immunosuppression, and the prevention and treatment of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"     \"Indications and contraindications for cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current survival in adults after orthotopic heart transplantation as well as survival after retransplantation will be reviewed here. The data presented are contained in the twenty-sixth official report of the Registry of the International Society for Heart and Lung Transplantation (ISHLT) published in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORICAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial enthusiasm following Christiaan Barnard's first human to human heart transplant in December 1967 waned when the high rate of postoperative complications became apparent. Although most cardiac surgery programs in the United States abandoned the procedure because of dismal survival within the first year, Stanford University and the Medical College of Virginia persevered. Many of the clinical techniques utilized today were developed at Stanford in the 1970s.",
"   </p>",
"   <p>",
"    The modern era of cardiac transplantation began with the introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -based immunosuppression in 1980. Following the institution of cyclosporine, survival rates improved significantly and cardiac transplantation became an accepted, widely used therapy. As an example, a review of 885 patients undergoing transplantation at Stanford found that the 5 and 10 year survival rates among patients treated with cyclosporine and OKT3 were 68 and 46 percent, respectively, compared to 41 and 24 percent with prior regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/2\">",
"     2",
"    </a>",
"    ]. The decrease in mortality was due to reductions in the 10 year incidence of death from rejection (5 versus 14 percent), infection (16 versus 50 percent), and graft coronary artery disease (9 versus 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were far superior to those obtained with previous medical therapy for heart failure. However, a randomized trial of heart medical therapy versus heart transplantation has never been performed, and the prognosis of moderate to severe heart failure continues to improve with medical therapies (ACE inhibitors, beta blockers, aldosterone antagonists) and device therapies (implantable cardioverter-defibrillator and cardiac resynchronization therapy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link&amp;anchor=H5#H5\">",
"     \"Indications and contraindications for cardiac transplantation\", section on 'Improving survival with medical and device therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcomes among transplant recipients have continued to improve over the past 30 years as a result of careful recipient and donor selection, advances in immunosuppression, and the prevention and treatment of infection. Major gains in survival have been largely limited to the first 6 to 12 months without improvement in the annual mortality rate after the first year. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Survival'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"     \"Prevention and treatment of cardiac allograft vasculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"     \"Lipid abnormalities after cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18458?source=see_link\">",
"     \"Induction and maintenance of immunosuppressive therapy in cardiac transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that may affect prognosis in an as yet undetermined fashion is the increasing use of ventricular assist devices as a \"bridge\" to transplantation and changes in transplant listing priority by the United Network for Organ Sharing (UNOS) in the United States. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OUTCOME AFTER FIRST HEART TRANSPLANT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most comprehensive information regarding patient survival after thoracic organ transplantation comes from data collected by the International Society for Heart and Lung Transplantation (ISHLT). This database includes mandatory reporting from centers in the United States and nonmandatory reporting from sites outside the United States. The 2007 report included data from over 76,000 cardiac transplants performed since 1982 by more than 300 transplant programs. Although center-specific data may vary, survival figures from data like the ISHLT registry are often quoted when providing patients with realistic expectations regarding survival after transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the early 1980s, the reported survival rates were almost 70 percent at one year after transplantation, and the organ half-life was 5.3 years. Conditional half-life, defined as organ half-life in those surviving one year, was 9.4 years. Patient survival has steadily improved since that time. The following findings were noted in the 2007 report from the Registry of the ISHLT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is appreciable mortality in the first six months followed by a mortality rate of about 3.4 percent per year thereafter (",
"      <a class=\"graphic graphic_figure graphicRef68472 \" href=\"UTD.htm?40/46/41709\">",
"       figure 1",
"      </a>",
"      ). The mortality during the first year is 1.4 times the mortality in the next four years combined.",
"     </li>",
"     <li>",
"      The half-life of patient survival has progressively improved from 8.9 years in 1982 to 1991 to 10.3 years in 1992 to 2001 to a projected half-life of approximately 11 years in 2002 to 2005. The major gains in survival are limited to the first 6 to 12 months, with the long-term attrition rate being unchanged (",
"      <a class=\"graphic graphic_figure graphicRef57686 \" href=\"UTD.htm?18/25/18846\">",
"       figure 2",
"      </a>",
"      ). The improvement is probably larger than it appears, since the risk profile of recipients and the age of donors continues to increase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The improvement in survival largely reflects improvements in immunosuppression and in the prevention and treatment of infection. For additional information see",
"    <a class=\"external\" href=\"file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry\">",
"     file://www.ishlt.org/registries/slides.asp?slides=heartLungRegistry",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Determinants of prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors in the recipient and donor are associated with a worse prognosis post-transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Recipient factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 report from the ISHLT registry identified a number of recipient factors associated with increased",
"    <strong>",
"     one year",
"    </strong>",
"    mortality for those transplanted between January 2002 and June 2005, with relative risk ranging from 3.38 to 1.22 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. The two most powerful predictors, requirement for short-term extracorporeal mechanical circulatory support and congenital heart disease as the indication for transplantation (relative risk [RR] 3.38 and 2.13), were present in less than 1 and 3 percent of recipients, respectively. Insulin-requiring diabetes prior to transplantation, or requiring dialysis or mechanical ventilation at the time of transplantation also increased the risk of mortality (RR 1.87, 1.83, 1.56, respectively). The following significant risk factors were present in &ge;10 percent of recipients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recipient with previous pregnancy (RR 1.28)",
"     </li>",
"     <li>",
"      Recipient with infection requiring IV drug therapy within 2 weeks prior to transplant",
"     </li>",
"     <li>",
"      Recipient requirement for long-term mechanical circulatory support device (1.27)",
"     </li>",
"     <li>",
"      Recipient with prior sternotomy (1.22)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were also a number of continuous risk factors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recipient age (J-shaped curve)",
"     </li>",
"     <li>",
"      Recipient weight (U-shaped curve, with better predictive power than body mass index)",
"     </li>",
"     <li>",
"      Transplant center volume (inverse linear)",
"     </li>",
"     <li>",
"      Increasing recipient pulmonary artery diastolic pressure, pulmonary vascular resistance, bilirubin, and creatinine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of a left ventricular assist device (LVAD) prior to transplantation does not appear to affect the rate of rejection, but may be associated with a small decrease in long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest experience with transplantation following LVAD use comes from a review of over 7600 patients from the ISHLT registry in whom such data were available; LVAD implantation was performed as a bridge to transplantation in 18 percent of Registry patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/3\">",
"     3",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Humoral sensitization (panel-reactive antibody [PRA] screen &gt;10 percent) was significantly increased with LVAD use (16.6 versus 7.6 percent without LVAD use), but there was no effect on the rate of rejection after transplant.",
"     </li>",
"     <li>",
"      LVAD use was associated with a small but significant reduction in survival at one year (82.3 versus 87.1 percent) and two years (77.8 versus 83.0 percent); this difference was not related to the presence or absence of humoral sensitization. A similar mortality difference was seen when only status 1A patients were analyzed, suggesting that the difference was not due to LVAD use being performed in sicker patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Increase in mortality was most prominent when transplantation was performed either within the first two weeks or after six months post LVAD placement. This may reflect at least in part the early deaths of unstable patients and the eventual development of device-related complications, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=see_link\">",
"     \"Intermediate- and long-term mechanical cardiac support\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the 2002 to 2005 ISHLT cohort, LVAD use was associated with an increased risk of one year mortality (n = 57, relative risk 1.99). However, LVAD use was not associated with increased risk of five year mortality among those surviving the first year in the cohort transplanted between January 1999 through June 2001.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Donor factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Donor factors can have an adverse impact on early prognosis. The 2007 ISHLT report for the January 2002 to June 2005 cohort identified both donor age (curvilinear) and donor heart ischemia time (linear) as imparting continuous impact on one year mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. A female donor and donor history of hypertension were no longer significant risk factors as they were in earlier eras.",
"   </p>",
"   <p>",
"    Because of the shortage of optimal heart donors, some transplant programs have begun to consider and accept hearts from \"suboptimal\" or \"marginal\" donors (eg, donors over age 63 and those with mild left ventricular hypertrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Long-term outcomes have yet to be assessed, but data suggest that one-year survival is similar to that of patients receiving \"optimal\" donors. However, the short-term outcome is reduced with donors with left ventricular hypertrophy who had hypertension or hypertrophy on the ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Elevations in serum troponin I and T, which are markers of myocardial damage, predict the development of early graft failure and may be useful for heart donor selection. This was illustrated in a retrospective review of 118 brain-dead donors who did not have renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/8\">",
"     8",
"    </a>",
"    ]. Elevated serum concentrations of troponin I (&gt;1.6",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    or troponin T (&gt;0.1",
"    <span class=\"nowrap\">",
"     &micro;g/L)",
"    </span>",
"    had a specificity of 94 and 99 percent, respectively, for predicting early graft failure; the odds ratio of developing graft failure was 43 and 57, respectively. These relationships were not seen with serum CK-MB.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Late mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for late mortality are less well defined. The 2007 report from the ISHLT registry evaluated risk factors for mortality at",
"    <strong>",
"     five years",
"    </strong>",
"    in patients transplanted between January 1999 and June 2001 who were alive at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most important risk factor was repeat transplantation (RR 3.86), (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Repeat cardiac transplantation'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Risk factors present in more than 10 percent of patients included recipient history of diabetes, drug-treated rejection prior to initial discharge, drug-treated infection prior to initial discharge, and rejection between discharge and first year (RR 1.52 to 1.26).",
"     </li>",
"     <li>",
"      Greater number of HLA mismatches (0-4 versus 5-6) was associated with reduced risk (RR 0.78).",
"     </li>",
"     <li>",
"      Donor age was a continuous risk factor for late mortality. The risk curve for recipient age was U-shaped, with lowest risk associated with age 50 to 55 years.",
"      <span class=\"nowrap\">",
"       Donor/recipient",
"      </span>",
"      BMI ratio was inversely related to mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Risk factors for mortality within",
"    <strong>",
"     ten years",
"    </strong>",
"    for transplants performed from January 1991 through June 1995 included repeat transplantation, recipient on ventilator at the time of transplant, HLA-DR and -B mismatches, preoperative diagnosis of coronary artery disease and male recipient of female donor. Significant continuous variables include recipient age, donor age, donor heart ischemia time, recipient height (inverse), center volume (inverse) and panel-reactive antibodies (PRA). When analysis was limited to three year survivors to focus on long-term risk factors, prior recipient pregnancy, preoperative coronary artery disease, HLA-DR mismatches, recipient age, donor age, and pretransplant recipient weight were significant predictors of ten year mortality.",
"   </p>",
"   <p>",
"    Risk factors for mortality within 15 years for transplants performed from January 1988 through June 1991 included repeat transplantation, recipient on ventilator at the time of transplant, preoperative coronary artery disease, male recipient of female donor heart and HLA-AA mismatch. &nbsp;Recipient and donor age were continuous variables associated with 15 year mortality. &nbsp;When analysis was limited to five year survivors to focus on long-term risk factors, only pretransplant diagnosis of \"other\", pretransplant diagnosis of coronary artery disease, number of HLA-A mismatches, recipient age, and donor age were predictors of 15 year mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Causes of death",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four major causes of death after cardiac transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute allograft rejection (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=see_link\">",
"       \"Acute cardiac allograft rejection: Diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infections other than cytomegalovirus (CMV); CMV infection was responsible for less than 1 percent of deaths in the ISHLT registry [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"       1",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"       \"Infection in the solid organ transplant recipient\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Allograft vasculopathy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=see_link\">",
"       \"Natural history and diagnosis of cardiac allograft vasculopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=see_link\">",
"       \"Prevention and treatment of cardiac allograft vasculopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lymphoma and other malignancies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"       \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"       \"Development of malignancy following solid organ transplantation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These causes differ in the time period at which they are most likely to occur, as illustrated by the following statistics from the 2007 report from the ISHLT registry, which identified the major causes of death between January 1992 and June 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. Graft failure (primary and non-specific) and acute rejection occur early, allograft vasculopathy (with associated late graft failure) and malignancy later, and non-CMV infection at any time, but particularly between 31 days and one year.",
"   </p>",
"   <p>",
"    As might be expected from registry data, the cause of death was often not verified. In particular, the rates of acute rejection early and allograft vasculopathy later represent minimum estimates, since it seems likely that at least some and perhaps many patients with graft failure (primary and nonspecific category) had one of these disorders after the period of perioperative complications.",
"   </p>",
"   <p>",
"    In the first 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Graft failure (primary and non-specific) - 40 percent of deaths",
"     </li>",
"     <li>",
"      Multiple organ failure - 14 percent",
"     </li>",
"     <li>",
"      Non-CMV infection - 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Between 31 days and one year:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Non-CMV infection - 33 percent",
"     </li>",
"     <li>",
"      Graft failure (primary and non-specific) - 18 percent",
"     </li>",
"     <li>",
"      Acute rejection - 12 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After 5 years:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Allograft vasculopathy and late graft failure (likely due to allograft vasculopathy)I &mdash; 30 percent",
"     </li>",
"     <li>",
"      Malignancies &mdash; 22 percent",
"     </li>",
"     <li>",
"      Non-CMV infection &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Non-CMV infection represented the leading single cause of death from six months post-transplant through ten year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the combination of allograft vasculopathy and late graft failure (most often due to allograft vasculopathy) accounted for more cumulative deaths than infections alone. Causes of death attributable to \"excess\" immunosuppression (infection and malignancy) were as common as causes reflecting inadequate immunosuppression (allograft vasculopathy, late graft failure and acute rejection).",
"   </p>",
"   <p>",
"    Types of infection in these patients are diverse, including common, community-acquired bacterial and viral diseases and uncommon opportunistic infections of clinical significance only in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The risk of infection in the heart transplant patient is determined by a semi-quantitative relationship between two factors: the epidemiologic exposures of the individual and the \"net state of immunosuppression,\" which is a measure of all of the factors that contribute to the individual's susceptibility (or resistance) to infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analyses of multiple data bases have shown that malignancies (both lymphoma and solid tumors) are more common in heart compared with renal transplant recipients probably due to the overall need for more intense immunosuppression. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link\">",
"     \"Development of malignancy following solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Repeat cardiac transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the factors limiting long-term survival in cardiac transplant recipients, some patients are considered candidates for retransplantation. In the 2007 report from the ISHLT registry, for the most recent cohort transplanted between January 1, 2004 and June 30, 2006, 3 percent of reported cases were retransplants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One-year survival for retransplantation improved compared with prior eras. Patients undergoing retransplantation during 2002 to 2005 experienced a",
"    <strong>",
"     one year",
"    </strong>",
"    survival rate of approximately 85 percent, the same as primary transplants performed during the same time period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. For the cohort retransplanted between January 1999 to June 2001 and surviving the first year, repeat transplantation was associated with an increased risk of",
"    <strong>",
"     five year",
"    </strong>",
"    mortality (RR 3.86). For cohorts transplanted earlier, repeat transplantation was a risk factor for 10 and 15 year mortality.",
"   </p>",
"   <p>",
"    In a preceding report of 514 patients, one-year mortality after retransplantation was related to the intertransplant interval, being substantially lower when the interval is less than two years (60 versus 75 percent) (",
"    <a class=\"graphic graphic_figure graphicRef65624 \" href=\"UTD.htm?36/15/37117\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An analysis of longer term survival data (up to ten years) on 20,787 primary heart transplants and 594 repeat heart transplants from the United Network for Organ Sharing (UNOS) database (from 1987 to 2004), found that repeat transplant patients were 71 percent more likely to die compared to primary transplant patients, after adjustment for potential confounders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/12\">",
"     12",
"    </a>",
"    ]. The magnitude of this difference was proportional to the severity of illness of the patient, with predictors of survival for repeat transplants generally being similar to those for primary transplants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Heart-lung transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart-lung transplantation should be reserved for patients who cannot be treated by heart or lung transplantation alone. Suitable candidates include patients with severe, irreversible disease of the lung parenchyma or vasculature who also have severely compromised left or right ventricular function or other cardiac diseases that would preclude a successful outcome with lung transplantation alone. The two major causes in the small number of procedures that are still performed are Eisenmenger syndrome associated with congenital heart disease and primary pulmonary hypertension with severe right ventricular failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. The outcomes in these patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=see_link\">",
"     \"Heart-lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heart-kidney transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simultaneous heart-kidney transplantation is considered in some centers for patients with combined advanced and irreversible heart and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. In the 2005 report from the ISHLT registry, survival in 336 simultaneous heart-kidney transplant recipients was similar to that in isolated heart transplants (N = 58,343) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. In comparison, survival was reduced in the 449 kidney after heart transplant recipients. Most of the mortality seemed to occur early after kidney transplantation. Limited data raise the possibility that heart-kidney transplantation may be associated with a lower risk of cardiac transplant vasculopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are two other issues related to impaired renal function and heart transplantation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Underlying moderate chronic kidney disease, defined as a stable plasma creatinine concentration above 2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (177",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"      or a creatinine clearance below 40",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      is a relative contraindication to isolated heart transplantation. Part of the concern in this setting is the superimposed nephrotoxicity of long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link&amp;anchor=H20#H20\">",
"       \"Indications and contraindications for cardiac transplantation\", section on 'Relative contraindications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"       \"Cyclosporine and tacrolimus nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Renal transplantation may be performed as a later procedure to treat end-stage renal disease that has developed in heart transplant recipients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=see_link&amp;anchor=H10#H10\">",
"       \"Renal function and nonrenal solid organ transplantation\", section on 'Cardiac transplantation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MEDICAL CONDITIONS AFTER CARDIAC TRANSPLANTATION THAT MAY AFFECT OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension, hyperlipidemia, diabetes mellitus, and renal dysfunction are all noted in a significant proportion of cardiac transplant recipients and the incidence of these morbidities at each post transplant time-point have been increasing over time. In the ISHLT registry, among heart transplant survivors with ten year follow-up between April 1994 and June 2006, the following rates were noted: hypertension in 98 percent, severe kidney disease in 14 percent (serum creatinine greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [221",
"    <span class=\"nowrap\">",
"     &micro;mol/L]",
"    </span>",
"    in 8 percent, long term dialysis in 5 percent, renal transplant in 1 percent), hyperlipidemia in 93 percent, diabetes in 37 percent, and angiographic allograft vasculopathy in 53 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=see_link\">",
"     \"Lipid abnormalities after cardiac transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=see_link\">",
"     \"New onset diabetes after transplant (NODAT) in renal transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     QUALITY OF LIFE AFTER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the ISHLT indicate that 90 percent of patients have no limitation of activity at one and five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"     1",
"    </a>",
"    ]. However, despite generally excellent functional capacity following cardiac transplantation, less than 30 percent of patients return to full-time work; less than 10 percent resume only part-time work and about 40 percent remain unemployed. In the United States, this discrepancy may be in part related to the link between employability and insurability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=see_link\">",
"       \"Patient information: Heart transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=see_link\">",
"       \"Patient information: Heart transplantation (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/1\">",
"      Taylor DO, Stehlik J, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/2\">",
"      Robbins RC, Barlow CW, Oyer PE, et al. Thirty years of cardiac transplantation at Stanford university. J Thorac Cardiovasc Surg 1999; 117:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/3\">",
"      Joyce DL, Southard RE, Torre-Amione G, et al. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/4\">",
"      Drakos SG, Kfoury AG, Long JW, et al. Effect of mechanical circulatory support on outcomes after heart transplantation. J Heart Lung Transplant 2006; 25:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/5\">",
"      Potapov EV, Loebe M, H&uuml;bler M, et al. Medium-term results of heart transplantation using donors over 63 years of age. Transplantation 1999; 68:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/6\">",
"      Marelli D, Laks H, Fazio D, et al. The use of donor hearts with left ventricular hypertrophy. J Heart Lung Transplant 2000; 19:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/7\">",
"      Jeevanandam V, Furukawa S, Prendergast TW, et al. Standard criteria for an acceptable donor heart are restricting heart transplantation. Ann Thorac Surg 1996; 62:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/8\">",
"      Potapov EV, Ivanitskaia EA, Loebe M, et al. Value of cardiac troponin I and T for selection of heart donors and as predictors of early graft failure. Transplantation 2001; 71:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/9\">",
"      Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998; 338:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/10\">",
"      Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/11\">",
"      Srivastava R, Keck BM, Bennett LE, Hosenpud JD. The results of cardiac retransplantation: an analysis of the Joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry. Transplantation 2000; 70:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/12\">",
"      Shuhaiber JH, Kim JB, Hur K, et al. Comparison of survival in primary and repeat heart transplantation from 1987 through 2004 in the United States. Ann Thorac Surg 2007; 83:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22775/abstract/13\">",
"      Groetzner J, Kaczmarek I, Mueller M, et al. Freedom from graft vessel disease in heart and combined heart- and kidney-transplanted patients treated with tacrolimus-based immunosuppression. J Heart Lung Transplant 2005; 24:1787.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3523 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-DB525E7F52-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22775=[""].join("\n");
var outline_f22_15_22775=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORICAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OUTCOME AFTER FIRST HEART TRANSPLANT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Determinants of prognosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Recipient factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Donor factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Late mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Causes of death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Repeat cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heart-kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MEDICAL CONDITIONS AFTER CARDIAC TRANSPLANTATION THAT MAY AFFECT OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      QUALITY OF LIFE AFTER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/3523\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/3523|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/46/41709\" title=\"figure 1\">",
"      Survival after heart transp",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/25/18846\" title=\"figure 2\">",
"      Improved survival heart TPL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/15/37117\" title=\"figure 3\">",
"      Survival retransplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28040?source=related_link\">",
"      Acute cardiac allograft rejection: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/99?source=related_link\">",
"      Heart-lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/1/18458?source=related_link\">",
"      Induction and maintenance of immunosuppressive therapy in cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/57/37785?source=related_link\">",
"      Intermediate- and long-term mechanical cardiac support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/25000?source=related_link\">",
"      Lipid abnormalities after cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18585?source=related_link\">",
"      Natural history and diagnosis of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26250?source=related_link\">",
"      New onset diabetes after transplant (NODAT) in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/5/92?source=related_link\">",
"      Patient information: Heart transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/36/26179?source=related_link\">",
"      Patient information: Heart transplantation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/12/42184?source=related_link\">",
"      Prevention and treatment of cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/28/34250?source=related_link\">",
"      Renal function and nonrenal solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22776="Lumbar spinal stenosis: Treatment and prognosis";
var content_f22_15_22776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lumbar spinal stenosis: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Kerry Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Steven J Atlas, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22776/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/15/22776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar spinal stenosis (LSS) refers to an anatomic condition that includes narrowing of the intraspinal (central) canal, lateral recess,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neural foramena. Spondylosis, or degenerative arthritis affecting the spine, is the most common cause of LSS and typically affects individuals over the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LSS is a cause of disability in the aging population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Treatment approaches are often not straightforward and require careful consideration of potential risks and benefits.",
"   </p>",
"   <p>",
"    This topic will discuss the prognosis and treatment of LSS, focusing on lumbar spondylosis. Other topics discuss more general issues related to the evaluation and treatment of low back pain, and also the pathophysiology, clinical features, and diagnosis of lumbar spinal stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=see_link\">",
"     \"Approach to the diagnosis and evaluation of low back pain in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"     \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of lumbar spinal stenosis (LSS) due to degenerative spondylosis is relatively benign. Among 32 patients with symptoms and neuroimaging consistent with LSS who were followed for a mean 49 months without surgical intervention, symptoms remained unchanged in 70 percent, improved in 15 percent, and worsened in 15 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/4\">",
"     4",
"    </a>",
"    ]. However, LSS causes discomfort, often limiting activities of daily living, and can lead to progressive disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NONSURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, a trial of conservative, nonsurgical treatment precedes surgical treatment. The exception is the rare patient with progressive neurologic deficits, especially the cauda equina syndrome, which indicates more urgent surgical decompression.",
"   </p>",
"   <p>",
"    Nonsurgical treatments used for lumbar spinal stenosis (LSS) have included physical therapy, analgesic and anti-inflammatory medications, and epidural steroid injections. &nbsp;High quality clinical trials supporting the utility of these treatments are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/5\">",
"     5",
"    </a>",
"    ]. Other treatments for low back pain not specific to LSS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link\">",
"     \"Treatment of acute low back pain\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link&amp;anchor=H3#H3\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\", section on 'Glucocorticoid and other injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical therapy is the mainstay of conservative management, but evidence-based support in the literature is lacking. Regimens are not standardized. Stretching, strengthening, and aerobic fitness are usually recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]. Goals of therapy include increased muscular stabilization and correction of posture. Techniques to increase lumbar flexion and reduce lumbar lordosis include strengthening of abdominal muscles. Abdominal corsets or braces can also help reduce lordosis and improve exercise tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/9\">",
"     9",
"    </a>",
"    ]; however, their use is controversial, as overuse can lead to increased weakness of abdominal and other core muscles. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=see_link\">",
"     \"Subacute and chronic low back pain: Pharmacologic and noninterventional treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One randomized study compared two six-week physical therapy regimens in 58 patients with LSS: manual physical therapy and treadmill walking versus lumbar flexion exercises, subtherapeutic ultrasound, and treadmill walking [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/10\">",
"     10",
"    </a>",
"    ]. At six weeks, a greater proportion of patients in the first treatment group reported improvement (79 versus 41 percent); the difference was not statistically significant at one year (62 versus 41 percent). The physical therapy regimens were not well standardized, making specific recommendations difficult. However, this study provides some support for physical therapy programs in managing patients with LSS.",
"   </p>",
"   <p>",
"    For overweight individuals, exercise for weight loss is an important goal to reduce lumbar lordosis and minimize axial strain on the spinal column. Bicycling and aquatic exercise programs may be good choices for patients with LSS. Dietary modification is also recommended as part of a weight loss program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pharmacotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug therapy for low back pain includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal anti-inflammatory drugs (NSAIDs), and opiates. No studies have clearly identified the superiority of one class of drugs over another, but the complication profile of each plays a role in the ultimate choice for the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/11\">",
"     11",
"    </a>",
"    ]. Of particular concern in the older age group is the associated cardiovascular risk associated with certain NSAIDs. The efficacy of these medications in managing isolated symptoms of neurogenic claudication is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of acute low back pain\", section on 'Pharmacotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Epidural injections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of epidural injections of corticosteroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anesthetics for LSS has not been rigorously investigated. Most studies of this approach include a heterogeneous patient population with back pain, radicular pain,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neurogenic claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited available evidence does not support the use of epidural injections in LSS. Uncontrolled observational studies suggest that injections of local anesthetic agents and corticosteroids are associated with reduced pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/15\">",
"     15",
"    </a>",
"    ]. However, a randomized study in 53 patients with LSS demonstrated that patients who received epidural injections of either local anesthetic (mepivicaine) or mepivicaine plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    achieved longer walking distances at one week, but not at one or three months compared with placebo injections [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of epidural injections for the treatment of low back pain in other settings is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of acute low back pain\", section on 'Injections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=see_link&amp;anchor=H3#H3\">",
"     \"Subacute and chronic low back pain: Nonsurgical interventional treatment\", section on 'Glucocorticoid and other injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical treatment of LSS is usually elective, in that the benefit of surgery in most cases is to alleviate symptoms and improve function, rather than to prevent neurologic impairment. Surgical approaches are generally utilized after nonsurgical options have been exhausted and in patients who are disabled by their symptoms. In the absence of neurologic deficits, delayed surgery appears to produce benefits that are similar to surgery when selected as the initial treatment choice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/17\">",
"     17",
"    </a>",
"    ]. In cohort studies of individuals with LSS who initially chose nonsurgical therapy, about 30 percent subsequently requested surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urgent surgery is required when neurologic deficits are rapidly progressive",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    when bladder dysfunction emerges. While this may occur with cauda equina syndrome or conus medullaris syndrome in the setting of trauma or an intraspinal canal tumor, it is very rarely a manifestation of clinical decompensation in LSS due to spondylosis. In the former cases, the degree of neurologic recovery is related to the speed at which the compressive lesion is corrected and the severity of baseline deficits prior to intervention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical approaches for degenerative LSS include single or multilevel decompressive laminectomy with or without lumbar fusion. Lumbar fusion (with or without instrumentation) is generally reserved for patients with spondylolisthesis, a condition in which one vertebral body translates anteriorly or posteriorly with respect to an adjacent vertebral body. In the absence of spondylolisthesis (or other complicated spine pathology) the more conservative procedure (decompressive laminectomy without fusion) is preferred as it is associated with a lower complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/19\">",
"     19",
"    </a>",
"    ]. A review of Medicare claims database demonstrated that as the frequency of complex fusion procedures for LSS increased, over the 2002 to 2007 time period, so did major complications, 30-day mortality, and resource use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Spinal stenosis without spondylolisthesis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Laminectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laminectomy, the most frequently used surgical procedure in this setting, involves removal of part or all of one or both lamina of the vertebra at the involved level (",
"    <a class=\"graphic graphic_figure graphicRef74811 \" href=\"UTD.htm?21/24/21896\">",
"     figure 1",
"    </a>",
"    ). In some cases the spinous process is removed as well; overlying connective tissues, ligaments, and muscle may be transected to gain access to the vertebra.",
"   </p>",
"   <p>",
"    A systematic review of randomized surgical studies of degenerative lumbar spondylosis found some limited evidence supporting the effectiveness of surgical management [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a subsequently-published multicenter study in the United States, 289 patients with symptomatic LSS but no spondylolisthesis were randomized to decompressive surgery versus nonsurgical care and followed for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/22\">",
"     22",
"    </a>",
"    ]. Two-thirds of those randomized to surgical treatment and 43 percent of those assigned to nonsurgical care underwent surgery during the study period. In this study, the intention-to-treat analysis did find a benefit for surgery for a measure of bodily pain, but not for disability or functional outcome. An as-treated analysis, which also included an observational cohort of an additional 365 patients, demonstrated a benefit for surgery on all outcome measures at three months and two years, that was maintained at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/23\">",
"     23",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    A smaller randomized trial of 94 patients also reported a benefit from surgical over conservative treatment that was smaller and diminished over time, with no significant benefit in disability at two years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A nonrandomized, prospective cohort study, the Maine Lumbar Spine Study followed 144 patients with LSS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/25\">",
"     25",
"    </a>",
"    ]. In this study, the 77 patients choosing surgery had more severe symptoms and worse functional status at baseline. Surgically treated patients reported greater improvement in symptoms and functional status compared with the nonsurgical group at one and five years. The relative benefit of surgery declined over time, and was no longer statistically significant after five years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/18\">",
"     18",
"    </a>",
"    ]. Over the 10 years of the study, 15 of 77 surgically treated patients underwent repeat surgery, and 21 of the 67 initial nonsurgical patients underwent surgery. Regardless of the initial treatment group, patients receiving subsequent surgery reported less improvement than those who did not undergo subsequent procedures.",
"   </p>",
"   <p>",
"    Other cohort studies in LSS have reported on the observed benefits associated with surgical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/17,26,27\">",
"     17,26,27",
"    </a>",
"    ]. All of these cohort studies have used heterogeneous and unvalidated patient outcome measures, making it difficult to assess and compare the magnitude of benefit. In general, 60 to 90 percent of patients report some improvement of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    quality of life in the first year after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/28\">",
"     28",
"    </a>",
"    ]. As with the Maine Lumbar Spine Study, the benefit from surgery gradually declines over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Intraspinous spacer implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potentially less invasive treatment option involves implanting a device between the spinous processes at one or two vertebral levels, relieving compression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/29\">",
"     29",
"    </a>",
"    ]. This procedure is said to be appropriate for those patients with spinal stenosis without spondylolisthesis who have intermittent claudication symptoms that are exacerbated in extension and relieved in flexion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A randomized, multicenter study in 191 patients compared the implantation of the X STOP implant, a titanium alloy device, to nonoperative treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/31\">",
"     31",
"    </a>",
"    ]. At six months, symptoms were relieved in 52 percent of treated patients, compared with 9 percent of controls. Benefit was maintained at two and four years of follow-up and was associated with reduced disability and improved quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/32-34\">",
"     32-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subsequent, uncontrolled observations have found that implantation of the X STOP device has been efficacious in many patients, if not in as large a proportion as was found in the clinical trial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/30,35,36\">",
"     30,35,36",
"    </a>",
"    ]. While radiologic improvement in spinal canal and neuroforaminal narrowing can be measured after surgery, these changes are not correlated with clinical benefit and are not maintained over time in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. Adverse effects also appear to be more commonly reported in general clinical experience; these include",
"    <span class=\"nowrap\">",
"     discitis/osteomyelitis,",
"    </span>",
"    device dislocations, spinous process fractures, recurrent disc herniation, hematoma, cerebrospinal fluid fistula, and foot drop [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/40-42\">",
"     40-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear how this newer procedure compares with the standard surgical procedure, decompressive laminectomy, in terms of effectiveness, side effects, recovery time and long-term outcomes. This treatment does not appear to be helpful in patients who have spondylolisthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spinal stenosis with spondylolisthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondylolisthesis, in which one vertebral body translates anteriorly or posteriorly with respect to an adjacent vertebral body can exacerbate spinal canal narrowing and may call for a different surgical approach [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/44\">",
"     44",
"    </a>",
"    ]. Most surgeons include fusion when operating on patients with spondylolisthesis. The addition of instrumentation (insertion of rigid implants such as a rod or screw) in fusion improves the rate of successful fusion but does not clearly impact clinical outcomes, and is associated with a higher complication rate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Similarly, intraoperative implantation of bone morphogenetic proteins has been shown to improve fusion rates, but has not been shown to clearly improve clinical outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. Administrative data of surgical outcomes from the Nationwide Inpatient Sample between 1993 and 2002 reported a 13 percent complication rate that included hematoma, as well as pulmonary, renal, and cardiac complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/51\">",
"     51",
"    </a>",
"    ]. Older patients and those with medical comorbidities are at greatest risk.",
"   </p>",
"   <p>",
"    A randomized study of 50 patients with single level spondylolisthesis compared lumbar decompression surgery with versus without spinal fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/52\">",
"     52",
"    </a>",
"    ]. After a mean follow-up of three years, patients with spinal fusion had significantly less back and lower limb pain and had better physical function. In this study, unsuccessful radiographic fusion did not correlate with poor outcome.",
"   </p>",
"   <p>",
"    A study of 304 patients with degenerative lumbar spondylolisthesis, and either neurogenic claudication or radiculopathy, randomly assigned patients to nonsurgical treatment or to decompressive laminectomy and fusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/53\">",
"     53",
"    </a>",
"    ]. Within two years of follow-up, 64 percent of those assigned to surgery and 49 percent of those assigned to conservative treatment underwent operative therapy. Intention-to-treat analysis found no difference in outcome between treatment groups while an as-treated (nonrandomized) analysis found a benefit from surgery in functional and disability assessments at both two and four years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While potentially effective, the procedure is expensive. In the first study described above, considering the expected benefit over two years of follow-up, surgery was estimated to cost $115,600 per QALY, an amount that is generally not considered highly cost-effective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deciding on surgical intervention in a patient with LSS requires a careful consideration of potential risks and benefits. Patients should know that the benefits of surgery decline over time and that repeat operations are performed in 15 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/17,18,26,27,56\">",
"     17,18,26,27,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical complication rates include mortality in 0.5 to 2.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/28,57\">",
"     28,57",
"    </a>",
"    ]. Other serious complications (eg, infection and deep venous thrombosis) occur in approximately 12 percent of patients. The patient's age and number of comorbidities impact significantly on surgical risk, as does the number of procedures performed by the surgeon and hospital, with more procedures associated with lower mortality and complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/28,57-59\">",
"     28,57-59",
"    </a>",
"    ]. Features of the surgical procedure, including the use of fusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    instrumentation and the number of levels operated on, may also impact complication rates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/20,44,60-63\">",
"     20,44,60-63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have identified varying predictors for outcome of surgical treatment of LSS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/25,26,64-70\">",
"     25,26,64-70",
"    </a>",
"    ]. Predictors of a good clinical outcome after surgery are quite variable between studies. A systematic review identified the following predictors in one or more high quality studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/65\">",
"     65",
"    </a>",
"    ]. Negative predictors were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Concomitant disorder influencing walking capacity",
"     </li>",
"     <li>",
"      Cardiovascular comorbidity",
"     </li>",
"     <li>",
"      Scoliosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positive predictors were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Younger age",
"     </li>",
"     <li>",
"      Better walking ability",
"     </li>",
"     <li>",
"      Better self-rated health",
"     </li>",
"     <li>",
"      Less comorbidity",
"     </li>",
"     <li>",
"      More pronounced canal stenosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Smoking has also been identified as being associated with negative surgical outcomes, including nonunion, delayed healing, and increased pseudarthrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. Animal studies have shown that nicotine administration reduces bone fusion rates, presumably by impairing revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Smoking cessation appears to be beneficial in improving outcomes after surgery. In one review of 357 patients undergoing spinal fusion, the nonunion rate of those who stopped smoking for six months or longer after surgery was similar to nonsmokers and significantly less than those who continued to smoke (17 versus 14 versus 26 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22776/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=see_link\">",
"       \"Patient information: Spinal stenosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lumbar spinal stenosis (LSS) is most often due to degenerative spondylosis, which typically affects individuals over the age of 60 years.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prognosis of LSS is benign in that neurologic disability is rare and most patients remain stable over several years of follow-up. However, for some patients, the symptoms become disabling and restrict activity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with LSS who do not have fixed or progressive neurologic deficits, we suggest conservative treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Physical therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral pain medication are often used, although their efficacy has not been rigorously evaluated (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Nonsurgical treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We suggest surgical therapy for patients who do not have an adequate clinical response to conservative therapy and who are functionally disabled by their symptoms and for patients who have a progressive neurologic deficit (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the absence of spondylolisthesis (or other complicated spine pathology) decompressive laminectomy without fusion is preferred over more complicated surgical techniques involving fusion with or without instrumentation (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      We recommend urgent surgical consultation for rare patients with a rapidly progressive cauda equina or conus medullaris syndrome or newly emerging bladder dysfunction (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Surgical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/1\">",
"      Atlas SJ, Delitto A. Spinal stenosis: surgical versus nonsurgical treatment. Clin Orthop Relat Res 2006; 443:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/2\">",
"      Katz JN, Harris MB. Clinical practice. Lumbar spinal stenosis. N Engl J Med 2008; 358:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/3\">",
"      Ciol MA, Deyo RA, Howell E, Kreif S. An assessment of surgery for spinal stenosis: time trends, geographic variations, complications, and reoperations. J Am Geriatr Soc 1996; 44:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/4\">",
"      Johnsson KE, Ros&eacute;n I, Ud&eacute;n A. The natural course of lumbar spinal stenosis. Clin Orthop Relat Res 1992; :82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/5\">",
"      Ammendolia C, Stuber K, de Bruin LK, et al. Nonoperative treatment of lumbar spinal stenosis with neurogenic claudication: a systematic review. Spine (Phila Pa 1976) 2012; 37:E609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/6\">",
"      Mazanec DJ, Podichetty VK, Hsia A. Lumbar canal stenosis: start with nonsurgical therapy. Cleve Clin J Med 2002; 69:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/7\">",
"      Rittenberg JD, Ross AE. Functional rehabilitation for degenerative lumbar spinal stenosis. Phys Med Rehabil Clin N Am 2003; 14:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/8\">",
"      Bodack MP, Monteiro M. Therapeutic exercise in the treatment of patients with lumbar spinal stenosis. Clin Orthop Relat Res 2001; :144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/9\">",
"      Willner S. Effect of a rigid brace on back pain. Acta Orthop Scand 1985; 56:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/10\">",
"      Whitman JM, Flynn TW, Childs JD, et al. A comparison between two physical therapy treatment programs for patients with lumbar spinal stenosis: a randomized clinical trial. Spine (Phila Pa 1976) 2006; 31:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/11\">",
"      Roelofs PD, Deyo RA, Koes BW, et al. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976) 2008; 33:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/12\">",
"      Cuckler JM, Bernini PA, Wiesel SW, et al. The use of epidural steroids in the treatment of lumbar radicular pain. A prospective, randomized, double-blind study. J Bone Joint Surg Am 1985; 67:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/13\">",
"      Koes BW, Scholten RJ, Mens JM, Bouter LM. Efficacy of epidural steroid injections for low-back pain and sciatica: a systematic review of randomized clinical trials. Pain 1995; 63:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/14\">",
"      Cannon DT, Aprill CN. Lumbosacral epidural steroid injections. Arch Phys Med Rehabil 2000; 81:S87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/15\">",
"      Ciocon JO, Galindo-Ciocon D, Amaranath L, Galindo D. Caudal epidural blocks for elderly patients with lumbar canal stenosis. J Am Geriatr Soc 1994; 42:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/16\">",
"      Fukusaki M, Kobayashi I, Hara T, Sumikawa K. Symptoms of spinal stenosis do not improve after epidural steroid injection. Clin J Pain 1998; 14:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/17\">",
"      Amundsen T, Weber H, Nordal HJ, et al. Lumbar spinal stenosis: conservative or surgical management?: A prospective 10-year study. Spine (Phila Pa 1976) 2000; 25:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/18\">",
"      Chang Y, Singer DE, Wu YA, et al. The effect of surgical and nonsurgical treatment on longitudinal outcomes of lumbar spinal stenosis over 10 years. J Am Geriatr Soc 2005; 53:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/19\">",
"      Carragee EJ. The increasing morbidity of elective spinal stenosis surgery: is it necessary? JAMA 2010; 303:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/20\">",
"      Deyo RA, Mirza SK, Martin BI, et al. Trends, major medical complications, and charges associated with surgery for lumbar spinal stenosis in older adults. JAMA 2010; 303:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/21\">",
"      Gibson JN, Waddell G. Surgery for degenerative lumbar spondylosis. Cochrane Database Syst Rev 2005; :CD001352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/22\">",
"      Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonsurgical therapy for lumbar spinal stenosis. N Engl J Med 2008; 358:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/23\">",
"      Weinstein JN, Tosteson TD, Lurie JD, et al. Surgical versus nonoperative treatment for lumbar spinal stenosis four-year results of the Spine Patient Outcomes Research Trial. Spine (Phila Pa 1976) 2010; 35:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/24\">",
"      Malmivaara A, Sl&auml;tis P, Heli&ouml;vaara M, et al. Surgical or nonoperative treatment for lumbar spinal stenosis? A randomized controlled trial. Spine (Phila Pa 1976) 2007; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/25\">",
"      Atlas SJ, Keller RB, Robson D, et al. Surgical and nonsurgical management of lumbar spinal stenosis: four-year outcomes from the maine lumbar spine study. Spine (Phila Pa 1976) 2000; 25:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/26\">",
"      Katz JN, Lipson SJ, Larson MG, et al. The outcome of decompressive laminectomy for degenerative lumbar stenosis. J Bone Joint Surg Am 1991; 73:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/27\">",
"      Katz JN, Lipson SJ, Chang LC, et al. Seven- to 10-year outcome of decompressive surgery for degenerative lumbar spinal stenosis. Spine (Phila Pa 1976) 1996; 21:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/28\">",
"      Zak PJ. Surgical management of spinal stenosis. Phys Med Rehabil Clin N Am 2003; 14:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/29\">",
"      Lauryssen C. Appropriate selection of patients with lumbar spinal stenosis for interspinous process decompression with the X STOP device. Neurosurg Focus 2007; 22:E5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/30\">",
"      Kuchta J, Sobottke R, Eysel P, Simons P. Two-year results of interspinous spacer (X-Stop) implantation in 175 patients with neurologic intermittent claudication due to lumbar spinal stenosis. Eur Spine J 2009; 18:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/31\">",
"      Zucherman JF, Hsu KY, Hartjen CA, et al. A prospective randomized multi-center study for the treatment of lumbar spinal stenosis with the X STOP interspinous implant: 1-year results. Eur Spine J 2004; 13:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/32\">",
"      Zucherman JF, Hsu KY, Hartjen CA, et al. A multicenter, prospective, randomized trial evaluating the X STOP interspinous process decompression system for the treatment of neurogenic intermittent claudication: two-year follow-up results. Spine (Phila Pa 1976) 2005; 30:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/33\">",
"      Kondrashov DG, Hannibal M, Hsu KY, Zucherman JF. Interspinous process decompression with the X-STOP device for lumbar spinal stenosis: a 4-year follow-up study. J Spinal Disord Tech 2006; 19:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/34\">",
"      Hsu KY, Zucherman JF, Hartjen CA, et al. Quality of life of lumbar stenosis-treated patients in whom the X STOP interspinous device was implanted. J Neurosurg Spine 2006; 5:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/35\">",
"      Siddiqui M, Smith FW, Wardlaw D. One-year results of X Stop interspinous implant for the treatment of lumbar spinal stenosis. Spine (Phila Pa 1976) 2007; 32:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/36\">",
"      Brussee P, Hauth J, Donk RD, et al. Self-rated evaluation of outcome of the implantation of interspinous process distraction (X-Stop) for neurogenic claudication. Eur Spine J 2008; 17:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/37\">",
"      Siddiqui M, Nicol M, Karadimas E, et al. The positional magnetic resonance imaging changes in the lumbar spine following insertion of a novel interspinous process distraction device. Spine (Phila Pa 1976) 2005; 30:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/38\">",
"      Siddiqui M, Karadimas E, Nicol M, et al. Influence of X Stop on neural foramina and spinal canal area in spinal stenosis. Spine (Phila Pa 1976) 2006; 31:2958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/39\">",
"      Sobottke R, Schl&uuml;ter-Brust K, Kaulhausen T, et al. Interspinous implants (X Stop, Wallis, Diam) for the treatment of LSS: is there a correlation between radiological parameters and clinical outcome? Eur Spine J 2009; 18:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/40\">",
"      Epstein NE. How often is minimally invasive minimally effective: what are the complication rates for minimally invasive surgery? Surg Neurol 2008; 70:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/41\">",
"      Epstein NE. X-Stop: foot drop. Spine J 2009; 9:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/42\">",
"      Barbagallo GM, Olindo G, Corbino L, Albanese V. Analysis of complications in patients treated with the X-Stop Interspinous Process Decompression System: proposal for a novel anatomic scoring system for patient selection and review of the literature. Neurosurgery 2009; 65:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/43\">",
"      Verhoof OJ, Bron JL, Wapstra FH, van Royen BJ. High failure rate of the interspinous distraction device (X-Stop) for the treatment of lumbar spinal stenosis caused by degenerative spondylolisthesis. Eur Spine J 2008; 17:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/44\">",
"      Sengupta DK, Herkowitz HN. Degenerative spondylolisthesis: review of current trends and controversies. Spine (Phila Pa 1976) 2005; 30:S71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/45\">",
"      Fischgrund JS, Mackay M, Herkowitz HN, et al. 1997 Volvo Award winner in clinical studies. Degenerative lumbar spondylolisthesis with spinal stenosis: a prospective, randomized study comparing decompressive laminectomy and arthrodesis with and without spinal instrumentation. Spine (Phila Pa 1976) 1997; 22:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/46\">",
"      Babu MA, Coumans JV, Carter BS, et al. A review of lumbar spinal instrumentation: evidence and controversy. J Neurol Neurosurg Psychiatry 2011; 82:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/47\">",
"      Deyo RA, Ching A, Matsen L, et al. Use of bone morphogenetic proteins in spinal fusion surgery for older adults with lumbar stenosis: trends, complications, repeat surgery, and charges. Spine (Phila Pa 1976) 2012; 37:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/48\">",
"      BMP use up sharply, but outcomes not improved. OR Manager 2012; 28:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/49\">",
"      Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011; 11:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/50\">",
"      Papakostidis C, Kontakis G, Bhandari M, Giannoudis PV. Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results. Spine (Phila Pa 1976) 2008; 33:E680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/51\">",
"      Kalanithi PS, Patil CG, Boakye M. National complication rates and disposition after posterior lumbar fusion for acquired spondylolisthesis. Spine (Phila Pa 1976) 2009; 34:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/52\">",
"      Herkowitz HN, Kurz LT. Degenerative lumbar spondylolisthesis with spinal stenosis. A prospective study comparing decompression with decompression and intertransverse process arthrodesis. J Bone Joint Surg Am 1991; 73:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/53\">",
"      Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical versus nonsurgical treatment for lumbar degenerative spondylolisthesis. N Engl J Med 2007; 356:2257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/54\">",
"      Weinstein JN, Lurie JD, Tosteson TD, et al. Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis. four-year results in the Spine Patient Outcomes Research Trial (SPORT) randomized and observational cohorts. J Bone Joint Surg Am 2009; 91:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/55\">",
"      Tosteson AN, Lurie JD, Tosteson TD, et al. Surgical treatment of spinal stenosis with and without degenerative spondylolisthesis: cost-effectiveness after 2 years. Ann Intern Med 2008; 149:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/56\">",
"      Martin BI, Mirza SK, Comstock BA, et al. Are lumbar spine reoperation rates falling with greater use of fusion surgery and new surgical technology? Spine (Phila Pa 1976) 2007; 32:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/57\">",
"      Turner JA, Ersek M, Herron L, Deyo R. Surgery for lumbar spinal stenosis. Attempted meta-analysis of the literature. Spine (Phila Pa 1976) 1992; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/58\">",
"      Li G, Patil CG, Lad SP, et al. Effects of age and comorbidities on complication rates and adverse outcomes after lumbar laminectomy in elderly patients. Spine (Phila Pa 1976) 2008; 33:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/59\">",
"      Farjoodi P, Skolasky RL, Riley LH. The effects of hospital and surgeon volume on postoperative complications after LumbarSpine surgery. Spine (Phila Pa 1976) 2011; 36:2069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/60\">",
"      Deyo RA, Ciol MA, Cherkin DC, et al. Lumbar spinal fusion. A cohort study of complications, reoperations, and resource use in the Medicare population. Spine (Phila Pa 1976) 1993; 18:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/61\">",
"      Cassinelli EH, Eubanks J, Vogt M, et al. Risk factors for the development of perioperative complications in elderly patients undergoing lumbar decompression and arthrodesis for spinal stenosis: an analysis of 166 patients. Spine (Phila Pa 1976) 2007; 32:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/62\">",
"      Cloyd JM, Acosta FL Jr, Ames CP. Complications and outcomes of lumbar spine surgery in elderly people: a review of the literature. J Am Geriatr Soc 2008; 56:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/63\">",
"      Park DK, An HS, Lurie JD, et al. Does multilevel lumbar stenosis lead to poorer outcomes?: a subanalysis of the Spine Patient Outcomes Research Trial (SPORT) lumbar stenosis study. Spine (Phila Pa 1976) 2010; 35:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/64\">",
"      J&ouml;nsson B, Annertz M, Sj&ouml;berg C, Str&ouml;mqvist B. A prospective and consecutive study of surgically treated lumbar spinal stenosis. Part II: Five-year follow-up by an independent observer. Spine (Phila Pa 1976) 1997; 22:2938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/65\">",
"      Aalto TJ, Malmivaara A, Kovacs F, et al. Preoperative predictors for postoperative clinical outcome in lumbar spinal stenosis: systematic review. Spine (Phila Pa 1976) 2006; 31:E648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/66\">",
"      Gunzburg R, Keller TS, Szpalski M, et al. Clinical and psychofunctional measures of conservative decompression surgery for lumbar spinal stenosis: a prospective cohort study. Eur Spine J 2003; 12:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/67\">",
"      Carreon LY, Glassman SD, Djurasovic M, et al. Are preoperative health-related quality of life scores predictive of clinical outcomes after lumbar fusion? Spine (Phila Pa 1976) 2009; 34:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/68\">",
"      Freedman MK, Hilibrand AS, Blood EA, et al. The impact of diabetes on the outcomes of surgical and nonsurgical treatment of patients in the spine patient outcomes research trial. Spine (Phila Pa 1976) 2011; 36:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/69\">",
"      Memtsoudis SG, Vougioukas VI, Ma Y, et al. Perioperative morbidity and mortality after anterior, posterior, and anterior/posterior spine fusion surgery. Spine (Phila Pa 1976) 2011; 36:1867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/70\">",
"      Radcliff KE, Rihn J, Hilibrand A, et al. Does the duration of symptoms in patients with spinal stenosis and degenerative spondylolisthesis affect outcomes?: analysis of the Spine Outcomes Research Trial. Spine (Phila Pa 1976) 2011; 36:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/71\">",
"      M&oslash;ller AM, Pedersen T, Villebro N, Munksgaard A. Effect of smoking on early complications after elective orthopaedic surgery. J Bone Joint Surg Br 2003; 85:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/72\">",
"      Andersen T, Christensen FB, Laursen M, et al. Smoking as a predictor of negative outcome in lumbar spinal fusion. Spine (Phila Pa 1976) 2001; 26:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/73\">",
"      Mooney V, McDermott KL, Song J. Effects of smoking and maturation on long-term maintenance of lumbar spinal fusion success. J Spinal Disord 1999; 12:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/74\">",
"      Lee TC, Ueng SW, Chen HH, et al. The effect of acute smoking on spinal fusion: an experimental study among rabbits. J Trauma 2005; 59:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/75\">",
"      Wing KJ, Fisher CG, O'Connell JX, Wing PC. Stopping nicotine exposure before surgery. The effect on spinal fusion in a rabbit model. Spine (Phila Pa 1976) 2000; 25:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22776/abstract/76\">",
"      Glassman SD, Anagnost SC, Parker A, et al. The effect of cigarette smoking and smoking cessation on spinal fusion. Spine (Phila Pa 1976) 2000; 25:2608.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7781 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-74CF0474CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22776=[""].join("\n");
var outline_f22_15_22776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NONSURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Epidural injections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Spinal stenosis without spondylolisthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Laminectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Intraspinous spacer implantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spinal stenosis with spondylolisthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/7781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/7781|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/24/21896\" title=\"figure 1\">",
"      Common pathoanatomical conditions of the lumbar spine",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/10/18601?source=related_link\">",
"      Approach to the diagnosis and evaluation of low back pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/44/40642?source=related_link\">",
"      Patient information: Spinal stenosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39753?source=related_link\">",
"      Subacute and chronic low back pain: Nonsurgical interventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/24/19850?source=related_link\">",
"      Subacute and chronic low back pain: Pharmacologic and noninterventional treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/21/13658?source=related_link\">",
"      Treatment of acute low back pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22777="Pregnancy in women with pre-existing chronic liver disease";
var content_f22_15_22777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pregnancy in women with pre-existing chronic liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Yannick Bacq, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22777/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/15/22777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver disease in pregnant women can be seen in three general settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has liver disease induced by pregnancy, such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acute fatty liver of pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=see_link\">",
"       \"Acute fatty liver of pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intrahepatic cholestasis of pregnancy (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link\">",
"       \"Intrahepatic cholestasis of pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hyperemesis gravidarum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=see_link\">",
"       \"Clinical features and evaluation of nausea and vomiting of pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=see_link\">",
"       \"Treatment and outcome of nausea and vomiting of pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Preeclampsia or the HELLP syndrome (hemolysis, elevated liver tests, and low platelets) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"       \"Preeclampsia: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient has developed a new liver disease during pregnancy",
"     </li>",
"     <li>",
"      The patient has pre-existing chronic liver disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy is unusual in women with severe chronic liver disease. Most such women are not of child-bearing age, or, because of the associated anovulatory state, they are infertile [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/1\">",
"     1",
"    </a>",
"    ]. However, women with less severe disease (eg, from chronic viral hepatitis) or those with noncirrhotic portal hypertension (eg, from congenital hepatic fibrosis or portal vein thrombosis) do not have diminished fertility and may become pregnant. When a woman with chronic liver disease becomes pregnant, two separate issues arise: (1) what will be the effect of the liver disease or its treatment on the pregnancy and fetus, and (2) how will the pregnancy affect the health of the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review pregnancy in women with pre-existing chronic liver disease, including the effects on the fetus and on the patient. Liver disease induced by pregnancy and the development of new liver disease during pregnancy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=see_link\">",
"     \"Approach to liver disease occurring during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CIRRHOSIS AND PORTAL HYPERTENSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy has a variable effect in women with cirrhosis and portal hypertension. Some women with cirrhosis can sustain pregnancy without any worsening of hepatic function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/2\">",
"     2",
"    </a>",
"    ], whereas others may develop jaundice with progressive liver failure, ascites, and hepatic coma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/3\">",
"     3",
"    </a>",
"    ]. Spontaneous rupture of a splenic artery aneurysm is a rare complication of pregnancy in women with portal hypertension and is also a known complication of pregnancy in patients without portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H7760030#H7760030\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic artery aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, the incidence of stillbirths and premature delivery may be increased in women with cirrhosis or portal hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/2,5-7\">",
"     2,5-7",
"    </a>",
"    ]. For example, in one study, spontaneous fetal loss occurred in 26 percent of pregnancies (19 percent were miscarriages prior to 20 weeks gestation, and 6 percent were stillbirths after 20 weeks gestation) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/7\">",
"     7",
"    </a>",
"    ]. However, published reports may be biased toward complications, leading to an overestimation of the risk.",
"   </p>",
"   <p>",
"    The increase in total blood volume associated with pregnancy may worsen pre-existing portal hypertension. However, prospective studies of the effect of pregnancy on portal hypertension and its complications are not available. Variceal hemorrhage during pregnancy or labor has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. One method to avoid straining during delivery is to place an epidural early in labor and allow the infant to descend with uterine contractions alone. Delivery is then assisted using low forceps or vacuum extraction.",
"   </p>",
"   <p>",
"    One study that looked at pregnancy outcomes in women with cirrhosis included 62 pregnancies in 29 women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/7\">",
"     7",
"    </a>",
"    ]. The live birth rate was 58 percent, with a median gestational age of 36 weeks. Higher model for end-stage liver disease",
"    <span class=\"nowrap\">",
"     (MELD)/MELD-Na",
"    </span>",
"    scores (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/39/14962?source=see_link\">",
"     calculator 2",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=see_link\">",
"     calculator 3",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?11/38/11874?source=see_link\">",
"     calculator 4",
"    </a>",
"    ) and higher Child-Pugh scores (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=see_link\">",
"     calculator 5",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=see_link\">",
"     calculator 6",
"    </a>",
"    ) were associated with preterm delivery. Significant liver-related complications occurred during six of the pregnancies (10 percent) and included variceal bleeding (three pregnancies), decompensation with development of significant ascites (two pregnancies), and hepatic encephalopathy (one patient). There was one fatality during pregnancy that was the result of variceal bleeding. Complications were associated with higher MELD scores (but not MELD-Na or Child-Pugh scores) at the time of conception. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=see_link\">",
"     \"Model for End-stage Liver Disease (MELD)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One approach to women with known cirrhosis who desire pregnancy is to perform an upper endoscopy to look for varices before pregnancy. If present, patients should be informed of the increased risk of gastrointestinal hemorrhage with pregnancy. Upper endoscopy should be performed in the second trimester in women who did not have it prior to pregnancy. Patients at high risk for variceal hemorrhage should be considered for primary prophylaxis with non-selective beta blockers (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"     nadolol",
"    </a>",
"    ). Prophylaxis with beta blockers may be continued during pregnancy, but newborns should be monitored during the first days of life because of risks of hypoglycemia and bradycardia. All patients should be monitored by a maternal fetal medicine specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=see_link\">",
"     \"Prediction of variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=see_link\">",
"     \"Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146901940\">",
"    <span class=\"h1\">",
"     CHRONIC VIRAL HEPATITIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146902162\">",
"    <span class=\"h2\">",
"     Chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis B in pregnancy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/61/3033?source=see_link\">",
"     \"Hepatitis B and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146902198\">",
"    <span class=\"h2\">",
"     Chronic hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women chronically infected with hepatitis C virus (HCV) can have an uneventful pregnancy without worsening of liver disease or other adverse effects on the mother or fetus. However, some studies evaluating the impact of chronic HCV on hepatic, maternal, and fetal outcomes have suggested potential harms.",
"   </p>",
"   <p>",
"    In a population-based cohort study, infants of HCV-positive mothers were more likely to be of low birthweight (odds ratio [OR] 2.2; 95% confidence interval [CI] 1.2-3.8), small for gestational age (OR 1.5; 95% CI 1.0-2.1), need assisted ventilation (OR 2.4; 95% CI 1.4-3.9), or require neonatal intensive care (OR 2.9, 95% CI 1.9-4.6) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/10\">",
"     10",
"    </a>",
"    ]. There were nonsignificant trends for low apgar scores (OR 1.5, 95% CI 0.9 to 2.5), prematurity (OR 1.5, 95% CI 1.0 to 2.4), and neonatal jaundice (OR 1.3, 95% CI 0.8 to 1.9) being associated with HCV. However, not all studies have detected these associations, and additional data are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An improvement in serum aminotransferase concentrations during pregnancy has been observed in some reports. As an example, in a series that included 266 pregnant women who were HCV RNA positive, the proportion of those with an elevated serum alanine aminotransferase level decreased from 56 percent at the beginning of pregnancy to 7 percent by the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/15\">",
"     15",
"    </a>",
"    ]. The levels then returned to 55 percent six months after delivery. The authors hypothesized that these changes may have been due to the effects of pregnancy leading to a decrease in the mothers' immune responses against HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/16\">",
"     16",
"    </a>",
"    ]. Similar results were noted in a smaller series of 26 patients that also noted a rise in HCV RNA titer during the third trimester despite the decline in the serum alanine aminotransferase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations suggest that women who are found to be infected with HCV during pregnancy and have normal serum aminotransferase concentrations should undergo repeat testing six months or more after pregnancy before concluding that the serum aminotransferases are stably normal.",
"   </p>",
"   <p>",
"    Studies have had conflicting results regarding the effect of pregnancy on histologic progression in women with chronic HCV. At least one study suggested that pregnancy may be associated with histologic deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/18\">",
"     18",
"    </a>",
"    ]. Twelve HCV positive women who underwent liver biopsies before and after pregnancy were compared with 12 matched HCV positive controls who underwent paired liver biopsies but did not have an intervening pregnancy. Women who had been pregnant were more likely to have deterioration in their necroinflammatory and fibrosis scores compared with women who had not been pregnant (83 versus 25 percent and 42 versus 8 percent, respectively). By contrast, another study found that pregnancy was associated with improvement in long-term progression of fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission of the virus from the mother to the infant does occur but appears to be much less efficient than for hepatitis B, occurring in about 5 to 10 percent of infants born to anti-HCV positive women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the risk of infection is approximately threefold higher in infants born to women co-infected with HCV and HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Transmission only occurs from mothers who are HCV-RNA positive (as opposed to those who are anti-HCV positive but HCV-RNA negative), and the risk of transmission may, like HIV, be in part related to the level of viremia at the time of birth. Prolonged rupture of membranes (&gt;6 hours) may increase the risk of transmission, so it is recommended that the second stage of labor be kept short [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/22\">",
"     22",
"    </a>",
"    ]. As with hepatitis B, cesarean delivery does not appear to reduce the risk of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=see_link\">",
"     \"Vertical transmission of hepatitis C virus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antiviral treatment of pregnant women is not recommended.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    must",
"    <strong>",
"     not",
"    </strong>",
"    be given during pregnancy because it has been shown to be teratogenic in animal models. In addition, interferon has been shown to increase spontaneous abortions in animal models. Early diagnosis of infection in newborns requires HCV-RNA testing since anti-HCV antibodies are passively transferred from the mother. There is no evidence that breastfeeding is a risk for infection among infants born to HCV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=see_link&amp;anchor=H14#H14\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H334873429\">",
"    <span class=\"h2\">",
"     Hepatitis E",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to hepatitis E in a woman who is pregnant are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=see_link\">",
"     \"Hepatitis E virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146902223\">",
"    <span class=\"h2\">",
"     Hepatitis G",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis G virus can be transmitted from mother to infant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/25\">",
"     25",
"    </a>",
"    ]. The clinical significance of this event is uncertain since it is unclear if this virus is pathogenic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=see_link\">",
"     \"GB virus C (hepatitis G) infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NON-VIRAL LIVER DISEASES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alcoholic liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholic liver disease is often associated with infertility. However, most alcoholics do not have liver disease and are able to become pregnant. Alcohol consumption during pregnancy can lead to fetal alcohol syndrome, which is characterized by typical facies, malformations, and developmental delay. In addition, infants with fetal alcohol syndrome may have liver disease characterized by fatty liver and portal and perisinusoidal fibrosis suggestive of alcohol-induced injury [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=see_link&amp;anchor=H11#H11\">",
"     \"Infants of mothers with substance abuse\", section on 'Alcohol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autoimmune hepatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in women with autoimmune hepatitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of autoimmune hepatitis\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Primary biliary cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The course of primary biliary cirrhosis (PBC) during pregnancy is uncertain. Case reports have demonstrated that the disease may remain quiescent, improve, or worsen during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Treatment of PBC most commonly involves",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     ursodeoxycholic acid",
"    </a>",
"    (UDCA), which studies suggest is safe during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=see_link&amp;anchor=H13#H13\">",
"     \"Intrahepatic cholestasis of pregnancy\", section on 'Ursodeoxycholic acid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recommendations for management of PBC during pregnancy have been proposed in an official guideline issued by the American Association for the Study of Liver Diseases (AASLD) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/31\">",
"     31",
"    </a>",
"    ]. The guideline recommends screening for varices in the second trimester and treating with beta blockers if indicated. The guideline for the management of primary biliary cirrhosis, as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     file://www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4981174\">",
"    <span class=\"h2\">",
"     Primary sclerosing cholangitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited with regard to pregnancy in women with primary sclerosing cholangitis (PSC) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/32-36\">",
"     32-36",
"    </a>",
"    ]. One series compared 229 patients with PSC with 569 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients with PSC did not differ significantly from healthy controls with regard to the number who had children or the mean number of children per person (53 versus 53 percent and 1.06 versus 1.01, respectively).",
"   </p>",
"   <p>",
"    Case reports suggest that pregnancies may be complicated by pruritus, the development of dominant strictures, or choledocholithiasis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12373?source=see_link\">",
"     Ursodeoxycholic acid",
"    </a>",
"    has been used successfully to control pruritus during pregnancy in women with PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Wilson disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have been anovulatory because of Wilson disease can regain their fertility when treated, often quite promptly. Maintaining therapy during pregnancy is important because interrupting therapy has been associated with hemolytic episodes with hepatic insufficiency and maternal death. The treatment of pregnant women with Wilson disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of Wilson disease\", section on 'Zinc and pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with Wilson disease and cirrhosis may be at increased risk for obstetrical complications such as intrauterine growth restriction and preeclampsia, and they should be referred to a maternal-fetal medicine specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of Wilson disease\", section on 'Penicillamine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of Wilson disease\", section on 'Trientine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=see_link&amp;anchor=H19#H19\">",
"     \"Treatment of Wilson disease\", section on 'Oral zinc'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Hepatic adenoma and focal nodular hyperplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic adenomas (liver cell adenomas) may grow during pregnancy and such lesions are at risk of spontaneous hemorrhage and rupture. In one report, 16 of 26 women diagnosed with hepatic adenomas during pregnancy presented with rupture, with seven maternal deaths and six fetal deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/37\">",
"     37",
"    </a>",
"    ]. Thirteen of these cases presented postpartum. By contrast, in a surgical series of patients with single and multiple hepatic adenomas that included nine pregnancies in patients with residual adenomas, only two patients experienced enlargement of the lesions, and there were no complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One suggested approach to women with hepatic adenomas who are pregnant is to start by looking for evidence of bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. If present, the patient will require definitive therapy with either open or laparoscopic liver resection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/39\">",
"     39",
"    </a>",
"    ]. Surgery is also recommended for women with lesions that are larger than 5 cm (preferably during the second trimester). Women with smaller lesions that do not have evidence of bleeding can be monitored with ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MR imaging.",
"   </p>",
"   <p>",
"    Hepatic adenomas should be distinguished from other benign tumors of the liver that are not characteristically hormonally responsive. One such lesion is focal nodular hyperplasia (FNH). In a series of 10 women with FNH who had 13 pregnancies, no increase in tumor size was seen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/41\">",
"     41",
"    </a>",
"    ]. However, there are case reports of hormone sensitivity and growth of FNH during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22791?source=see_link\">",
"     \"Focal nodular hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=see_link\">",
"     \"Hepatic adenoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Familial hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unconjugated hyperbilirubinemia of Gilbert's syndrome is not exacerbated by pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/43\">",
"     43",
"    </a>",
"    ]. By comparison, the conjugated hyperbilirubinemia of Dubin-Johnson syndrome may worsen during gestation but returns to baseline levels after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link&amp;anchor=H3#H3\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Dubin-Johnson syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Familial intrahepatic cholestatic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of these rare diseases include Alagille syndrome and Byler's syndrome (progressive familial intrahepatic cholestasis). Reports of pregnancy in such patients are infrequent, but if pregnancy occurs, the underlying cholestasis may worsen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link&amp;anchor=H29#H29\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Alagille syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link&amp;anchor=H21#H21\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\", section on 'Progressive familial intrahepatic cholestasis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Porphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;These genetic disorders of heme metabolism can be exacerbated by estrogenic hormones and may cause maternal and fetal problems during pregnancy. Porphyria cutanea tarda, which is often associated with chronic hepatitis C, has rarely been reported to have its initial presentation during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/46\">",
"     46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=see_link\">",
"     \"Porphyria cutanea tarda and hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurrent attacks may occur during pregnancy in patients with acute intermittent porphyria, variegate porphyria, or hereditary coproporphyria and may be associated with intrauterine growth restriction or, rarely, maternal death [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a population-based study, women with the heritable form of porphyria cutanea tarda or with active acute porphyria during pregnancy had an excess risk of prenatal death (adjusted odds ratio [AOR] 4.9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/49\">",
"     49",
"    </a>",
"    ]. Sporadic porphyria cutanea tarda was associated with an excess risk of small for gestational age (AOR 2.0), and for first-time mothers, low birth weight (AOR 3.4) and premature delivery (AOR 3.5).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Budd-Chiari syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with Budd-Chiari syndrome (BCS) have become pregnant after the BCS has been treated and is well controlled. However, fetal outcomes remain relatively poor, possibly because of underlying prothrombotic disorders. In one study of 24 pregnancies, seven were lost prior to week 20, and there was one stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, two patients delivered between weeks 20 and 31, and 11 delivered between weeks 32 and 36. Finally, two of the women developed symptomatic thrombotic complications. Patients should be informed of fetal and maternal risk of such pregnancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link&amp;anchor=H12#H12\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\", section on 'Budd-Chiari syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo orthotopic liver transplantation often regain their fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/51\">",
"     51",
"    </a>",
"    ]. Delaying conception until at least 24 months after transplantation is advised to allow for stabilization of the immunosuppressive regimen and to assure that the transplanted organ is functioning well [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery,",
"    <span class=\"nowrap\">",
"     hypertension/preeclampsia,",
"    </span>",
"    fetal growth restriction, and gestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52-60\">",
"     52-60",
"    </a>",
"    ]. The higher risk of preterm birth appears to be due in part to episodes of graft rejection and early onset preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52\">",
"     52",
"    </a>",
"    ]. Pregnancy induced hypertension and preeclampsia may be related to an increased incidence of baseline renal dysfunction in these women and use of immunosuppressive therapy. The risk appears to be higher with use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    A than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , but the number of reported patients is small [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52,61\">",
"     52,61",
"    </a>",
"    ]. Gestational diabetes is likely provoked by chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    administration, thus these patients may benefit from diabetes screening in the first trimester, as well as between 24 and 28 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Liver transplant patients require life-long immunosuppression. A slightly increased risk of teratogenicity has been suggested with standard immunosuppressive regimens that include corticosteroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , but the magnitude of the risk is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52,61\">",
"     52,61",
"    </a>",
"    ]. Increased monitoring of blood levels of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is needed because of increased hepatic clearance of cyclosporin during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Pregnancies in women who have undergone liver transplantation should be managed together with a maternal-fetal medicine specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although pregnancy does not increase the risk of maternal mortality in liver transplant recipients, these women should be aware of their prognosis for long-term survival and ability to care for a child. In one series of women who underwent liver transplantation from 1992 to 2002, five of 29 died between 10 and 54 months postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both fetus and mother have survived liver transplantation performed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22777/abstract/62,64-67\">",
"     62,64-67",
"    </a>",
"    ]. Obviously, such heroic surgery must be considered with extreme care. If the condition prompting transplantation is caused by the pregnancy (eg, acute fatty liver of pregnancy), then prompt diagnosis followed by interruption of the pregnancy with maximal support of the mother is the treatment of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H146896108\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnancy is unusual in women with severe chronic liver disease. Most such women are not of child-bearing age, or, because of the associated anovulatory state, they are infertile. However, women with less severe disease or those with noncirrhotic portal hypertension do not have diminished fertility and may become pregnant. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy has a variable effect in women with cirrhosis and portal hypertension. Worsening jaundice with progressive liver failure, ascites, and hepatic coma can occur, but some women with cirrhosis can sustain pregnancy without any worsening of hepatic function. In addition, the incidence of stillbirths and premature deliveries may be increased. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cirrhosis and portal hypertension'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The increase in total blood volume associated with pregnancy may worsen pre-existing portal hypertension. One approach to women with known cirrhosis who desire pregnancy is to perform an upper endoscopy to look for varices before pregnancy (or during the second trimester if not performed prior to pregnancy). If present, patients should be informed of the increased risk of upper gastrointestinal hemorrhage with pregnancy. Patients at high risk for variceal hemorrhage should be considered for primary prophylaxis with non-selective beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/15/35063?source=see_link\">",
"       nadolol",
"      </a>",
"      ). Newborns whose mothers were receiving beta blockers should be monitored during the first days of life because of risks of hypoglycemia and bradycardia.",
"     </li>",
"     <li>",
"      Pregnancy is generally well tolerated by women who are chronic carriers of hepatitis B virus (HBV). Reactivation of the virus and exacerbation of the disease during or after gestation are uncommon. The overall risk of HBV transmission from the mother to infant is about 40 percent. Transmission at birth is more likely if the mother is hepatitis B e antigen (HBeAg) positive or has high circulating levels of HBV DNA. Prenatal screening of all pregnant women for HBsAg is now performed routinely in many countries. Neonates born to HBsAg positive women should receive hepatitis B immunoglobulin and HBV vaccine at birth, regardless of HBeAg status of the mother. (See",
"      <a class=\"local\" href=\"#H146902162\">",
"       'Chronic hepatitis B'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=see_link&amp;anchor=H4#H4\">",
"       \"Epidemiology, transmission, and prevention of hepatitis B virus infection\", section on 'Perinatal transmission'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women chronically infected with hepatitis C virus (HCV) can have an uneventful pregnancy without worsening of liver disease or other adverse effects on the mother or fetus, though some studies have suggested potential harms. Transmission of the virus from mother to infant occurs but appears to be much less efficient than for hepatitis B, occurring in about 5 to 10 percent of infants born to anti-HCV positive women. The risk of infection is approximately threefold higher in infants born to women co-infected with HCV and HIV. There is no evidence that breastfeeding is a risk for infection among infants born to HCV-infected women. (See",
"      <a class=\"local\" href=\"#H146902198\">",
"       'Chronic hepatitis C'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Antiviral treatment of pregnant women with hepatitis C or unusual precautions to reduce the risk of transmission (eg, performing a cesarean delivery) are not recommended. In particular,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      must",
"      <strong>",
"       not",
"      </strong>",
"      be given during pregnancy because it is teratogenic.",
"     </li>",
"     <li>",
"      Patients who have undergone orthotopic liver transplantation often regain their fertility. Delaying conception until at least 24 months after transplantation is advised to allow for stabilization of the immunosuppressive regimen and to assure that the transplanted organ is functioning well. Pregnancy outcomes for both the mother and infant in liver transplant recipients are generally good, but there is an increased incidence of preterm delivery,",
"      <span class=\"nowrap\">",
"       hypertension/preeclampsia,",
"      </span>",
"      fetal growth restriction, and gestational diabetes. In addition, there may be a slightly increased risk of teratogenicity with standard immunosuppressive regimens, but the magnitude of the risk is uncertain. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other liver diseases that may have an effect on or be affected by pregnancy include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hepatitis G (see",
"      <a class=\"local\" href=\"#H146902223\">",
"       'Hepatitis G'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Autoimmune hepatitis (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Autoimmune hepatitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary biliary cirrhosis (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Primary biliary cirrhosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary sclerosing cholangitis (see",
"      <a class=\"local\" href=\"#H4981174\">",
"       'Primary sclerosing cholangitis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Wilson disease (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Wilson disease'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Hepatic adenomas (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Hepatic adenoma and focal nodular hyperplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Focal nodular hyperplasia (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Hepatic adenoma and focal nodular hyperplasia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Familial hyperbilirubinemia (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Familial hyperbilirubinemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Familial intrahepatic cholestatic syndromes (Alagille syndrome and progressive familial intrahepatic cholestasis) (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Familial intrahepatic cholestatic syndromes'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Porphyria (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Porphyria'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link&amp;anchor=H12#H12\">",
"       \"Intercurrent hepatobiliary disease during pregnancy\", section on 'Budd-Chiari syndrome'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/1\">",
"      Varma RR. Course and prognosis of pregnancy in women with liver disease. Semin Liver Dis 1987; 7:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/2\">",
"      Tan J, Surti B, Saab S. Pregnancy and cirrhosis. Liver Transpl 2008; 14:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/3\">",
"      Schweitzer IL, Peters RL. Pregnancy in hepatitis B antigen positive cirrhosis. Obstet Gynecol 1976; 48:53S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/4\">",
"      Hillemanns P, Knitza R, M&uuml;ller-H&ouml;cker J. Rupture of splenic artery aneurysm in a pregnant patient with portal hypertension. Am J Obstet Gynecol 1996; 174:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/5\">",
"      Cheng YS. Pregnancy in liver cirrhosis and/or portal hypertension. Am J Obstet Gynecol 1977; 128:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/6\">",
"      Schreyer P, Caspi E, El-Hindi JM, Eshchar J. Cirrhosis--pregnancy and delivery: a review. Obstet Gynecol Surv 1982; 37:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/7\">",
"      Westbrook RH, Yeoman AD, O'Grady JG, et al. Model for end-stage liver disease score predicts outcome in cirrhotic patients during pregnancy. Clin Gastroenterol Hepatol 2011; 9:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/8\">",
"      Soto-Albors CE, Rayburn WF, Taylor L, Musselman M. Portal hypertension and hypersplenism in pregnancy secondary to chronic schistosomiasis. A case report. J Reprod Med 1984; 29:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/9\">",
"      Britton RC. Pregnancy and esophageal varices. Am J Surg 1982; 143:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/10\">",
"      Pergam SA, Wang CC, Gardella CM, et al. Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort. Am J Obstet Gynecol 2008; 199:38.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/11\">",
"      Jaffery T, Tariq N, Ayub R, Yawar A. Frequency of hepatitis C in pregnancy and pregnancy outcome. J Coll Physicians Surg Pak 2005; 15:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/12\">",
"      Floreani A, Paternoster D, Zappala F, et al. Hepatitis C virus infection in pregnancy. Br J Obstet Gynaecol 1996; 103:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/13\">",
"      Latt NC, Spencer JD, Beeby PJ, et al. Hepatitis C in injecting drug-using women during and after pregnancy. J Gastroenterol Hepatol 2000; 15:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/14\">",
"      Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004; 40:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/15\">",
"      Conte D, Fraquelli M, Prati D, et al. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/16\">",
"      Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/17\">",
"      Gervais A, Bacq Y, Bernuau J, et al. Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol 2000; 32:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/18\">",
"      Fontaine H, Nalpas B, Carnot F, et al. Effect of pregnancy on chronic hepatitis C: a case-control study. Lancet 2000; 356:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/19\">",
"      Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/20\">",
"      Zanetti AR, Tanzi E, Paccagnini S, et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 1995; 345:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/21\">",
"      Thaler MM, Park CK, Landers DV, et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/22\">",
"      Mast EE, Hwang LY, Seto DS, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis 2005; 192:1880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/23\">",
"      Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HIV- mothers: a meta-analysis. Arch Gynecol Obstet 2011; 283:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/24\">",
"      Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998; 47:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/25\">",
"      Feucht HH, Zollner B, Polywka S, Laufs R. Vertical transmission of hepatitis G. Lancet 1996; 347:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/26\">",
"      Lefkowitch JH, Rushton AR, Feng-Chen KC. Hepatic fibrosis in fetal alcohol syndrome. Pathologic similarities to adult alcoholic liver disease. Gastroenterology 1983; 85:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/27\">",
"      Whelton MJ, Sherlock S. Pregnancy in patients with hepatic cirrhosis. Management and outcome. Lancet 1968; 2:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/28\">",
"      Olsson R, Tysk C, Aldenborg F, Holm B. Prolonged postpartum course of intrahepatic cholestasis of pregnancy. Gastroenterology 1993; 105:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/29\">",
"      Rabinovitz M, Appasamy R, Finkelstein S. Primary biliary cirrhosis diagnosed during pregnancy. Does it have a different outcome? Dig Dis Sci 1995; 40:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/30\">",
"      Poupon R, Chr&eacute;tien Y, Chazouill&egrave;res O, Poupon RE. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005; 42:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/31\">",
"      Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 2000; 31:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/32\">",
"      Landon MB, Soloway RD, Freedman LJ, Gabbe SG. Primary sclerosing cholangitis and pregnancy. Obstet Gynecol 1987; 69:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/33\">",
"      Christensen KL, Andersen BN, Vilstrup H. [Primary sclerosing cholangitis with itching treated during pregnancy with ursodeoxycholic acid]. Ugeskr Laeger 1997; 159:7151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/34\">",
"      Janczewska I, Olsson R, Hultcrantz R, Broom&eacute; U. Pregnancy in patients with primary sclerosing cholangitis. Liver 1996; 16:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/35\">",
"      Gossard AA, Lindor KD. Pregnancy in a patient with primary sclerosing cholangitis. J Clin Gastroenterol 2002; 35:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/36\">",
"      Wellge BE, Sterneck M, Teufel A, et al. Pregnancy in primary sclerosing cholangitis. Gut 2011; 60:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/37\">",
"      Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am J Surg 2004; 187:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/38\">",
"      Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/39\">",
"      Wilson CH, Manas DM, French JJ. Laparoscopic liver resection for hepatic adenoma in pregnancy. J Clin Gastroenterol 2011; 45:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/40\">",
"      Noels JE, van Aalten SM, van der Windt DJ, et al. Management of hepatocellular adenoma during pregnancy. J Hepatol 2011; 54:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/41\">",
"      Weimann A, M&ouml;ssinger M, Fronhoff K, et al. Pregnancy in women with observed focal nodular hyperplasia of the liver. Lancet 1998; 351:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/42\">",
"      Scott LD, Katz AR, Duke JH, et al. Oral contraceptives, pregnancy, and focal nodular hyperplasia of the liver. JAMA 1984; 251:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/43\">",
"      Friedlaender P, Osler M. Icterus and pregnancy. Am J Obstet Gynecol 1967; 97:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/44\">",
"      Cohen L, Lewis C, Arias IM. Pregnancy, oral contraceptives, and chronic familial jaundice with predominantly conjugated hyperbilirubinemia (Dubin-Johnson syndrome). Gastroenterology 1972; 62:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/45\">",
"      Romero R, Reece EA, Riely C, Hobbins JC. Arteriohepatic dysplasia in pregnancy. Am J Obstet Gynecol 1983; 147:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/46\">",
"      Rajka G. Pregnancy and porphyria cutanea tarda. Acta Derm Venereol 1984; 64:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/47\">",
"      Brodie MJ, Moore MR, Thompson GG, et al. Pregnancy and the acute porphyrias. Br J Obstet Gynaecol 1977; 84:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/48\">",
"      Kanaan C, Veille JC, Lakin M. Pregnancy and acute intermittent porphyria. Obstet Gynecol Surv 1989; 44:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/49\">",
"      Toll&aring;nes MC, Aarsand AK, Sandberg S. Excess risk of adverse pregnancy outcomes in women with porphyria: a population-based cohort study. J Inherit Metab Dis 2011; 34:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/50\">",
"      Rautou PE, Angermayr B, Garcia-Pagan JC, et al. Pregnancy in women with known and treated Budd-Chiari syndrome: maternal and fetal outcomes. J Hepatol 2009; 51:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/51\">",
"      Douglas NC, Shah M, Shah M, Sauer MV. Fertility and reproductive disorders in female solid organ transplant recipients. Semin Perinatol 2007; 31:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/52\">",
"      Nagy S, Bush MC, Berkowitz R, et al. Pregnancy outcome in liver transplant recipients. Obstet Gynecol 2003; 102:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/53\">",
"      Radomski JS, Moritz MJ, Mu&ntilde;oz SJ, et al. National Transplantation Pregnancy Registry: analysis of pregnancy outcomes in female liver transplant recipients. Liver Transpl Surg 1995; 1:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/54\">",
"      Armenti VT, Radomski JS, Moritz MJ, et al. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 1997; :101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/55\">",
"      Patapis P, Irani S, Mirza DF, et al. Outcome of graft function and pregnancy following liver transplantation. Transplant Proc 1997; 29:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/56\">",
"      Scantlebury V, Gordon R, Tzakis A, et al. Childbearing after liver transplantation. Transplantation 1990; 49:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/57\">",
"      Ville Y, Fernandez H, Samuel D, et al. Pregnancy in liver transplant recipients: course and outcome in 19 cases. Am J Obstet Gynecol 1993; 168:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/58\">",
"      Rayes N, Neuhaus R, David M, et al. Pregnancies following liver transplantation--how safe are they? A report of 19 cases under cyclosporine A and tacrolimus. Clin Transplant 1998; 12:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/59\">",
"      Wu A, Nashan B, Messner U, et al. Outcome of 22 successful pregnancies after liver transplantation. Clin Transplant 1998; 12:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/60\">",
"      Raakow R, Neuhaus R, B&uuml;scher U, et al. Parenthood following liver transplantation. Transplant Proc 2001; 33:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/61\">",
"      Jain A, Venkataramanan R, Fung JJ, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation 1997; 64:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/62\">",
"      Roberts M, Brown AS, James OF, Davison JM. Interpretation of cyclosporin A levels in pregnancy following orthoptic liver transplantation. Br J Obstet Gynaecol 1995; 102:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/63\">",
"      Keller F, Griesshammer M, H&auml;ussler U, et al. Pregnancy and renal failure: the case for application of dosage guidelines. Drugs 2001; 61:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/64\">",
"      Laifer SA, Darby MJ, Scantlebury VP, et al. Pregnancy and liver transplantation. Obstet Gynecol 1990; 76:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/65\">",
"      Merritt WT, Dickstein R, Beattie C, et al. Liver transplantation during pregnancy: anesthesia for two procedures in the same patient with successful outcome of pregnancy. Transplant Proc 1991; 23:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/66\">",
"      Friedman E, Moses B, Engelberg S, et al. Malignant insulinoma with hepatic failure complicating pregnancy. South Med J 1988; 81:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22777/abstract/67\">",
"      Kato T, Nery JR, Morcos JJ, et al. Successful living related liver transplantation in an adult with fulminant hepatic failure. Transplantation 1997; 64:415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3561 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-9F9DC17642-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22777=[""].join("\n");
var outline_f22_15_22777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H146896108\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CIRRHOSIS AND PORTAL HYPERTENSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H146901940\">",
"      CHRONIC VIRAL HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146902162\">",
"      Chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146902198\">",
"      Chronic hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H334873429\">",
"      Hepatitis E",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H146902223\">",
"      Hepatitis G",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NON-VIRAL LIVER DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alcoholic liver disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4981174\">",
"      Primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Hepatic adenoma and focal nodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Familial hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Familial intrahepatic cholestatic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Porphyria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H146896108\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?21/23/21874?source=related_link\" title=\"calculator 1\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/39/14962?source=related_link\" title=\"calculator 2\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?18/2/18466?source=related_link\" title=\"calculator 3\">",
"      Calculator: MELD score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?11/38/11874?source=related_link\" title=\"calculator 4\">",
"      Calculator: MELDNa score for end-stage liver disease (not appropriate for patients under the age of 12) (SI units)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?27/26/28065?source=related_link\" title=\"calculator 5\">",
"      Calculator: Child Pugh classification for severity of liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?28/28/29121?source=related_link\" title=\"calculator 6\">",
"      Calculator: Child Pugh classification for severity of liver disease (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26198?source=related_link\">",
"      Approach to liver disease occurring during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41207?source=related_link\">",
"      Clinical features and evaluation of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4602?source=related_link\">",
"      Epidemiology, transmission, and prevention of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22791?source=related_link\">",
"      Focal nodular hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=related_link\">",
"      GB virus C (hepatitis G) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/63/15352?source=related_link\">",
"      Hepatic adenoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/61/3033?source=related_link\">",
"      Hepatitis B and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/11/33976?source=related_link\">",
"      Hepatitis E virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28746?source=related_link\">",
"      Infants of mothers with substance abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=related_link\">",
"      Intercurrent hepatobiliary disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/32/4617?source=related_link\">",
"      Intrahepatic cholestasis of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15770?source=related_link\">",
"      Model for End-stage Liver Disease (MELD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30421?source=related_link\">",
"      Porphyria cutanea tarda and hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/60/21446?source=related_link\">",
"      Prediction of variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/49/27418?source=related_link\">",
"      Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/20/29002?source=related_link\">",
"      Treatment and outcome of nausea and vomiting of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/11/23737?source=related_link\">",
"      Treatment of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40058?source=related_link\">",
"      Treatment of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26936?source=related_link\">",
"      Vertical transmission of hepatitis C virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22778="Overview of botulinum toxin for cosmetic indications";
var content_f22_15_22778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of botulinum toxin for cosmetic indications",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Jean Carruthers, MD, FRCSC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Alastair Carruthers, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/15/22778/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/15/22778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H24777424\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin is an injectable neuromodulator derived from neurotoxins produced by Clostridium botulinum, the bacterium responsible for botulism. Through the inhibition of neurotransmission between peripheral nerve endings and muscle fibers, botulinum toxin weakens or paralyzes skeletal muscle. Initially used for medical indications, botulinum toxin injection has now become one of the most requested procedures in facial rejuvenation.",
"   </p>",
"   <p>",
"    When used appropriately, botulinum toxin injection is an overwhelmingly safe method for improving cosmetic defects that are caused by or exacerbated by muscle contraction, such as prominent glabellar rhytides. The effects of botulinum toxin are transient; muscular function typically returns to baseline within a few months.",
"   </p>",
"   <p>",
"    The mechanism of action, formulations, clinical use, and safety of botulinum toxin injections for cosmetic indications will be reviewed here. The use of botulinum toxin for specific cosmetic or medical indications is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link\">",
"     \"Botulinum toxin for cosmetic indications: Treatment of specific sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of dystonia\", section on 'Botulinum toxin injections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of myoclonus\", section on 'Botulinum toxin injections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24777431\">",
"    <span class=\"h1\">",
"     DISCOVERY AND DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical relevance of C. botulinum, a gram-positive bacillus, was first recognized in 1897, when the toxin produced by the organism was identified as the etiologic agent of botulism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Since then, seven serotypes of botulinum toxin (A, B, C1, D, E, F, and G) produced by different strains of the bacterium have been identified. The pharmacologic properties of the serotypes differ, and only serotypes A and B are available for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Botulinum toxin type A is the most common form of botulinum toxin used in aesthetic clinical practice.",
"   </p>",
"   <p>",
"    The clinical utility of botulinum toxin initially became evident in the treatment of strabismus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/6\">",
"     6",
"    </a>",
"    ]. Subsequently, botulinum toxin has been utilized for a variety of other medical conditions characterized by muscular hyperactivity, including blepharospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/7\">",
"     7",
"    </a>",
"    ], hemifacial spasm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and cervical dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of dystonia\", section on 'Botulinum toxin injections'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of myoclonus\", section on 'Botulinum toxin injections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1992, we published the first report of the use of botulinum toxin for a cosmetic indication. This report documented the benefit of botulinum toxin type A for the treatment of glabellar frown lines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/11\">",
"     11",
"    </a>",
"    ]. Botulinum toxin is now utilized for multiple cosmetic concerns that can be improved with local muscle relaxation, such as other dynamic rhytides on the upper face and skin lines located on the lower face and neck [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/12-18\">",
"     12-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4082356\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical utility of botulinum toxin stems from the ability of the toxin to prevent muscular contraction through inhibiting the release of acetylcholine from peripheral nerve cells into neuromuscular junctions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Botulinum toxins are peptides that are composed of one heavy chain and one light chain. After the heavy chain of the injected toxin binds to receptors on the terminal ends of nerve cells, the peptide enters the cytoplasm through endocytosis. Once in the cytoplasm, the light chain cleaves components of SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor), a complex of proteins necessary for the exocytosis of acetylcholine. The sites of cleavage within the SNARE protein complex differ among the serotypes; while botulinum toxin types A, C1, and E cleave SNAP-25 (synaptosome-associated protein of 25 kd), serotypes B, D, F, and G cleave VAMP (vesicle-associated membrane protein). VAMP is also known as synaptobrevin.",
"   </p>",
"   <p>",
"    As a result of this cleavage, acetylcholine remains in the neuron, where it is unable to bind to receptors on muscle fibers and stimulate muscle contraction (chemodenervation). The inhibitory effect of botulinum toxin is temporary; recovery of muscular function often becomes clinically evident approximately three months after treatment as the neuromuscular junction begins to recover. The development of new collateral nerve ends may be partially responsible for recovery; however, these terminal buds appear to be transient, and recovery of the original nerve terminal eventually occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24777445\">",
"    <span class=\"h1\">",
"     FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two serotypes of botulinum toxin have been formulated for clinical use, including botulinum toxin type A (the most common serotype used for cosmetic applications) and botulinum toxin type B. In order to prevent confusion between products, in 2009, the US Food and Drug Administration (FDA) recommended the use of specific names, rather than serotypes, to refer to the available formulations of botulinum toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/20\">",
"     20",
"    </a>",
"    ]. Commercially available formulations of botulinum toxin type A in North America include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     RimabotulinumtoxinB",
"    </a>",
"    is the established name for botulinum toxin type B.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081645\">",
"    <span class=\"h2\">",
"     OnabotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the formulations of botulinum toxin type A that are available or in development,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    (Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    Cosmetic, Vistabel",
"    <sup>",
"     &reg;",
"    </sup>",
"    , Vistabex",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; Allergan, Inc., Irvine, CA) has been studied most extensively. OnabotulinumtoxinA is supplied as a preservative-free, vacuum-dried powder that contains the C. botulinum type A neurotoxin complex (50 or 100 units per vial) plus human albumin and sodium chloride. OnabotulinumtoxinA was approved by the US FDA in 2002 for the treatment of glabellar rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/21\">",
"     21",
"    </a>",
"    ], but also is widely used for the treatment of other skin lines and for facial contouring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081652\">",
"    <span class=\"h2\">",
"     AbobotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially marketed in Europe,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    (Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; Ipsen Ltd., United",
"    <span class=\"nowrap\">",
"     Kingdom/Medicis,",
"    </span>",
"    Scottsdale, AZ and Azzalure",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; Galderma, France) is another formulation of botulinum toxin type A utilized for cosmetic therapy. Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    is supplied in vials that contain 300 or 500 units of lyophilized abobotulinumtoxinA plus serum albumin and lactose. Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    became commercially available in North America in 2009, and has US FDA approval for the treatment of glabellar lines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081673\">",
"    <span class=\"h2\">",
"     IncobotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     IncobotulinumtoxinA",
"    </a>",
"    (Xeomin",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; Merz Pharmaceuticals, Greensboro, NC or Bocouture",
"    <sup>",
"     &reg;",
"    </sup>",
"    ), a newer formulation of botulinum toxin type A, is approved for medical use and for injection of glabellar lines in multiple countries, including the United States. Xeomin is supplied as a lyophilized powder that contains botulinum toxin A (50 or 100 units), human albumin, and sucrose. IncobotulinumtoxinA is free of complexing proteins, which some authors believe may result in a reduced risk of sensitization and antibody formation against the toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21137531\">",
"     'Immunogenicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714881\">",
"    <span class=\"h2\">",
"     RimabotulinumtoxinB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     RimabotulinumtoxinB",
"    </a>",
"    is commercially available as Myobloc",
"    <sup>",
"     &reg;",
"    </sup>",
"    or NeuroBloc",
"    <sup>",
"     &reg;",
"    </sup>",
"    (Solstice Neurosciences",
"    <span class=\"nowrap\">",
"     Inc./Eisai",
"    </span>",
"    Co., Ltd.). Myobloc",
"    <sup>",
"     &reg;",
"    </sup>",
"    , which is distributed in the United States, Canada, and Korea, is supplied in liquid form in vials that contain 5000 units of botulinum toxin type B per milliliter plus human serum albumin, sodium succinate, and sodium chloride. It is the primary agent used for the treatment of cervical dystonia, and compared to botulinum toxin type A, has been less studied for cosmetic indications. However, rimabotulinumtoxinB has been used successfully for the treatment of facial rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/25-28\">",
"     25-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H714960\">",
"    <span class=\"h2\">",
"     Topical botulinum toxin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Topical formulations of botulinum toxin type A may have promise for the treatment of dynamic rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In a randomized trial of 36 adults with moderate to severe lateral canthal lines, two 30&ndash;minute applications of a gel containing botulinum toxin type A separated by four weeks were superior to placebo for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/29\">",
"     29",
"    </a>",
"    ]. Additional studies are necessary to determine the role of topical botulinum toxin for cosmetic indications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715017\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other botulinum toxin products available or in development include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Chinese botulinum toxin A (CBTX-A) &ndash;",
"      </strong>",
"      available in China, marketed as Prosigne",
"      <sup>",
"       &reg;",
"      </sup>",
"      in Brazil",
"     </li>",
"     <li>",
"      <strong>",
"       Neuronox",
"      </strong>",
"      <strong>",
"       <sup>",
"        &reg;",
"       </sup>",
"      </strong>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      a formulation of botulinum toxin type A widely used in Korea and Southeast Asia",
"     </li>",
"     <li>",
"      <strong>",
"       PurTox",
"      </strong>",
"      <strong>",
"       <sup>",
"        &reg;",
"       </sup>",
"      </strong>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      a form of botulinum toxin A free of complexing proteins that is in Phase 3 testing for glabellar rhytides",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24777452\">",
"    <span class=\"h1\">",
"     COSMETIC USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 1992, botulinum toxin has been used cosmetically in a number of clinical settings, ranging from the simple treatment of facial lines to more advanced facial sculpting. Examples of conditions that have been treated successfully with botulinum toxin include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glabellar rhytides (",
"      <a class=\"graphic graphic_picture graphicRef71122 \" href=\"UTD.htm?4/3/4149\">",
"       picture 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Horizontal lines on the forehead (",
"      <a class=\"graphic graphic_picture graphicRef50165 \" href=\"UTD.htm?11/4/11334\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lateral canthal lines (crow&rsquo;s feet) (",
"      <a class=\"graphic graphic_picture graphicRef59956 \" href=\"UTD.htm?3/52/3908\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Depressed brow (",
"      <a class=\"graphic graphic_picture graphicRef71706 \" href=\"UTD.htm?31/11/31920\">",
"       picture 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypertrophic orbicularis oculi muscle (small palpebral aperture)",
"     </li>",
"     <li>",
"      Rhytides from upper nasalis muscle contraction (bunny lines) (",
"      <a class=\"graphic graphic_picture graphicRef52791 graphicRef64576 \" href=\"UTD.htm?7/12/7364\">",
"       picture 5A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nostril flare",
"     </li>",
"     <li>",
"      Drooping nasal tip",
"     </li>",
"     <li>",
"      Nasolabial folds (selected patients) (",
"      <a class=\"graphic graphic_picture graphicRef77905 \" href=\"UTD.htm?40/43/41648\">",
"       picture 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vertical perioral rhytides (",
"      <a class=\"graphic graphic_picture graphicRef50746 \" href=\"UTD.htm?29/48/30465\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mouth frown (",
"      <a class=\"graphic graphic_picture graphicRef76339 \" href=\"UTD.htm?33/8/33921\">",
"       picture 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gummy smile",
"     </li>",
"     <li>",
"      Melomental folds (marionette lines) (",
"      <a class=\"graphic graphic_picture graphicRef55290 \" href=\"UTD.htm?33/55/34673\">",
"       picture 9",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mental crease (horizontal crease on the chin) (",
"      <a class=\"graphic graphic_picture graphicRef80633 \" href=\"UTD.htm?33/21/34128\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peau d&rsquo;orange chin (",
"      <a class=\"graphic graphic_picture graphicRef76750 \" href=\"UTD.htm?36/0/36864\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Masseteric hypertrophy (square jaw)",
"     </li>",
"     <li>",
"      Horizontal neck lines (",
"      <a class=\"graphic graphic_picture graphicRef69540 \" href=\"UTD.htm?7/12/7360\">",
"       picture 12",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Platysmal bands on the neck (",
"      <a class=\"graphic graphic_picture graphicRef64918 \" href=\"UTD.htm?17/34/17967\">",
"       picture 13",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The approach to the treatment of specific clinical features with botulinum toxin is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link\">",
"     \"Botulinum toxin for cosmetic indications: Treatment of specific sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493518\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the clinical effects of botulinum toxin begin to appear in one to three days, peak in one to four weeks, and gradually decline after three to four months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/12\">",
"     12",
"    </a>",
"    ]. However, the duration of response is dependent upon the injection site, dose, and specific formulation of botulinum toxin utilized [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/32\">",
"     32",
"    </a>",
"    ]. Some patients, particularly those who have received repeated injections in the same area, may experience benefits for six months or longer. This may be at least partially due to the development of muscle atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493526\">",
"    <span class=\"h3\">",
"     OnabotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of multiple randomized trials support the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    for the treatment of dynamic rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/21,34-37\">",
"     21,34-37",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, 120-day trial of 264 patients with moderate to severe glabellar lines found that treatment with 20 units of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      was superior to placebo at all study time points [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/21\">",
"       21",
"      </a>",
"      ]. By day seven, glabellar line severity at maximum frown was scored as absent or mild in 167 out of 203 patients treated with botulinum toxin compared with 3 out of 61 patients treated with placebo (82 versus 5 percent). Similar results were noted at 30 days, but treatment effect was substantially reduced by day 120 (26 versus 0 percent).",
"     </li>",
"     <li>",
"      Similar findings were noted in a second placebo-controlled randomized trial that used a similar protocol in 273 patients with moderate to severe glabellar lines [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/34\">",
"       34",
"      </a>",
"      ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days after treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      (77 versus 7 percent), but the amount of benefit was reduced at 120 days (24 versus 3 percent).",
"     </li>",
"     <li>",
"      In a randomized dose-response trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      for moderate or severe crow&rsquo;s feet in 162 patients, all doses of onabotulinumtoxinA were superior to placebo for improvement in rhytid severity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/35\">",
"       35",
"      </a>",
"      ]. Thirty days after treatment, improvement was detected in 85, 87, 52, 46, and 16 percent of patients who received bilateral injections of botulinum toxin (18 units, 12 units, 6 units, or 3 units) or placebo, respectively. Higher doses of onabotulinumtoxinA were associated with a longer duration of action and a greater magnitude of effect.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493534\">",
"    <span class=\"h3\">",
"     AbobotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    for dynamic rhytides is supported by randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase 3 randomized trial that investigated the efficacy of 50 units of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"       abobotulinumtoxinA",
"      </a>",
"      for the treatment of moderate to severe glabellar lines in 158 patients, treatment with abobotulinumtoxinA was superior to placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/39\">",
"       39",
"      </a>",
"      ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days with abobotulinumtoxinA (90 versus 8 percent). A significant difference in effect between treatment and placebo remained at day 120, but was no longer statistically significant by day 150.",
"     </li>",
"     <li>",
"      Similar findings were noted in a second phase 3 randomized trial in which 816 men and women were randomly assigned to receive 50 to 80 U of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"       abobotulinumtoxinA",
"      </a>",
"      (dose based upon muscle mass) or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/40\">",
"       40",
"      </a>",
"      ]. Glabellar line severity at maximum frown was much more likely to be mild or absent at 30 days (85 versus 3 percent). The median duration of treatment effect in the botulinum toxin group was 109 days.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H715028\">",
"    <span class=\"h3\">",
"     IncobotulinumtoxinA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    was investigated in two unpublished randomized trials in which patients with moderate to severe glabellar lines at maximum frown were treated with either 20 units of incobotulinumtoxinA (n = 366) or placebo (n = 181) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/41\">",
"     41",
"    </a>",
"    ]. Successful treatment was defined as improvement from severe lines to mild or absent lines or from moderate lines to absent lines. Thirty days after injection, 77 and 71 percent of patients treated with incobotulinumtoxinA achieved treatment success compared with none of the patients treated with placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493637\">",
"    <span class=\"h3\">",
"     RimabotulinumtoxinB",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     rimabotulinumtoxinB",
"    </a>",
"    for dynamic wrinkles has been supported by the results of randomized trials and open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/25,28,42-44\">",
"     25,28,42-44",
"    </a>",
"    ]. RimabotulinumtoxinB also may be useful for patients who fail to respond to botulinum toxin type A. RimabotulinumtoxinB was effective in an open-label study of 20 women with vertical glabellar rhytides that were refractory to or had a diminishing response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420443\">",
"    <span class=\"h3\">",
"     Comparative efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few randomized trials have directly compared different formulations of botulinum toxin for cosmetic indications. The results of small randomized trials suggest the following differences among the agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The onset of action of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"       rimabotulinumtoxinB",
"      </a>",
"      appears to be faster than that of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/44,45,47\">",
"       44,45,47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       OnabotulinumtoxinA",
"      </a>",
"      provides the longest duration of efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/45-47\">",
"       45-47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain with injection is less with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       onabotulinumtoxinA",
"      </a>",
"      than with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"       rimabotulinumtoxinB",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/45\">",
"       45",
"      </a>",
"      ]. The increased pain associated with injection of rimabotulinumtoxinB is thought to be related to its acidic pH (pH = 5.6), a property necessary for the product to remain stable in solution. Dilution of rimabotulinumtoxinB with preserved saline appears to decrease the pain associated with injection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies are necessary to confirm these findings. Dose conversions among the formulations are not standardized, and it is conceivable that studies utilizing different doses of these agents might find conflicting results. As an example, the duration of action of botulinum toxin is dose-dependent. In a randomized trial that compared two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     rimabotulinumtoxinB",
"    </a>",
"    , the duration of efficacy was longer with the higher dose (10 to 12 weeks versus 6 to 8 weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon studies in patients with hyperhidrosis and cervical dystonia, it has been proposed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    may diffuse more extensively within tissue than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    , which may contribute to a higher incidence of adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. However, additional studies are necessary to confirm whether these findings are applicable to cosmetic use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    have similar levels of clinical potency, safety, and duration of effect when used for medical indications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/23,55-59\">",
"     23,55-59",
"    </a>",
"    ], and at least two randomized trials have compared the efficacy of incobotulinumtoxinA and onabotulinumtoxinA for cosmetic use. In a 12-week trial comparing treatment of moderate to severe glabellar lines with incobotulinumtoxinA (n = 284) versus onabotulinumtoxinA (n = 97), the two agents were similarly effective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, an intraindividual trial with 12 patients found similar efficacy between these agents in the treatment of periorbital rhytides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522661\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absolute contraindications to botulinum toxin injection include infection at the site of injection or known hypersensitivity to any component of the product.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     AbobotulinumtoxinA",
"    </a>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be given to patients with allergies to cow&rsquo;s milk protein; this limitation does not apply to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     rimabotulinumtoxinB",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Relative contraindications to treatment include neuromuscular disorders that could amplify the effect of the toxin, such as myasthenia gravis, Eaton-Lambert syndrome, myopathies, or amyotrophic lateral sclerosis. Caution should also be exercised in patients taking drugs that can interfere with neuromuscular transmission (eg, aminoglycosides, cholinesterase inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    , and curare-type nondepolarizing blockers) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     OnabotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/30/7653?source=see_link\">",
"     rimabotulinumtoxinB",
"    </a>",
"    are pregnancy class C agents (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ), and injection generally should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in pregnant women. The risks of maternal-infant transmission of botulinum toxin in lactating women are unknown; thus, we avoid their use in this population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1493835\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familiarity with facial anatomy and facial muscle function is essential for proper technique (",
"    <a class=\"graphic graphic_figure graphicRef58011 \" href=\"UTD.htm?3/46/3815\">",
"     figure 1",
"    </a>",
"    ). Improper injection can result in cosmetically unfavorable results or functional disability. For example, botulinum toxin injection for horizontal forehead lines may result in unsightly lowering of the brow if the frontalis muscle is excessively weakened. (See",
"    <a class=\"local\" href=\"#H525807\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25308474\">",
"    <span class=\"h2\">",
"     Preparing for treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to treatment, the clinician should determine whether the patient&rsquo;s concerns are appropriate for treatment with botulinum toxin. Botulinum toxin is effective for aesthetic concerns that are caused by underlying muscle contraction. Individuals with other signs of aging, such as lentigines, telangiectasias, textural changes, and skin laxity often require additional cosmetic procedures to achieve satisfactory rejuvenation. (See",
"    <a class=\"local\" href=\"#H4081882\">",
"     'Use as adjunctive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If the cosmetic defect can be improved with botulinum toxin, and patient characteristics do not indicate that treatment is contraindicated, the patient should then be thoroughly informed about the expected duration of treatment benefit, the need for retreatment, and the potential adverse effects of botulinum toxin injection. Patients who have unrealistic expectations for treatment results are likely to remain dissatisfied regardless of the clinical outcome. We have found that digital photographs, taken both before and after treatment are useful for assessing improvement. (See",
"    <a class=\"local\" href=\"#H24777599\">",
"     'Side effects and complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because botulinum toxin weakens or paralyzes muscles, the effect of injections on other bodily functions also must be considered. For example, singers or individuals who play wind instruments are not always good candidates for perioral injections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730154\">",
"    <span class=\"h3\">",
"     Reconstitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     OnabotulinumtoxinA",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    must be reconstituted in saline prior to use. Preferred dilution volumes vary widely among clinicians. Package inserts suggest use of the following dilutions when treating glabellar lines with 20 Units of Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    Cosmetic or 50 Units of Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Botox",
"      </strong>",
"      <strong>",
"       <sup>",
"        &reg;",
"       </sup>",
"      </strong>",
"      <strong>",
"       Cosmetic &ndash;",
"      </strong>",
"      2.5 mL of sterile 0.9% sodium chloride added to the 100 unit vial or 1.25 mL of 0.9% sodium chloride to the 50 unit vial. Both dilutions result in a dose of 4",
"      <span class=\"nowrap\">",
"       units/0.1",
"      </span>",
"      mL. Diluent volumes for Xeomin",
"      <sup>",
"       &reg;",
"      </sup>",
"      are similar.",
"     </li>",
"     <li>",
"      <strong>",
"       Dysport",
"      </strong>",
"      <strong>",
"       <sup>",
"        &reg;",
"       </sup>",
"      </strong>",
"      <strong>",
"       &ndash;",
"      </strong>",
"      2.5 mL or 1.5 mL of 0.9% sodium chloride added to the 300 unit vial. This results in doses of 10",
"      <span class=\"nowrap\">",
"       units/0.08",
"      </span>",
"      mL and 10",
"      <span class=\"nowrap\">",
"       units/0.05",
"      </span>",
"      mL, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We often prefer to use smaller dilution volumes to allow more precise administration of the toxin. In our experience, this appears to improve the duration of effect and reduce the risk of side effects secondary to excessive spread of the toxin to adjacent tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/64\">",
"     64",
"    </a>",
"    ]. We customarily utilize concentrations 100",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    in our practice. The use of larger dilution volumes may be beneficial in settings in which treatment of large areas is desired [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/65\">",
"     65",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Unpreserved saline is the diluent recommended by the manufacturers of Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    Cosmetic, Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Xeomin",
"    <sup>",
"     &reg;",
"    </sup>",
"    ; however, in clinical practice, many clinicians reconstitute these products in saline preserved with benzyl alcohol to reduce the pain associated with injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/66\">",
"     66",
"    </a>",
"    ]. In a small randomized trial in which patients with dynamic rhytides on the upper face were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    in either preservative-containing or preservative-free saline, use of preserved saline reduced patient discomfort and did not alter treatment efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/67\">",
"     67",
"    </a>",
"    ]. Similar findings were observed in a small randomized trial with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/68\">",
"     68",
"    </a>",
"    ]. The possibility of allergy to benzyl alcohol must be considered when using preserved saline for reconstitution.",
"   </p>",
"   <p>",
"    Opinion varies on the delayed use of botulinum toxin after reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/66\">",
"     66",
"    </a>",
"    ]. Although the package inserts for Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    Cosmetic and Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    recommend refrigerating these products at 2 to 8&deg;C and then discarding them if they are not used within 24 or 4 hours after reconstitution, respectively, many clinicians refrigerate reconstituted vials for longer periods of time in anticipation of future use. One randomized trial in which 85 patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    that was reconstituted in preservative-free 0.9% saline and refrigerated at 4&deg;C for periods of time ranging from one day to six weeks found no significant difference in efficacy among solutions of different ages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/69\">",
"     69",
"    </a>",
"    ]. In addition, other randomized trials have documented retained treatment efficacy with botulinum toxin type A reconstituted one to two weeks prior to use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/70-72\">",
"     70-72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H691466002\">",
"    <span class=\"h3\">",
"     Dose conversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose conversions among the formulations botulinum toxin A are not standardized. The results of a systematic review and subsequent randomized trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    :",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    dose ratios lower than 3:1 (eg, 2:1 or 2.5:1) are appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. We typically utilize a dose ratio of 2.5:1 when transitioning between these products. In clinical practice,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    and abobotulinumtoxinA are administered in a 1:1 ratio; however, further study is necessary to determine whether this conversion is accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1730226\">",
"    <span class=\"h3\">",
"     Preoperative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pain from injection is well-tolerated by many patients. In addition to the use of preserved saline, pain from injection can be minimized with application of ice to the treatment site prior to treatment or the use of topical anesthetic agents or vibrational anesthesia.",
"   </p>",
"   <p>",
"    Bruising is most likely to occur after periorbital and perioral injections. Avoidance of inhibitors of platelet function for 7 to 10 days prior to periorbital injection (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , vitamin E, alcohol) is preferable in patients who can discontinue these agents safely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25308481\">",
"    <span class=\"h2\">",
"     During treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small volume (eg, 0.3 mL), insulin syringe with a 31-gauge needle is typically used for injection. Use of a syringe that lacks a needle hub will minimize product waste.",
"   </p>",
"   <p>",
"    The appropriate dose of botulinum toxin is determined by the treatment location and muscle mass; men typically have stronger and larger facial muscles and require higher doses than women. The number of injections and appropriate spacing of injections is dependent on the specific cosmetic defect. Local anatomic landmarks are used to guide the placement of injections.",
"   </p>",
"   <p>",
"    Many clinicians, including ourselves, sometimes massage the treatment site after injection in an attempt to spread the toxin, which theoretically could increase the efficacy of treatment. The benefit of this procedure has not been formally studied, and if performed, care should be taken to avoid massaging in a direction that could promote movement of the toxin to untargeted areas. We generally avoid massage for injection sites above the brow due to a concern for inducing brow ptosis. (See",
"    <a class=\"local\" href=\"#H525807\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=see_link&amp;anchor=H4080955#H4080955\">",
"     \"Botulinum toxin for cosmetic indications: Treatment of specific sites\", section on 'Horizontal forehead rhytides'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25308488\">",
"    <span class=\"h2\">",
"     After treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;When treating the periorbital region, we apply gentle direct pressure immediately after withdrawal of the needle to reduce the occurrence of bruising.",
"   </p>",
"   <p>",
"    Although there is a lack of data to confirm the efficacy of these measures, we and many other clinicians instruct patients to engage in actions that theoretically may minimize excessive diffusion of the toxin to untargeted areas and improve the efficacy of treatment. To minimize excessive spread of the toxin, we instruct patients to remain upright for at least two to four hours after injection and recommend that they avoid pressing or rubbing the treated areas for 24 hours. We also tell patients to contract and relax the treated muscles as much as possible for two to three hours after the procedure. In theory, contracting muscles may facilitate uptake of the toxin by neurons, accelerating the appearance of clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The manufacturers of Botox",
"    <sup>",
"     &reg;",
"    </sup>",
"    Cosmetic, Dysport",
"    <sup>",
"     &reg;",
"    </sup>",
"    , and Xeomin",
"    <sup>",
"     &reg;",
"    </sup>",
"    recommend that treatments should be spaced by at least three months. However, for patients in whom the response to treatment is unpredictable (patients receiving an initial treatment or a dosing change), we schedule an appointment for reassessment two to three weeks after treatment. If the desired effect has not been achieved, we perform additional injections at that time to improve treatment results; subsequent injections are performed at longer intervals. In patients who have received large doses (eg, greater than 100 units of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    ), we wait one to two months before administering touch-up injections in an attempt to reduce the risk for immunogenicity. (See",
"    <a class=\"local\" href=\"#H21137531\">",
"     'Immunogenicity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24777599\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS AND COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients are appropriately selected and proper dosing and injection technique are utilized, the use of botulinum toxin for cosmetic indications appears to be relatively safe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/20\">",
"     20",
"    </a>",
"    ]. Side effects are usually mild and transient and most commonly include swelling or bruising at the injection site, mild headache, or flu-like symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/78\">",
"     78",
"    </a>",
"    ]. Undesired impairment of muscle function may also occur, but is usually associated with poor injection technique or inappropriate patient selection. Because smaller doses are less likely to cause unintended adverse effects, a conservative approach to treatment is advisable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H525807\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion of botulinum toxin occasionally results in effects on muscles or glands adjacent to the targeted musculature. Diffusion of toxin in the upper face can result highly undesirable adverse effects that last for 2 to 12 weeks, including brow ptosis (excessive weakening of the frontalis muscle) and eyelid ptosis (weakening of the upper eyelid levator muscle secondary to diffusion into the orbital septum). In addition, a quizzical or \"cockeyed\" appearance (&ldquo;Mr. Spock&rdquo; eyebrow) can result from preferential weakening of the medial frontalis muscles, which allows unaffected lateral muscle fibers of the frontalis to elevate the lateral brow. Other adverse effects that can occur in the upper face include diplopia, ectropion, lower eyelid droop, epiphora (excessive tearing), decreased strength of eye closure, and dry eye [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the lower face, complications of treatment typically involve effects on muscle function and facial expression. These adverse effects usually are due to the use of excessive doses or injection into inappropriate locations. Flaccid cheek, incompetent mouth, asymmetrical smile, and loss of the ability to whistle are most likely to occur when injections are placed too close to the mouth, injections are performed in the mental fold, or when botulinum toxin interacts with the orbicularis oris muscle. The administration of high doses in the neck area can lead to dysphagia and weakness of the neck flexors.",
"   </p>",
"   <p>",
"    Eyelid ptosis can be partially improved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/28/36291?source=see_link\">",
"     apraclonidine",
"    </a>",
"    drops given two to three times per day until resolution. This usually results in 1 to 2 mm of eyelid elevation. The quizzical-appearing brow can be remedied through injection of the lateral frontalis musculature. Other functional adverse effects that cannot be improved with compensatory treatment resolve as the effect of botulinum toxin diminishes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24777620\">",
"    <span class=\"h2\">",
"     Clinical safety record",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the available data on botulinum toxin reveals an impressive safety record. The authors of a 2004 systematic review and meta-analysis of randomized trials (n = 1425) found no reports of serious adverse effects in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    for medical or cosmetic purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/79\">",
"     79",
"    </a>",
"    ]. Serious adverse effects reported to the FDA have also been low in number; between 1989 and 2003, only 36 serious adverse effects associated with cosmetic use were reported. Examples of the serious adverse effects that were documented included injection site reactions, headache, focal facial paralysis, muscle weakness, flu-like symptoms, dysphagia, respiratory compromise, cardiac arrhythmia, seizure, ocular abnormalities, and allergic reactions. Of note, 13 of the patients who experienced serious adverse effects had underlying medical conditions that may have contributed to the observed event (eg, respiratory compromise in a patient with asthma and cardiac arrhythmia in a patient with a history of heart murmur).",
"   </p>",
"   <p>",
"    Although the risk of serious adverse effects is low with cosmetic use, side effects such as aspiration, dysphagia, pneumonia, anaphylaxis, and death have been reported in association with the use of botulinum toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/80-83\">",
"     80-83",
"    </a>",
"    ]. As a result, in 2009, the US FDA instituted a requirement for boxed warnings on product labels and a Risk Evaluation and Mitigation Strategy (a consumer guide outlining the risks associated with treatment) for all botulinum toxin products [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/84-86\">",
"     84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the effect of botulinum toxin is temporary, patients require additional treatment to maintain improvement. The safety of repetitive treatment with botulinum toxin was evaluated in a retrospective study of more than 4000 treatments in 945 patients treated for lines in the upper face [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/87\">",
"     87",
"    </a>",
"    ]. Patients had to have received a minimum of three consecutive treatment cycles. Only mild to moderate adverse effects were detected; bruising and ptosis were most common. In addition, the incidence of side effects decreased with repeated injections, a finding that has been reported in studies of the medical use of botulinum toxin type A [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Repeat injections with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    have also been well tolerated in large open label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21137531\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The commercially available preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"     abobotulinumtoxinA",
"    </a>",
"    are complexed with clostridial proteins, a characteristic that may have an effect on the immunogenicity of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/12,92,93\">",
"     12,92,93",
"    </a>",
"    ]. Although antibody formation against botulinum toxin has been linked to reduced treatment efficacy in some reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/94-97\">",
"     94-97",
"    </a>",
"    ], the occurrence of this phenomenon appears to be rare, particularly in patients treated for cosmetic indications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. In a meta-analysis composed of randomized trials and open label studies published between 1999 and 2007, out of 2240 patients treated with onabotulinumtoxinA for a variety of indications (including 718 patients treated for glabellar lines), only 11 patients exhibited seroconversion. A lack of response to treatment followed conversion to seropositivity in only three patients, none of whom were treated for purely aesthetic indications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Injecting the lowest effective doses, with the longest feasible intervals between injections, may minimize the potential for immunogenicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/88,100\">",
"     88,100",
"    </a>",
"    ]. Because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"     incobotulinumtoxinA",
"    </a>",
"    is free of complexing proteins, the immunogenicity of this product may be different from the previously available complexed products [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/23,24,92\">",
"     23,24,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081882\">",
"    <span class=\"h1\">",
"     USE AS ADJUNCTIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum toxin is highly effective in the treatment of dynamic rhytides. However, deeper rhytides and skin folds or other signs of skin aging are often best treated with botulinum toxin plus soft tissue augmentation, laser skin resurfacing, or surgical intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081889\">",
"    <span class=\"h2\">",
"     Soft-tissue augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of cosmetic fillers in conjunction with botulinum toxin can be of value, particularly when treating the brow, nasojugal folds, perioral region, and the neck [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/101\">",
"     101",
"    </a>",
"    ]. This technique may be particularly useful in patients who present for the treatment of deep rhytides that are evident at rest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=see_link\">",
"     \"Injectable soft tissue fillers: Overview of clinical use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=see_link\">",
"     \"Injectable soft tissue fillers: Semipermanent agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=see_link\">",
"     \"Injectable soft tissue fillers: Permanent agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When given one week prior to treatment with fillers, botulinum toxin decreases the dynamic component of the targeted rhytid, leading to increased longevity of the filling agent in tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/101-104\">",
"     101-104",
"    </a>",
"    ]. In small randomized trials and a retrospective study, combination therapy with botulinum toxin A and cosmetic fillers has been associated superior efficacy and improved patient satisfaction compared to monotherapy with either procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/104-107\">",
"     104-107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081896\">",
"    <span class=\"h2\">",
"     Lasers/light therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional and fractional laser resurfacing are effective treatments for features of skin aging, including the treatment of rhytides. Impairment of muscle action with botulinum toxin before resurfacing may improve healing and collagen remodelling after laser treatment, contributing to improved aesthetic results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/103,108-110\">",
"     103,108-110",
"    </a>",
"    ]. In addition, postoperative injections may prolong the results of laser resurfacing by reducing the rate of wrinkle recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/108,111,112\">",
"     108,111,112",
"    </a>",
"    ]. In one randomized bilateral comparison trial of 33 patients treated with periorbital injections of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"     onabotulinumtoxinA",
"    </a>",
"    or placebo prior to and after erbium:yttrium aluminum garnet (Er:YAG) laser resurfacing, greater improvement in rhytides, and other signs of photoaging were observed in sites treated with botulinum toxin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/113\">",
"     113",
"    </a>",
"    ]. Postoperative onabotulinumtoxinA also prolonged the correction of dynamic rhytides in a placebo-controlled randomized bilateral comparison trial of 40 patients treated with carbon dioxide laser resurfacing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/112\">",
"     112",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=see_link&amp;anchor=H18975495#H18975495\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Approach to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of botulinum toxin injections to the treatment of photoaging with intense pulsed light (IPL) was associated with increased overall aesthetic benefit in two small, randomized trials. Further studies are necessary to explore the effects of combination therapy with botulinum toxin and IPL. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4081903\">",
"    <span class=\"h2\">",
"     Surgery and wound healing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemodenervation with botulinum toxin is a useful adjunct to many aesthetic surgeries. Treatment before and after surgical procedures can be of value for stabilizing musculature during healing, thereby reducing the risk for wound dehiscence and improving outcomes of surgical procedures for facial aging (eg, brow lifts, blepharoplasty, facelifts) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/103\">",
"     103",
"    </a>",
"    ]. Moreover, pretreating the underlying musculature with botulinum toxin type A can allow for the use of finer sutures, contributing to improved aesthetic outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/114-117\">",
"     114-117",
"    </a>",
"    ]. Botulinum toxin also reduces tension on the wound edge, allowing for faster healing with less prominent scarring [",
"    <a class=\"abstract\" href=\"UTD.htm?22/15/22778/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H522914\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botulinum toxin, the causative agent of botulism, is used clinically for a variety of indications. Through the controlled inhibition of local neurotransmission, botulinum toxin injections improve aesthetic concerns that are caused or exacerbated by muscular contraction. The effect of treatment is temporary; muscle recovery often becomes clinically evident a few months after treatment. (See",
"      <a class=\"local\" href=\"#H4082356\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanisms of action and clinical properties of botulinum toxin vary according to serotype. Botulinum toxin type A is the primary form of botulinum toxin utilized for cosmetic treatment. Botulinum toxin type B has been less extensively studied for cosmetic indications, but also appears to be effective in this setting. (See",
"      <a class=\"local\" href=\"#H24777445\">",
"       'Formulations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24777452\">",
"       'Cosmetic use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Various formulations of botulinum toxin A are available worldwide.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10681?source=see_link\">",
"       OnabotulinumtoxinA",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"       abobotulinumtoxinA",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/48/43781?source=see_link\">",
"       incobotulinumtoxinA",
"      </a>",
"      are the formulations available for clinical use in North America. These products are approved by the US Food and Drug Administration for the treatment of glabellar lines, and have been used off-label for other cosmetic indications. Few high quality studies have directly compared the efficacy of different formulations of botulinum toxin. &nbsp;(See",
"      <a class=\"local\" href=\"#H24777445\">",
"       'Formulations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24777452\">",
"       'Cosmetic use'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Absolute contraindications to treatment with botulinum toxin include infection at the injection site and hypersensitivity to product components.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12549?source=see_link\">",
"       AbobotulinumtoxinA",
"      </a>",
"      should",
"      <strong>",
"       not",
"      </strong>",
"      be given to patients who are allergic to cow&rsquo;s milk protein. (See",
"      <a class=\"local\" href=\"#H522661\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Careful patient selection and patient education, as well as thorough understanding of head and neck anatomy and appropriate injection technique are critical for the achievement of desired results and minimization of adverse effects. Common complications of botulinum toxin injection include transient swelling, bruising, and headache. When administered appropriately, serious adverse effects associated with the use of botulinum toxin for cosmetic indications are rare. &nbsp;(See",
"      <a class=\"local\" href=\"#H1493835\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24777599\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improper placement of injections or diffusion of the toxin to untargeted areas after injection can result in excessive muscle weakness that can cause temporary disfigurement or functional impairments. Some cosmetic defects such as eyelid ptosis and a quizzical-appearing brow can be improved with therapeutic interventions. In other cases, improvement is dependent upon the diminishing effect of botulinum toxin over time. (See",
"      <a class=\"local\" href=\"#H24777599\">",
"       'Side effects and complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulinum toxin can be used in conjunction with other aesthetic procedures to improve clinical outcomes. Patients undergoing injection of cosmetic fillers, ablative laser resurfacing, or facial cosmetic surgeries may benefit from the concomitant use of botulinum toxin. (See",
"      <a class=\"local\" href=\"#H4081882\">",
"       'Use as adjunctive therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Therapy with Botulinum Toxin, Jankovic J, Hallet M (Eds), Marcel Dekker, 1994. p.15.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/2\">",
"      Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997; 40:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/3\">",
"      Burke GS. Notes on Bacillus botulinus. J Bacteriol 1919; 4:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/4\">",
"      Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001; 8 Suppl 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     Dolly JO, Lisk G, Foran PG, et al. Insights into the extended duration of neuroparalysis by botulinum neurotoxin A relative to the other shorter-acting serotypes: differences between motor nerve terminals and cultured neurons. In: Scientific and Therapeutic Aspects of Botulinum Toxin, 1st ed, Brin MF, Jankovic J, Hallett M (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, PA 2002. p.91.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/6\">",
"      Scott AB. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/7\">",
"      Wabbels B, Reichel G, Fulford-Smith A, et al. Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm 2011; 118:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/8\">",
"      Carruthers J, Stubbs HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci 1987; 14:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/9\">",
"      Borodic GE, Cheney M, McKenna M. Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 1992; 90:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/10\">",
"      Tsui JK, Eisen A, Mak E, et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 1985; 12:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/11\">",
"      Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/12\">",
"      Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg 2001; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/13\">",
"      Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/14\">",
"      Lowe NJ, Yamauchi P. Cosmetic uses of botulinum toxins for lower aspects of the face and neck. Clin Dermatol 2004; 22:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/15\">",
"      Dayan SH, Maas CS. Botulinum toxins for facial wrinkles: beyond glabellar lines. Facial Plast Surg Clin North Am 2007; 15:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/16\">",
"      Fagien S, Carruthers JD. A comprehensive review of patient-reported satisfaction with botulinum toxin type a for aesthetic procedures. Plast Reconstr Surg 2008; 122:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/17\">",
"      Carruthers A, Carruthers J, Lei X, et al. OnabotulinumtoxinA treatment of mild glabellar lines in repose. Dermatol Surg 2010; 36 Suppl 4:2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/18\">",
"      Blitzer A, Brin MF, Keen MS, Aviv JE. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/19\">",
"      Meunier FA, Schiavo G, Molg&oacute; J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002; 96:105.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration Press Announcements. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175013.htm (Accessed on March 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/21\">",
"      Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/22\">",
"      Carruthers J, Carruthers A. The evolution of botulinum neurotoxin type A for cosmetic applications. J Cosmet Laser Ther 2007; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/23\">",
"      Jost WH, Bl&uuml;mel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs 2007; 67:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/24\">",
"      Frevert J, Dressler D. Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? Biologics 2010; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/25\">",
"      Ramirez AL, Reeck J, Maas CS. Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 2002; 126:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/26\">",
"      Alster TS, Lupton JR. Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 2003; 29:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/27\">",
"      Kim EJ, Ramirez AL, Reeck JB, Maas CS. The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines. Plast Reconstr Surg 2003; 112:88S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/28\">",
"      Sadick NS. Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2,400 and 3,000 U for the treatment of glabellar wrinkles. Dermatol Surg 2003; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/29\">",
"      Brandt F, O'Connell C, Cazzaniga A, Waugh JM. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol Surg 2010; 36 Suppl 4:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/30\">",
"      Collins A, Nasir A. Topical botulinum toxin. J Clin Aesthet Dermatol 2010; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/31\">",
"      Chajchir I, Modi P, Chajchir A. Novel topical BoNTA (CosmeTox, toxin type A) cream used to treat hyperfunctional wrinkles of the face, mouth, and neck. Aesthetic Plast Surg 2008; 32:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/32\">",
"      Flynn TC. Botulinum toxin: examining duration of effect in facial aesthetic applications. Am J Clin Dermatol 2010; 11:183.",
"     </a>",
"    </li>",
"    <li>",
"     Murray C, Solish N. Botulinum toxin injections. In: Comprehensive dermatologic drug therapy, 2nd ed, Wolverton, SE.  (Eds), Elsevier Inc., 2007. p.851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/34\">",
"      Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 2003; 112:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/35\">",
"      Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/36\">",
"      Grimes PE, Shabazz D. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI. Dermatol Surg 2009; 35:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/37\">",
"      Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/38\">",
"      Rubin MG, Dover J, Glogau RG, et al. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/39\">",
"      Brandt F, Swanson N, Baumann L, Huber B. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009; 35:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/40\">",
"      Kane MA, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new U.S. Botulinum Toxin Type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase III, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124:1619.",
"     </a>",
"    </li>",
"    <li>",
"     Xeomin [package insert]. Greensboro, NC: Merz Pharmaceuticals, LLC; 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/42\">",
"      Carruthers A, Carruthers J, Flynn TC, Leong MS. Dose-finding, safety, and tolerability study of botulinum toxin type B for the treatment of hyperfunctional glabellar lines. Dermatol Surg 2007; 33:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/43\">",
"      Sadick NS. Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 2002; 28:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/44\">",
"      Flynn TC, Clark RE 2nd. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 2003; 29:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/45\">",
"      Matarasso SL. Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/46\">",
"      Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg 2005; 31:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/47\">",
"      Lowe NJ, Yamauchi PS, Lask GP, et al. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 2002; 4:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/48\">",
"      van Laborde S, Dover JS, Moore M, et al. Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol 2003; 48:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/49\">",
"      Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/50\">",
"      Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/51\">",
"      Trindade de Almeida AR, Marques E, de Almeida J, et al. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/52\">",
"      Cliff SH, Judodihardjo H, Eltringham E. Different formulations of botulinum toxin type A have different migration characteristics: a double-blind, randomized study. J Cosmet Dermatol 2008; 7:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/53\">",
"      Pickett A, Dodd S, Rzany B. Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications. J Cosmet Laser Ther 2008; 10:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/54\">",
"      Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010; 9:s7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/55\">",
"      Dressler D. [Pharmacological aspects of therapeutic botulinum toxin preparations]. Nervenarzt 2006; 77:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/56\">",
"      Roggenk&auml;mper P, Jost WH, Bihari K, et al. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/57\">",
"      Dressler D. Routine use of Xeomin in patients previously treated with Botox: long term results. Eur J Neurol 2009; 16 Suppl 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/58\">",
"      Jankovic J. Clinical efficacy and tolerability of Xeomin in the treatment of blepharospasm. Eur J Neurol 2009; 16 Suppl 2:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/59\">",
"      Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm 2010; 117:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/60\">",
"      Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg 2010; 36 Suppl 4:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/61\">",
"      Prager W, Wissm&uuml;ller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg 2010; 36 Suppl 4:2155.",
"     </a>",
"    </li>",
"    <li>",
"     Allergan, Inc. Botox&reg; Cosmetic (botulinum toxin type A) purified neurotoxin complex (prescribing information). Allergan, Inc, Irvine, CA 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/63\">",
"      Feily A, Fallahi H, Zandian D, Kalantar H. A succinct review of botulinum toxin in dermatology; update of cosmetic and noncosmetic use. J Cosmet Dermatol 2011; 10:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/64\">",
"      Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 2003; 29:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/65\">",
"      Hsu TS, Dover JS, Arndt KA. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 2004; 140:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/66\">",
"      Liu A, Carruthers A, Cohen JL, et al. Recommendations and current practices for the reconstitution and storage of botulinum toxin type A. J Am Acad Dermatol 2012; 67:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/67\">",
"      Alam M, Dover JS, Arndt KA. Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial. Arch Dermatol 2002; 138:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/68\">",
"      Allen SB, Goldenberg NA. Pain difference associated with injection of abobotulinumtoxinA reconstituted with preserved saline and preservative-free saline: a prospective, randomized, side-by-side, double-blind study. Dermatol Surg 2012; 38:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/69\">",
"      Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 2003; 29:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/70\">",
"      Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg 2007; 23:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/71\">",
"      Lizarralde M, Guti&eacute;rrez SH, Venegas A. Clinical efficacy of botulinum toxin type A reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg 2007; 33:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/72\">",
"      Yang GC, Chiu RJ, Gillman GS. Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox. Arch Facial Plast Surg 2008; 10:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/73\">",
"      Hexsel D, Brum C, do Prado DZ, et al. Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol 2012; 67:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/74\">",
"      Hexsel D, Dal'Forno T, Hexsel C, et al. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg 2008; 34:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/75\">",
"      Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg 2009; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/76\">",
"      Flynn TC. Advances in the use of botulinum neurotoxins in facial esthetics. J Cosmet Dermatol 2012; 11:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/77\">",
"      Jandhyala R. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence. J Drugs Dermatol 2012; 11:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/78\">",
"      Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 2009; 61:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/79\">",
"      Naumann M, Jankovic J. Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin 2004; 20:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/80\">",
"      Cot&eacute; TR, Mohan AK, Polder JA, et al. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 2005; 53:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/81\">",
"      LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997; 12:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/82\">",
"      Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis? J Forensic Sci 2005; 50:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/83\">",
"      Nong LB, He WQ, Xu YH, et al. [Severe respiratory failure after injection of botulinum toxin: case report and review of the literature]. Zhonghua Jie He He Hu Xi Za Zhi 2008; 31:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/84\">",
"      Kuehn BM. FDA requires black box warnings on labeling for botulinum toxin products. JAMA 2009; 301:2316.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Information for health care professionals: onabotulinumtoxinA (marketed as Botox/Botox  Cosmetic), abobotulinumtoxinA (marketed as Dysport) and rimabotulinumtoxinB (marketed as Myobloc). file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm174949.htm (Accessed on March 28, 2011).",
"    </li>",
"    <li>",
"     Food and Drug Administration. Early communication about an ongoing safety review: Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B). 2008. file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm (Accessed on July 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/87\">",
"      Rzany B, Dill-M&uuml;ller D, Grablowitz D, et al. Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients. Dermatol Surg 2007; 33:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/88\">",
"      Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 2005; 20:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/89\">",
"      Defazio G, Abbruzzese G, Girlanda P, et al. Botulinum toxin A treatment for primary hemifacial spasm: a 10-year multicenter study. Arch Neurol 2002; 59:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/90\">",
"      Cohen JL, Schlessinger J, Cox SE, et al. An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines. Aesthet Surg J 2009; 29:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/91\">",
"      Monheit GD, Cohen JL, Reloxin Investigational Group. Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study. J Am Acad Dermatol 2009; 61:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/92\">",
"      Sattler G. Current and future botulinum neurotoxin type A preparations in aesthetics: a literature review. J Drugs Dermatol 2010; 9:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/93\">",
"      Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/94\">",
"      Lee SK. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007; 33:S105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/95\">",
"      Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995; 45:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/96\">",
"      Dressler D. New formulation of BOTOX. Complete antibody-induced therapy failure in hemifacial spasm. J Neurol 2004; 251:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/97\">",
"      Dressler D, Wohlfahrt K, Meyer-Rogge E, et al. Antibody-induced failure of botulinum toxin a therapy in cosmetic indications. Dermatol Surg 2010; 36 Suppl 4:2182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/98\">",
"      Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX&reg;) across multiple indications. Mov Disord 2010; 25:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/99\">",
"      Lawrence I, Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J 2009; 29:S66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/100\">",
"      Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994; 9:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/101\">",
"      Coleman KR, Carruthers J. Combination therapy with BOTOX and fillers: the new rejuvnation paradigm. Dermatol Ther 2006; 19:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/102\">",
"      Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/103\">",
"      Fagien S, Brandt FS. Primary and adjunctive use of botulinum toxin type A (Botox) in facial aesthetic surgery: beyond the glabella. Clin Plast Surg 2001; 28:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/104\">",
"      Carruthers J, Carruthers A, Maberley D. Deep resting glabellar rhytides respond to BTX-A and Hylan B. Dermatol Surg 2003; 29:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/105\">",
"      Carruthers J, Carruthers A. A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 2003; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/106\">",
"      Patel MP, Talmor M, Nolan WB. Botox and collagen for glabellar furrows: advantages of combination therapy. Ann Plast Surg 2004; 52:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/107\">",
"      Carruthers A, Carruthers J, Monheit GD, et al. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg 2010; 36 Suppl 4:2121.",
"     </a>",
"    </li>",
"    <li>",
"     Carruthers J, Carruthers A. Combining botulinum toxin injection and laser for facial rhytides. In: Skin Resurfacing, Coleman WP, Lawrence N (Eds), Williams and Wilkins, Baltimore, MD 1998. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/109\">",
"      Worcester S. Use of Botox before and after laser facial resurfacing. Skin Allergy News 2000; 31:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/110\">",
"      Zimbler MS, Holds JB, Kokoska MS, et al. Effect of botulinum toxin pretreatment on laser resurfacing results: a prospective, randomized, blinded trial. Arch Facial Plast Surg 2001; 3:165.",
"     </a>",
"    </li>",
"    <li>",
"     Alster TS. Laser resurfacing of rhytides. In: Manual of Cutaneous Laser Techniques, Alster TS (Ed), Lippincott-Raven Publishers, Philadelphia, PA 19997. p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/112\">",
"      West TB, Alster TS. Effect of botulinum toxin type A on movement-associated rhytides following CO2 laser resurfacing. Dermatol Surg 1999; 25:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/113\">",
"      Yamauchi PS, Lask G, Lowe NJ. Botulinum toxin type A gives adjunctive benefit to periorbital laser resurfacing. J Cosmet Laser Ther 2004; 6:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/114\">",
"      Gassner HG, Sherris DA, Otley CC. Treatment of facial wounds with botulinum toxin A improves cosmetic outcome in primates. Plast Reconstr Surg 2000; 105:1948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/115\">",
"      Sherris DA, Gassner HG. Botulinum toxin to minimize facial scarring. Facial Plast Surg 2002; 18:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/116\">",
"      Gassner HG, Sherris DA. Chemoimmobilization: improving predictability in the treatment of facial scars. Plast Reconstr Surg 2003; 112:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/117\">",
"      Gassner HG, Brissett AE, Otley CC, et al. Botulinum toxin to improve facial wound healing: A prospective, blinded, placebo-controlled study. Mayo Clin Proc 2006; 81:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/118\">",
"      Wilson AM. Use of botulinum toxin type A to prevent widening of facial scars. Plast Reconstr Surg 2006; 117:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/15/22778/abstract/119\">",
"      Flynn TC. Use of intraoperative botulinum toxin in facial reconstruction. Dermatol Surg 2009; 35:182.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13643 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-189.41.172.26-8D498AE9A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22778=[""].join("\n");
var outline_f22_15_22778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H522914\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24777424\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24777431\">",
"      DISCOVERY AND DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4082356\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24777445\">",
"      FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081645\">",
"      OnabotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081652\">",
"      AbobotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081673\">",
"      IncobotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H714881\">",
"      RimabotulinumtoxinB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H714960\">",
"      Topical botulinum toxin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H715017\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24777452\">",
"      COSMETIC USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1493518\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493526\">",
"      - OnabotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493534\">",
"      - AbobotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H715028\">",
"      - IncobotulinumtoxinA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1493637\">",
"      - RimabotulinumtoxinB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1420443\">",
"      - Comparative efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H522661\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1493835\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25308474\">",
"      Preparing for treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1730154\">",
"      - Reconstitution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H691466002\">",
"      - Dose conversion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1730226\">",
"      - Preoperative measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25308481\">",
"      During treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25308488\">",
"      After treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24777599\">",
"      SIDE EFFECTS AND COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H525807\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24777620\">",
"      Clinical safety record",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21137531\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4081882\">",
"      USE AS ADJUNCTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081889\">",
"      Soft-tissue augmentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081896\">",
"      Lasers/light therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4081903\">",
"      Surgery and wound healing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H522914\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13643|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/46/3815\" title=\"figure 1\">",
"      Muscles of the face",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13643|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/3/4149\" title=\"picture 1\">",
"      Glabellar rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/4/11334\" title=\"picture 2\">",
"      Horizontal forehead rhytides at rest and contraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/52/3908\" title=\"picture 3\">",
"      Lateral canthal rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/11/31920\" title=\"picture 4\">",
"      Brow ptosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/18/8481\" title=\"picture 5A\">",
"      Bunny lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/22/39278\" title=\"picture 5B\">",
"      Bunny lines lateral view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/43/41648\" title=\"picture 6\">",
"      Nasolabial folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/48/30465\" title=\"picture 7\">",
"      Perioral rhytides",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/8/33921\" title=\"picture 8\">",
"      Mouth frown",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/55/34673\" title=\"picture 9\">",
"      Melomental folds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/21/34128\" title=\"picture 10\">",
"      Mental crease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/0/36864\" title=\"picture 11\">",
"      Peau d orange chin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/12/7360\" title=\"picture 12\">",
"      Horizontal neck lines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/34/17967\" title=\"picture 13\">",
"      Platysmal bands",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/36/1610?source=related_link\">",
"      Ablative laser resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/20/14665?source=related_link\">",
"      Botulinum toxin for cosmetic indications: Treatment of specific sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/26/27049?source=related_link\">",
"      Injectable soft tissue fillers: Overview of clinical use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/26/26024?source=related_link\">",
"      Injectable soft tissue fillers: Permanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/23/23930?source=related_link\">",
"      Injectable soft tissue fillers: Semipermanent agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=related_link\">",
"      Treatment of dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6537?source=related_link\">",
"      Treatment of myoclonus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_15_22779="Avoiding bias screening";
var content_f22_15_22779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Avoiding bias in screening",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Bias",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        How to avoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead time",
"       </td>",
"       <td>",
"        Appears to improve survival time but actually increases \"disease\" time after disease detection",
"       </td>",
"       <td>",
"        Use mortality rather than survival rates.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Length time",
"       </td>",
"       <td>",
"        Outcome appears better in screened group because more cancers with a good prognosis are detected",
"       </td>",
"       <td>",
"        Compare outcomes in RCT with control group and one offered screening. Count all outcomes regardless of method of detection.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Compliance",
"       </td>",
"       <td>",
"        Outcome in screened group appears better due to compliance, not screening",
"       </td>",
"       <td>",
"        Compare outcomes in RCT with control group and one offered screening. Count all outcomes regardless of compliance.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fletcher RH, Fletcher SW. Prevention. In: Clinical Epidemiology - The Essentials, 4th ed. Lippincott Williams &amp; Wilkins, Baltimore 2005. Copyright &copy; 2005 Lippincott Williams and Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22779=[""].join("\n");
var outline_f22_15_22779=null;
var title_f22_15_22780="Opioid withdrawal - Rapid overview";
var content_f22_15_22780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68306&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Opioid withdrawal: Rapid overview",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Clinical and laboratory features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opioid-dependent individuals typically experience withdrawal after administration of an antagonist or within 6-48 hours of cessation of opioid use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iatrogenic withdrawal is potentially life-threatening, while naturally-occurring withdrawal is usually not.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs of opioid withdrawal include mydriasis, yawning, increased bowel sounds, and piloerection. Mental status is usually normal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms of opioid withdrawal include dysphoria, restlessness, rhinorrhea, lacrimation, myalgias, arthralgias, nausea, vomiting, abdominal cramping, diarrhea, tachycardia, and hypertension. Opioid addicts may identify themselves as \"dope sick.\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnostic evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The diagnosis of opioid withdrawal is made by history alone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laboratory evaluation is helpful only to assess associated conditions (eg, serum electrolyte concentrations in the setting of significant vomiting or diarrhea).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If withdrawal is naturally-occurring, the physician may opt to manage the patient with either opioid or non-opioid adjunctive medication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluid resuscitation if needed due to losses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methadone 10 mg IM or 20 mg oral is usually sufficient to relieve symptoms of withdrawal without producing intoxication.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adjunctive medications include clonidine 0.1 to 0.3 mg orally every hour while monitoring blood pressure and heart rate, as well as benzodiazepines, antiemetics, and antidiarrheals.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For iatrogenic withdrawal (due to an opioid antagonist) only adjunctive medications should be used, not opioids. Refer to separate table on Medications used in management of opioid withdrawal.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22780=[""].join("\n");
var outline_f22_15_22780=null;
var title_f22_15_22781="Burn extent in children";
var content_f22_15_22781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified Lund and Browder chart",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Area",
"       </td>",
"       <td class=\"subtitle1\">",
"        Birth to 1 year",
"       </td>",
"       <td class=\"subtitle1\">",
"        1 to 4 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        5 to 9 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        10 to 14 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        15 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neck",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anterior trunk",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior trunk",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R buttock",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L buttock",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Genitalia",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R upper arm",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L upper arm",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R lower arm",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L lower arm",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R hand",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L hand",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R thigh",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L thigh",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        8.5",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R leg",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L leg",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        R foot",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L foot",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Numbers refer to % total body surface area involved.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lund, CC, Browder, NC, Surg Gynecol Obstet 1944; 79:352.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22781=[""].join("\n");
var outline_f22_15_22781=null;
var title_f22_15_22782="Contents: Pediatric sports medicine";
var content_f22_15_22782=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/34/1568\">",
"       Family Medicine and General Practice",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric sports medicine",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric sports medicine",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Ankle injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/20/31050\">",
"           Clinical features and management of ankle pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/23/14711\">",
"           Evaluation of foot and ankle pain in the young athlete",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Elbow injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/25/22937\">",
"           Elbow injuries in the young athlete",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Exercise",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/31/43513\">",
"           Overview of aerobic exercise testing in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Heel and foot injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/41/23190\">",
"           Clinical features and management of foot pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/6/28775\">",
"           Clinical features and management of heel pain in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/23/14711\">",
"           Evaluation of foot and ankle pain in the young athlete",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Knee injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/9/5273\">",
"           Approach to the young athlete with acute knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/34/29223\">",
"           Approach to the young athlete with chronic knee pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12392\">",
"           Osgood-Schlatter disease (tibial tuberosity avulsion)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24581\">",
"           Patellar dislocations in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/50/28455\">",
"           Traumatic causes of acute knee pain and injury in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/61/4056\">",
"           Treatment of knee injuries in the young athlete",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Musculoskeletal injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/62/8169\">",
"           Musculoskeletal injury in the young athlete: Overview of rehabilitation for nonoperative injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44775\">",
"           Musculoskeletal injury in the young athlete: Overview of treatment principles for nonoperative injuries",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/6/12392\">",
"           Osgood-Schlatter disease (tibial tuberosity avulsion)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neck injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41368\">",
"           Approach to the young athlete with neck pain or injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/28/15815\">",
"           Field care and evaluation of the young athlete with acute neck injury",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/8/23689\">",
"           Overview of cervical spinal cord and cervical peripheral nerve injuries in the young athlete",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/49/11033\">",
"           Overview of musculoskeletal neck injuries in the young athlete",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Nutrition",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/6/40040\">",
"           Calcium requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/11/23735\">",
"           Dietary energy requirements in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/7/27769\">",
"           High altitude disease: Unique pediatric considerations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/61/14298\">",
"           Overview of physical activity and strength training in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Physical examination",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/13/36058\">",
"           The preparticipation sports examination in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wrist injuries",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38855\">",
"           Causes of chronic wrist pain in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/43/32440\">",
"           Evaluation of wrist pain and injury in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/8/32905\">",
"           Overview of acute wrist injuries in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-54CD166E29-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_15_22782=[""].join("\n");
var outline_f22_15_22782=null;
var title_f22_15_22783="Haemophilus chocolate agar";
var content_f22_15_22783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae on chocolate agar plate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Haemophilus influenzae does not grow on a sheep blood agar plate, but does produce small, translucent colonies on chocolate agar.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_15_22783=[""].join("\n");
var outline_f22_15_22783=null;
